Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data
Conditions: Atrial Fibrillation
Sponsor: Brigham and Women's Hospital

Prediction of Findings from the Ongoing COBRRA-AF Trial Using Healthcare 
Database Analyses 
DUPLICATE – COBRRA AF 
March 7th, 2022 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
1. RCT Details 
This section provides a high-level overview of an ongoing RCT that the described real-world evidence study is trying to replicate 
as closely as possible given the limitations inherent in the healthcare databases. 
1.1 Title 
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients with Atrial Fibrillation 
(COBRRA - AF) 
1.2 Intended aim(s) 
To compare the incidence of major and clinically relevant non-major bleeding events in patients with non-valvular atrial 
fibrillation diagnosed by an ECG. 
1.3 Primary endpoint for replication 
Time from randomization to the first confirmed, adjudicated occurrence of a major bleeding or clinically relevant non-major 
bleeding event up to 365 days after initiating anticoagulation treatment. 
1.4 Required power for primary endpoint and noninferiority margin (if applicable) 
The hazard ratio for the clinical trial is unknown because the trial is ongoing. Based upon Proietti et al., a systematic review 
of observational studies of apixaban safety in atrial fibrillation patients, we calculated power based on an array of potential 
effect sizes. 1,2 
1.5 Secondary endpoint for replication (assay sensitivity) and RCT finding 
Secondary cardiovascular objectives: 
• 
To assess the frequency of major bleeding events and non-major clinically relevant bleeding events as separate 
outcomes 
Stroke 
All-cause mortality 
• 
• 
1.6 Trial estimate 
The trial is ongoing and scheduled to complete in December of 2025. 
1 
 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
2.  Person responsible for implementation of replication in Aetion 
Luke Zabotka, BA and Mufaddal Mahesri, MD, MPH, implemented the study design in the Aetion Evidence Platform. They are not 
responsible for the validity of the design and analytic choices. All implementation steps are recorded, and the implementation 
history is archived in the platform. 
3. Data Source(s) 
Optum CDM, IBM® MarketScan®, CMS NOAC 
4. Study Design Diagram 
The study design diagram visualizes key aspects of the longitudinal study design for expedited review. 
Figure 1. 
2 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
3 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
5. Cohort Identification 
5.1 Cohort Summary 
An active-comparator, new-user design, propensity score matched, cohort study will be applied to compare patients that received 
apixaban vs. rivaroxaban. Patients will enter the cohort upon initiation of apixaban or rivaroxaban after a 180 day washout without 
anticoagulant exposure. They will be required to have a diagnosis code indicating non-valvular atrial fibrillation in the prior 180 days, 
and be age 18 or older on the date of initiation of therapy. Subjects will be excluded if they have had any indication of stage IV or V 
CKD, ESRD, an active bleeding episode, cancer, obesity, liver disease, or another indication for long-term anticoagulation, such as 
hospitalization for DVT or PE, in the prior 180 days. Patients will also be excluded if they have used any contraindicated medications 
in the prior 180 days or had an indication for atrial fibrillation that was not non-valvular. All patients were required to have 
continuous enrollment for 180 days prior to cohort entry to ensure incident use of the study drugs. 
5.2 Important steps for cohort formation 
New use of the exposure (apixaban or rivaroxaban) is defined as no use of either drug in the 180 days prior to cohort entry. The 
first eligible cohort entry date will be selected after applying all inclusion-exclusion criteria. 
5.2.1 Eligible cohort entry dates 
The apixaban indication for prevention of stroke or systemic embolism in patients with atrial fibrillation was approved by 
the FDA on December 28th, 2012. Rivaroxaban was initially approved for the same indication on November 4th, 2011. 
■ 
IBM® MarketScan®: Dec 28, 2012 – December 31, 2019 (end of available data) 
■ 
Optum CDM: Dec 28, 2012 – June 30, 2020 (end of available data) 
■ 
CMS NOAC: Dec 28, 2012 – Dec 31, 2017 (end of available data) 
5.2.2 Specify inclusion/exclusion criteria for cohort entry and define the index date 
Inclusion and exclusion criteria were adapted from the trial as closely as possible. Definitions for all inclusion/exclusion are 
provided in Appendix and are summarized in the flowcharts below. 
5.3 Flowchart of the study cohort assembly 
For Apixaban vs. Rivaroxaban 
4 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
5 
 
Optum CDM 
IBM® MarketScan® 
CMS - NOAC 
 
Less 
Excluded 
Patients 
Remaining Patients 
 
Less 
Excluded 
Patients 
Remaining 
Patients 
Less 
Excluded 
Patients 
Remaining 
Patients 
All patients in our database 
 
81,796,156 
 
205,537,714  
6,886,908 
Patients with 
Apixaban/Rivaroxaban [measured 
between Dec 28, 2012 and June 30, 
2020.] 
 
856,974 
 
 
685,749 
 
 
2,232,416 
 
Excluded due to insufficient 
enrollment [-180, 0] 
-118,628 
(14%) 
738,346 
 
-54,038 
(8%) 
631,711 
 
-373,136 
(17%) 
1,859,280 
 
After wash-out for prior use of 
reference (Rivaroxaban) [-180, -1] 
-206,560 
(28%) 
531,786 
 
-211,703 
(34%) 
420,008 
 
-601,148 
(32%) 
1,258,132 
 
After wash-out for prior use of 
exposure (Apixaban) [-180, -1] 
-278,943 
(52%) 
252,843 
 
-170,997 
(41%) 
249,011 
 
-549,695 
(44%) 
708,437 
 
Excluded because patient qualified 
in >1 exposure category 
-13 (<1%) 
 
252,830 
 
-24 (<1%) 
 
248,987 
 
-54 (<1%) 
 
708,383 
 
Exclusion of Missing Age [-180, 0] 
-7 (<1%) 
252,823 
-0 (<1%) 
248,987 
-151 (<1%) 
708,232 
Exclusion of Gender (Exclude 
Missing Values) [start of all available 
data, 0] 
-17 (<1%) 
 
252,806 
 
-0 (<1%) 
 
248,987 
 
-- 
 
-- 
 
Inclusion of Age >= 18 [0,0] 
-170 (<1%) 
252,636 
-415 (<1%) 
248,572 
-- 
-- 
Inclusion of Non-Valvular A-fib [- 
180,0] 
-104,252 
(41%) 
148,384 
 
-132,025 
(53%) 
116,547 
 
-264,650 
(37%) 
443,581 
 
Exclusion of Anticoagulant Use [- 
180, 0] 
-7,414 (5%) 
 
140,970 
 
-6,140 (5%) 
 
110,407 
 
-34,042 
(8%) 
409,539 
 
Exclusion of CKD Stage 4/5 or ESRD 
[-180,0] 
-2,876 (2%) 
 
138,094 
 
-994 (<1%) 
 
109,413 
 
-7,617 (2%) 
 
401,922 
 
Exclusion of Dialysis or Renal 
Transplant) [-180, 0] 
-158 (<1%) 
 
137,936 
 
-119 (<1%) 
 
109,294 
 
-421 (<1%) 
 
401,501 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
*CMS cell suppression policies may result in omitted data 
6. Variables 
6.1 Exposure-related variables: 
Study drug: 
The study exposure of interest is defined by a prescription drug claim indicating apixaban dispensation. New initiation will be 
defined by no such records of apixaban in the prior 180 days before treatment initiation (washout period) and fulfillment of study 
eligibility criteria. 
Comparator agent: 
6 
Exclusion of Bleeding History [-180, 
0] 
-2,721 (2%) 
 
135,215 
 
-3,332 (3%) 
 
105,962 
 
-23,500 
(6%) 
378,001 
 
Exclusion of Cancer [-180,0] 
 
-5,556 (4%) 
 
129,659 
 
-3,177 (3%) 
 
102,785 
 
-14,538 
(4%) 
363,463 
 
Exclusion of Weight > 120 kg [-180, 
0] 
-6,963 (5%) 
 
122,696 
 
-3,322 (3%) 
 
99,463 
 
-10,521 
(3%) 
352,942 
 
Exclusion of Significant Liver 
Disease [-180, 0] 
-1,781 (1%) 
 
120,915 
 
-892 (<1%) 
 
98,571 
 
-3,233 
(<1%) 
349,709 
 
Exclusion of Use of Contraindicated 
Medications [-180, 0] 
-693 (<1%) 
 
120,222 
 
-596 (<1%) 
 
97,975 
 
-2,762 
(<1%) 
346,947 
 
Exclusion of Dual Antiplatelet 
Therapy [-180,0] 
-3,219 (3%) 
 
117,003 
 
-2,642 (3%) 
 
95,333 
 
-9,829 (3%) 
 
337,118 
 
Exclusion of Other Heart Conditions 
[-180,0] 
-3,603 (3%) 
 
113,400 
 
-3,056 (3%) 
 
92,277 
 
-7,962 (2%) 
 
329,156 
 
Exclusion of Other Indication of 
Long-Term Anticoagulation [-180, 0] 
-489 (<1%) 
 
112,911 
 
-293 (<1%) 
 
91,984 
 
-1,447 
(<1%) 
327,709 
 
Exclusion of Pregnancy [-180,0] 
-3 (<1%) 
112,908 
-4 (<1%) 
91,980 
-- 
-- 
Exclusion of Coagulopathy [-180,0] 
-958 (<1%) 
111,950 
-320 (<1%) 
91,660 
-- 
-- 
Final cohort 
 
111,950 
 
91,660 
 
325,926 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
The comparator is defined by a prescription drug claim indicating rivaroxaban dispensation. New initiation will be defined by no such 
records of rivaroxaban in the prior 180 days before treatment initiation (washout period) and fulfillment of study eligibility criteria. 
6.2 Preliminary Covariates: 
• 
• 
• 
Age 
Gender 
CCI score 
The covariate listed above represents only a small subset of the covariate vector that will ultimately be controlled for in the 
design and analysis. We use the covariates above only for initial feasibility analyses to judge whether there is likely to be 
sufficient overlap between treatment groups to proceed with the study. Remaining covariates are defined only after the study 
has passed the initial feasibility analysis and the initial power assessment and are listed in Table 1 (Appendix B). 
6.3 Outcome variables and study follow-up: 
6.3.1 Outcome variables 
Safety outcome variables of interest (definitions provided in Appendix): 
■ 
Primary outcome: Major bleeding and clinically relevant non-major bleeding through 365 days of treatment with 
apixaban or rivaroxaban. 
Secondary outcomes: 
o To assess the frequency of major bleeding events and clinically relevant non-major bleeding individually 
o To assess the frequency of intracranial and extracranial bleeding events 
o Stroke 
o All-cause mortality 
■ 
6.3.2 Study follow-up 
7 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
Both as-treated (AT) and intention-to-treat (ITT) analyses will be conducted with treatment defined as the index drug on day of 
cohort entry. The as-treated will be the primary analysis. An allowable gap of 10 days between records indicating each treatment will 
qualify as “continuous therapy” with respect to follow-up in the as-treated analysis. 
The follow-up will start the day after drug initiation (i.e., cohort entry date), and will continue until the earliest date of the following 
events: 
• 
• 
• 
• 
• 
• 
• 
• 
The first occurrence of the outcome of interest 
The date of end of continuous registration in the database 
End of the study period at 365 days 
Measured death event occurs 
Switch 
Discontinuation (10-day allowable grace period and risk window) 
Nursing home admission 
Initiation of another anticoagulant (dabigatran, heparin, warfarin, etc.) 
In the secondary ITT analysis, we will not censor for discontinuation, switching among study drugs, or addition of other 
anticoagulants 
7. Initial Feasibility Analysis 
Aetion report name: 
For apixaban vs. rivaroxaban 
Optum CDM - https://bwh-dope.aetion.com/projects/details/1813/rwrs/78411 
IBM® MarketScan®- https://bwh-dope.aetion.com/projects/details/1814/rwrs/78632 
CMS NOAC - https://bwh-dope.aetion.com/projects/details/1814/rwrs/78632 
Date conducted: 01/28/2022 
Complete Aetion feasibility analysis using age, gender, and CCI as the only covariates and the primary endpoint (Section 6.3.1) as the 
outcome. No measures of association will be computed, nor will incidence rates be stratified by treatment group. 
• 
Report patient characteristics by treatment group 
8 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
■ 
Apixaban vs Rivaroxaban 
9 
 
Optum CDM 
IBM® MarketScan® 
CMS - NOAC 
 
Variable 
 
Rivaroxaban 
- 
Comparator 
Apixaban - 
Exposure 
 
Difference 
 
Rivaroxaban 
- Comparator 
Apixaban 
- Exposure 
 
Difference 
 
Rivaroxaban 
- 
Comparator 
Apixaban - 
Exposure 
 
Difference 
 
Number 
of patients 
39,628 
 
72,322 
 
 
41,932 
 
49,503 
 
 
148,933 
 
176,546 
 
 
Age 
 
 
 
 
 
 
 
 
 
...mean 
(sd) 
71.62 (10.97) 
 
74.33 (10.15) 
 
-2.71 (-2.84, 
-2.58) 
66.38 (12.81) 
 
68.13 
(13.18) 
-1.75 (-1.92, 
-1.58) 
76.19 (8.31) 
 
77.68 (8.32) 
 
-1.49 (-1.55, 
-1.44) 
...median 
[IQR] 
73.00 [66.00, 
80.00] 
75.00 [68.00, 
82.00] 
 
65.00 [58.00, 
76.00] 
67.00 
[59.00, 
79.00] 
 
76.00 [70.00, 
82.00] 
77.00 [72.00, 
84.00] 
 
Gender 
 
 
 
 
 
 
 
 
 
 
M 
 
22,048 
(55.6%) 
35,362 
(48.9%) 
6.7% (6.1%, 
7.4%) 
25,981 (62.0%) 
28,450 
(57.5%) 
4.5% (3.8%, 
5.1%) 
69,102 
(46.4%)  
74,655 (42.3%) 
4.1% (3.8%, 
4.5%) 
F 
 
17,580 
(44.4%) 
36,960 
(51.1%) 
-6.7% (- 
7.4%, -6.1%) 
15,951 (38.0%) 
21,053 
(42.5%) 
-4.5% (- 
5.1%, -3.8%) 
79,831 
(53.6%) 
101,891 
(57.7%) 
-4.1% (- 
4.5%, -3.8%) 
U 
 
 
 
 
 
 
 
 
 
 
CCI (180 
Days 
 
 
 
 
 
 
 
 
 
... mean 
(sd) 
2.18 (2.11) 
 
2.63 (2.37) 
 
-0.45 (-0.48, 
-0.42) 
1.53 (1.58) 
 
1.80 (1.80) 
 
-0.27 (-0.29, 
-0.24) 
1.83 (1.81) 
 
2.04 (1.95) 
 
-0.21 (-0.22, 
-0.20) 
...median 
[IQR] 
2.00 [1.00, 
3.00] 
2.00 [1.00, 
4.00] 
 
1.00 [0.00, 
2.00] 
1.00 [0.00, 
3.00] 
 
1.00 [0.00, 
3.00] 
2.00 [1.00, 
3.00] 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
• 
Report summary parameters of study population FEASIBILITY- FOR STUDY OUTCOME 
■ 
For Apixaban vs Rivaroxaban 
• 
Report median follow-up time by treatment group 
■ 
For Apixaban vs Rivaroxaban 
• 
Report reasons for censoring in the overall study population 
10 
FOLLOW-UP TIME FOR STUDY OUTCOME 
Median Follow-Up Time (Days) [IQR] – At 10 days gap 
Patient Group 
Optum CDM IBM® MarketScan® 
CMS - NOAC 
Overall Patient Population 
98 [38, 235] 
98 [38, 222] 
98 [38, 222] 
Referent - Rivaroxaban 
98 [38, 222] 
98 [38, 219] 
98 [38, 219] 
Exposure - Apixaban 
98 [38, 243] 
98 [38, 225] 
98 [38, 226] 
FEASIBILITY FOR STUDY OUTCOME 
 
Optum CDM 
IBM® MarketScan® 
CMS - NOAC 
Number of patients in full cohort 
111,950 
91,660 
325,926 
Number of patients dropped as incomplete cases 
0 
0 
0 
Number of patients that did not begin follow-up 
115 
225 
447 
Number of patients in analytic cohort 
111,835 
91,435 
325,489 
Number of events 
2,226 
2,570 
17,135 
Number of person-years 
44,062.25 
35,513.75 
126,012.26 
Number of patients in group: Rivaroxaban - Comparator 
39,574 
41,932 
148,933 
Number of patients in group: Apixaban - Exposure 
72,261 
49,503 
176,546 
Risk per 1,000 patients 
19.9 
28.11 
52.65 
Rate per 1,000 person-years 
50.52 
72.37 
135.98 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
■ 
For Apixaban vs Rivaroxaban 
• Report overall risk of the primary outcome. 
8. Initial Power Assessment 
Aetion report name: 
■ 
For Apixaban vs Rivaroxaban 
• 
Optum CDM - https://bwh-dope.aetion.com/projects/details/1813/rwrs/78412 
• 
• 
IBM® MarketScan®- https://bwh-dope.aetion.com/projects/details/1814/rwrs/78633 
CMS NOAC - https://bwh-dope.aetion.com/projects/details/1831/rwrs/78415 
Date conducted: 01/21/2022 and 01/28/2022 
In order to complete the initial power analysis, a dummy outcome indicating a 90-day gap in database enrollment will be used. This 
11 
 
Optum CDM 
IBM® MarketScan® 
CMS - NOAC 
Pooled 
Risk per 1,000 patients 
20.2089659 
27.7425893 
53.4783969 
41.4990646 
CENSORING REASONS FOR STUDY OUTCOME 
Reasons 
Optum CDM IBM® MarketScan® 
CMS - NOAC 
Outcome 
2,226 (2.0%) 
2,570 (2.8%) 
17,135 (5.3%) 
Death 
852 (0.8%) 
38 (0.0%) 
3,744 (1.2%) 
Start of an additional exposure 
1,423 (1.3%) 
1,250 (1.4%) 
5,584 (1.7%) 
End of index exposure 
71,747 (64.2%) 
55,668 (60.9%) 
189,840 (58.3%) 
Maximum follow-up time reached 
16,894 (15.1%) 
12,797 (14.0%) 
42,722 (13.1%) 
End of patient data 
18 (0.0%) 
5,277 (5.8%) 
38,454 (11.8%) 
End of patient enrollment 
5,827 (5.2%) 
11,391 (12.5%) 
4,681 (1.4%) 
Other Anticoagulant Use + Nursing Home Admission 
12,848 (11.5%) 
2,444 (2.7%) 
23,319 (7.2%) 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. A 1:1 
PS-matched comparative analysis was performed, including age, gender, and CCI score as the only covariates. Power calculations are 
based on the formulas from Chow et al. (2008). 
• 
Stop analyses until feasibility and power are reviewed by primary investigators and FDA. Reviewers evaluate the results of the 
analyses described above in Sections 7 and 8, including numbers of patients, patient characteristics, follow-up time, and reasons 
for censoring by treatment group, as well as overall rates of outcomes and study power. These parameters are re-evaluated and 
reported in the subsequent sections, after incorporating feedback and refining the protocol. 
This emulation is of a trial that is not yet completed. The trial investigators have not published their power calculations. Therefore, we 
present a range of power calculations for different effect sizes given the feasibility counts and an alpha of 0.05. The range in potential 
hazard rations comes from a meta- analysis of safety and efficacy studies of apixaban in patients with atrial fibrillation (Proietti et al. 
2017). The target enrollment for the trial is 3,028 participants. We anticipate a pooled analytic cohort of 529,536 subjects. 
1. Pooled 
2. Optum CDM 
12 
Superiority Analysis - Pooled 
 
 
 
 
 
Number of patients matched 
454,312 
454,312 
454,312 
454,312 
454,312 
Reference 
227,156 
227,156 
227,156 
227,156 
227,156 
Exposure 
227,156 
227,156 
227,156 
227,156 
227,156 
Risk per 1,000 patients 
41.4155034 
41.4155034 
41.4155034 
41.4155034 
41.4155034 
Alpha (2-sided 
0.05 
0.05 
0.05 
0.05 
0.05 
 
 
 
 
 
 
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected 
18815.5602 
18815.5602 
18815.5602 
18815.5602 
18815.5602 
Power 
1 
1 
1 
1 
1 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
3. IBM® MarketScan® 
4. CMS – NOAC 
13 
Superiority Analysis – CMS NOAC 
 
 
 
 
 
Number of patients matched 
292,620 
292,620 
292,620 
292,620 
292,620 
Superiority Analysis - MarketScan 
 
 
 
 
 
Number of patients matched 
82,730 
82,730 
82,730 
82,730 
82,730 
Reference 
41,365 
41,365 
41,365 
41,365 
41,365 
Exposure 
41,365 
41,365 
41,365 
41,365 
41,365 
Risk per 1,000 patients 
28.0384028 
28.0384028 
28.0384028 
28.0384028 
28.0384028 
Alpha (2-sided 
0.05 
0.05 
0.05 
0.05 
0.05 
 
 
 
 
 
 
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected 
2319.61706 
2319.61706 
2319.61706 
2319.61706 
2319.61706 
Power 
0.99967945 
1 
1 
1 
1 
Superiority Analysis - Optum 
 
 
 
 
 
Number of patients matched 
78,962 
78,962 
78,962 
78,962 
78,962 
Reference 
39,481 
39,481 
39,481 
39,481 
39,481 
Exposure 
39,481 
39,481 
39,481 
39,481 
39,481 
Risk per 1,000 patients 
19.8838767 
19.8838767 
19.8838767 
19.8838767 
19.8838767 
Alpha (2-sided 
0.05 
0.05 
0.05 
0.05 
0.05 
 
 
 
 
 
 
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected 
1570.07067 
1570.07067 
1570.07067 
1570.07067 
1570.07067 
Power 
0.99307189 
0.99999984 
1 
1 
1 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
5. Stop analyses until feasibility and power are reviewed by primary investigators, FDA, and assigned members of advisory 
board. 
9. Balance Assessment 
Aetion report name: 
• 
Rivaroxaban versus Apixaban 
o Optum - https://bwh-dope.aetion.com/projects/details/1813/rwrs/79770 
o MarketScan - https://bwh-dope.aetion.com/projects/details/1814/rwrs/79771 
o CMS NOAC - https://bwh-dope.aetion.com/projects/details/1831/rwrs/79772 
Date conducted: 02/25/2022 
After review of initial feasibility and power analyses, complete creation of the remaining covariates from Section 6.2. Again, using the 
14 
Reviewed by PI: 
 
Date reviewed: 
 
Reviewed by FDA: 
 
Date reviewed: 
 
Reasons for stopping 
analysis (if required): 
 
Reference 
146,310 
146,310 
146,310 
146,310 
146,310 
Exposure 
146,310 
146,310 
146,310 
146,310 
146,310 
Risk per 1,000 patients 
52.5732835 
52.5732835 
52.5732835 
52.5732835 
52.5732835 
Alpha (2-sided 
0.05 
0.05 
0.05 
0.05 
0.05 
 
 
 
 
 
 
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected 
23075.9913 
15383.9942 
15383.9942 
15383.9942 
15383.9942 
Power 
1 
1 
1 
1 
1 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
dummy outcome of a 90-day gap in database enrollment, complete a 1:1 PS-matched analysis. The PS should include the complete 
list of covariates. 
6. Provide plot of PS distributions stratified by treatment group. 
a. See Appendix B 
7. Report covariate balance after matching. 
a. See Appendix B 
i. CMS cell suppression policy may result in omitted data 
8. Report reasons for censoring by treatment group. 
9. Report follow-up time by treatment group. 
15 
FOLLOW-UP TIME FOR STUDY OUTCOME 
Median Follow-Up Time (Days) [IQR] – At 10 days gap 
Patient Group 
Optum CDM IBM® MarketScan® 
CMS - NOAC 
Overall Patient Population 
98 [38, 238] 
98 [38, 227] 
98 [38, 228] 
Referent - Rivaroxaban 
98 [38, 225] 
98 [38, 224] 
98 [38, 225] 
Exposure - Apixaban 
98 [38, 245] 
98 [38, 231] 
98 [38, 231] 
Censoring Reasons for Study Outcome 
Reasons 
Overall 
Referent 
Exposure 
Death 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
Start of an additional exposure 
5,906 (1.1%) 
2,416 (1.0%) 
3,490 (1.2%) 
End of index exposure 
8,557 (1.6%) 
4,649 (2.0%) 
3,908 (1.3%) 
Maximum follow-up time 
328,427 (62.1%) 
147,012 (63.8%) 
181,415 (60.8%) 
End of patient data 
74,371 (14.1%) 
31,658 (13.7%) 
42,713 (14.3%) 
End of patient enrollment 
44,450 (8.4%) 
16,025 (7.0%) 
28,425 (9.5%) 
Other Anticoagulant Therapy + Nursing Home 
Admission 
22,230 (4.2%) 
9,772 (4.2%) 
12,458 (4.2%) 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
10. Final Power Assessment 
Date conducted: 02/09/2022 
10. Re-calculate power in the appropriate excel table, using the revised number of matched patients from the PS-match in 
Section 9. All other parameters in the table should be the same as in Section 8. 
1. Pooled 
2. Optum CDM 
16 
Superiority Analysis - Optum 
 
 
 
 
 
Number of patients matched 
68,134 
68,134 
68,134 
68,134 
68,134 
Reference 
34,067 
34,067 
34,067 
34,067 
34,067 
Exposure 
34,067 
34,067 
34,067 
34,067 
34,067 
Risk per 1,000 patients 
19.8838767 
19.8838767 
19.8838767 
19.8838767 
19.8838767 
Alpha (2-sided) 
0.05 
0.05 
0.05 
0.05 
0.05 
 
 
 
 
 
 
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Superiority Analysis - Pooled 
 
 
 
 
 
Number of patients matched 
368,214 
368,214 
368,214 
368,214 
368,214 
Reference 
184,107 
184,107 
184,107 
184,107 
184,107 
Exposure 
184,107 
184,107 
184,107 
184,107 
184,107 
Risk per 1,000 patients 
41.4155034 
41.4155034 
41.4155034 
41.4155034 
41.4155034 
Alpha (2-sided) 
0.05 
0.05 
0.05 
0.05 
0.05 
 
 
 
 
 
 
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected 
15249.7682 
15249.7682 
15249.7682 
15249.7682 
15249.7682 
Power 
1 
1 
1 
1 
1 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
3. IBM® MarketScan® 
4. CMS – NOAC 
17 
Superiority Analysis – CMS NOAC 
 
 
 
 
 
Number of patients matched 
238,234 
238,234 
238,234 
238,234 
238,234 
Reference 
119,117 
119,117 
119,117 
119,117 
119,117 
Exposure 
119,117 
119,117 
119,117 
119,117 
119,117 
Risk per 1,000 patients 
52.5732835 
52.5732835 
52.5732835 
52.5732835 
52.5732835 
Alpha (2-sided) 
0.05 
0.05 
0.05 
0.05 
0.05 
 
 
 
 
 
 
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected 
12524.7436 
12524.7436 
12524.7436 
12524.7436 
12524.7436 
Power 
1 
1 
1 
1 
1 
Superiority Analysis - MarketScan 
 
 
 
 
 
Number of patients matched 
61,846 
61,846 
61,846 
61,846 
61,846 
Reference 
30,923 
30,923 
30,923 
30,923 
30,923 
Exposure 
30,923 
30,923 
30,923 
30,923 
30,923 
Risk per 1,000 patients 
28.0384028 
28.0384028 
28.0384028 
28.0384028 
28.0384028 
Alpha (2-sided) 
0.05 
0.05 
0.05 
0.05 
0.05 
 
 
 
 
 
 
Desired HR from RCT 
0.8 
0.7 
0.6 
0.5 
0.4 
Number of events expected 
1734.06306 
1734.06306 
1734.06306 
1734.06306 
1734.06306 
Power 
0.99638561 
0.99999998 
1 
1 
1 
Number of events expected 
1354.76806 
1354.76806 
1354.76806 
1354.76806 
1354.76806 
Power 
0.98409053 
0.99999793 
1 
1 
1 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
• 
Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of 
advisory board. 
11. Study Confidence and Concerns 
Deadline for voting on study confidence and listing concerns: 
Date votes and concerns are summarized: 
• 
• 
If final feasibility and power analyses are reviewed and approved, proceed to the remaining protocol steps. 
All study team and advisory board members that review this protocol should at this stage provide their level of confidence for the 
success of the RWD study in the Google Form. This form also provides space for reviewers to list any concerns that they feel may 
contribute to a failure to replicate the findings of the RCT, including differences in study populations, poor measurement of study 
variables, or residual confounding. All responses will be kept confidential and individual-level results will only be shared with the 
individual respondent. 
After the deadline for voting has passed, provide the distribution of responses and summarize all concerns here. 
• 
12. Register study protocol on clinicalTrials.gov 
Date conducted: 
• Register the study on clinicalTrials.gov and upload this document. 
13. Comparative Analyses 
Aetion report name: 
Date conducted: 
18 
Reviewed by PI: 
 
Date reviewed: 
 
Reviewed by FDA: 
 
Date reviewed: 
 
Reasons for stopping 
analysis (if required): 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
13.1 
For primary analysis: 
13.2 
For sensitivity analyses: 
14. Requested Results 
14.1 
Table 1: Baseline characteristics before and after adjustment 
14.2 
Table 2: Follow-up time 
14.3 
Table 3: Censoring events 
19 
 
Overall 
Referent 
Exposure 
Patient Group 
Median Follow-Up Time (Days) [IQR] 
Overall Patient Population 
 
Referent 
 
Exposure 
 
Variable 
 
Before adjustment 
After adjustment 
Referent 
Exposure 
Std. diff. 
Referent 
Exposure 
Std. diff. 
Number of patients  
 
- 
 
 
- 
Age categories 
 
 
 
 
 
 
… 
 
 
 
 
 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
14.4 
Table 4: Results from primary analyses; 
HR, Hazard Ratio; CI, Confidence Interval. 
14.5 
Table 5: Results from secondary analyses; 
15. References 
1. Chow S, Shao J, Wang H. 2008. Sample Size Calculations in Clinical Research. 2nd Ed. Chapman & Hall/CRC Biostatistics 
Series. page 177 
2. Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-World Use of Apixaban for Stroke Prevention in Atrial 
Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2018 Jan;49(1):98-106. doi: 10.1161/STROKEAHA.117.018395. 
Epub 2017 Nov 22. PMID: 29167388. 
20 
Analysis 
 
No. exposed events 
 
No. referent events 
 
Exposed rate 
 
Referent rate 
 
HR (95% CI) 
 
Crude 
 
 
 
 
 
Analysis 1 
 
 
 
 
 
Analysis 2 
 
 
 
 
 
... 
 
 
 
 
 
Outcome 
 
 
 
Death 
 
 
 
Start of an additional exposure 
 
 
 
End of index exposure 
 
 
 
Specified date reached 
 
 
 
End of patient data 
 
 
 
End of patient enrollment 
 
 
 
… 
 
 
 
 
 

 
# 
COBRRA - AF trial definitions 
Implementation in routine care 
References/Rationale 
Color coding 
 
 
 
Please see the following Google Drive for further details or any missing information: https://drive.google.com/drive/folders/1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV?usp=sharing 
 
 
 
 
ICD-10 codes are not listed in this document because of excel cell size limitations and excessive number of ICD-10 codes. Full ICD-10 code lists will be available in the above Google Drive Folder (link 
above). ICD-9 to ICD-10 code conversions were completed using a SAS macro that implements forward/ backward mapping based on the CMS ICD-9 to ICD-10 mapping 
 
 
TRIAL DETAILS 
Criteria 
EXPOSURE vs. COMPARISON 
Can be replicated in claims 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
2 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
 
Apixaban 5 mg PO, twice daily for 12 months of treatment. A dose reduction to 2.5 mg twice daily will apply if 
patients meet 2 of the following 3 criteria: age > 80 years, weight , 60 kg; creatinine > 133 micromol/L 
vs. 
Rivaroxaban 20 mg PO, once daily for 12 months of treatment. A dose reduction to 15 mg daily will apply to patients 
with creatinine clearance < 50 ml/min 
 
*Patients with AF who are receiving DOAC should have their renal function assessd at baseline and at least annually 
 
 
 
 
Apixaban: 
vs. 
Rivaroxaban: 
 
 
 
 
 
 
 
Using dummy definitions 
for measuring in claims 
 
 
PRIMARY OUTCOME 
 
 
Can't be measured in claims 
 
 
 
 
The rate of adjudicated clinically relevant bleeding (CRB) events [Time frame: For the duration of the study: 12 
months] CRB events are defined as the compsoite of major bleeding (MB) events and clinically relevant non-major 
bleeding (CRNMB) events 
 
Mesaured [0, 365] in any diagnosis position in an inpatient setting (transfusion codes required for non-critical sites) 
 
Major Bleeding: 
See "Major Bleeding" Sheet 
 
Measured [0, 365] in any diagnosis position in an inpatient setting (transfusion codes not required for non-critical sites) 
Clinically Relevant Non-Major Bleeding Events: 
See "CRNM Bleeds Sheet" 
 
Graham DJ, Reichman ME, Wernecke M, et al. 
Stroke, Bleeding, and Mortality Risks in Elderly 
Medicare Beneficiaries Treated With 
Dabigatran or Rivaroxaban for Nonvalvular 
Atrial Fibrillation. JAMA Intern 
                             
doi:10.1001/jamainternmed.2016.5954 
 
 
 
 
Can't be measured in claims 
but not important for the 
analysis 
 
INCLUSION CRITERIA 
 
 
 
Confirmed new diagnosis of AF on ECG with an indication to start anticoagulation according to Canadian 
Cardiovascular Society guidelines 
Measured [-180, 0] in any diagnosis position in either an inpatient or outpatient care setting 
 
Atrial fibrillation (Non-Valvular) 
ICD-9 Diagnosis: 427.31 
ICD-10 Diagnosis: I48.0, I48.1, I48.2, I48.91 
 
Prescribing guidelines for AF in Canada: 
https://ccs.ca/app/uploads/2020/11/AF_Gui_2 
018_PG_EN_web.pdf 
Age >= 18 years 
Age >= 18 
 
EXCLUSION CRITERIA 
 
 
 
 
Have received >72 hours of thereapeutic anticoagulation 
 
Measured [- 180, 0] in prescription claims 
 
Use of Anticoagulants:  
Adeparin Sodium, Porcine, Argatroban, Argatroban in 0.9% Sodium Chloride, Argatroban in Sodium Chloride, Iso-osmotic, Bivalirudin, Dabigatran Etexilate Mesylate, Dalteparin Sodium Porcine, 
Danaparoid Sodium Porcine, Desirudin, Edoxaban Tosylate, Enoxaparin Sodium, Fonaparinux Sodium, Heparin Sodium Beef, Heparin Sodium Porcine (0.45% NaCl, 0.9% NaCl, 0.9% NaCl/PF), 
Heparin Sodium Porcine/Dextrose (5% in water or 5% in water/PF), Heparin Sodium Procine/PF, Lepirudin Recombinant, Tinzaparin Sodium Porcine, and Warfarin Sodium 
 
 
 
 
 
Creatine clearance < 15 ml/min calculated with the Cockcroft-Gault formula 
 
Measured [-180, 0 ] in any diagnosis position and inpatient or outpatient care setting 
 
CKD stage 4/5/ESRD 
ICD-9 Diagnosis: 584.4x, 585.5x, 585.6x 
ICD-10 Diagnosis: N18.4x, N18.5x, N18.6x 
 
Dialysis/Renal Transplant 
See Sheet "Dialysis and Renal Transplant" 
 
 
Any contradiction for anticoagulation with apixaban or rivaroxaban as determined by the treating physician such as, 
but not limited to one of the following: 
 
 
 
 
 
 
 
 
1) Active Bleeding 
 
Mesaured [-180, 0 ] in any diagnosis position and in an inpatient setting (transfusion codes required for non-critical sites) 
 
Major Bleeding 
See "Major Bleeding" Sheet 
Measured [-180,0] in any diagnosis position in an inpatient setting (transfusion codes not required for non-critical sites) 
Clinically Relevant Non-Major Bleeding Events 
See "CRNM Bleeds Sheet" 
 
 
 
 
 
 
 
 
 
2) Other Indication for anticoagulation (e.g. mechanical valves, venous thromosis) 
 
Measuered [-180, 0] in any diagnosis position in an inpatient or oupatient setting: 
DVT 
ICD-9 Diagnosis: 451.1x, 451.2x, 451.81, 451.9x, 453.1x, 453.2x, 453.8x, 453.9x, 453.40, 453.41, 453.42, 453.0 
ICD-10 Diagnosis: I80.1x, I80.2, I80.3, I80.9, I82.0, I82.1, I82.2x (except I82.21), I82.4x, I82.6x, I82.890, I82.90, I81.A1x, I82.B1x, I82.C1x 
 
PE 
ICD-9 Diagnosis: 415.1, 415.10, 415.11, 415.12, 415.13, 415.5, 415.16, 417.17, 415.19, 415.199 
ICD-10 Diagnosis: I26.0, I26.01, I26.02, I26.9, I26.92, I26.99, I26.90 
 
Prosthetic Heart Valve 
ICD-9 Diagnosis: V43.3 
ICD-10 Diagnosis: Z95.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A 

6 
7 
8 
9 
10 
11 
 
 
 
3) Dual Antiplatelet Use 
 
Measured [-180, 0] in prescription claims 
 
Use of Antiplaelets 
Any of the following: cilostazol, dipyridamole, ticlopidine HCl, aspirin, clopidogrel bisulfate, prasugrel HCl, ticagerlor, aspirin/dipyridamole, ezetimibe 
 
 
 
 
 
 
 
 
 
 
 
4) Known liver disease with coagulopathy 
 
Measured [-180,0] in any diagnosis position in an inpatient or outpatient setting 
 
Significant Liver Disease 
ICD-9 Diagnosis: 070.xx, 570.xx- 573.xx, 456.0x-456.2x, 576.8x, 782.4x, 789.5x 
ICD -10 Diagnosis: B16.1 ,B17.11 ,B17.2 ,B17.9 ,B18.2 ,B18.8 ,K71.0 ,K71.10 ,K71.2 ,K71.3 ,K71.51 ,K72.01 ,K72.10 ,K73.9 ,K74.3 ,K74.69 ,K75.2 ,K75.81 ,K75.89 ,K76.0 
,K76.1 ,K76.3 ,K76.6 ,K76.89 ,B19.0 ,B19.9 ,I85.11 ,K71.11 ,K71.7 ,K71.9 ,K72.11 ,K74.1 ,K74.4 ,K74.5 ,K75.3 ,K76.7 ,K87 ,R18.8 ,B15.9 ,B16.0 ,B16.2 ,B16.9 ,B18.0 ,B18.9 
,B19.10 ,B19.11 ,K70.10 ,K70.41 ,K71.4 ,K71.50 ,K72.91 ,K74.0 ,K74.2 ,K74.60 ,K75.1 ,K76.2 ,K76.81 ,K83.8 ,R17 ,B15.0 ,B19.21 ,B25.1 ,I85.00 ,K70.0 ,K70.11 ,K70.2 ,K70.9 
,K72.00 ,K72.90 ,K73.1 ,K73.8 ,K75.0 ,K76.9 ,R18.0 ,B17.0 ,B17.10 ,B17.8 ,B18.1 ,B19.20 ,I85.01 ,I85.10 ,K70.30 ,K70.31 ,K70.40 ,K71.6 ,K71.8 ,K73.0 ,K73.2 ,K75.4 ,K75.9 
,K76.4 ,K76.5 ,K77 ,K83.5 
ICD-9 Procedure: 39.1x, 42.91 
ICD-10 Procedure: See "Liver Bypass" Sheet 
 
Coagulopathy 
ICD-9 Diagnosis: 286, 286.1, 286.4, 286.5, 286.52, 286.53, 286.59, 287.5, 286.0, 286.2, 286.3, 286.6, 286.7, 286.9, 287.1, 287.3, 287.4 
 
ICD-10 Dignosis: D67, D68, D68.1, D68.2, D68.3, D68.31, D68.311, D68.318, D68.4, D68.52, D68.61, D68.69, D68.8, D69.41, D69.49, D69.51, D69.59, D65, D66, D68.0, 
D68.312, D68.32, D68.5, D68.51, D68.59, D68.6, D68.62, D68.9, D69.1, D69.3, D69.4, D69.42, D69.5, D69.6 
 
 
 
 
 
 
 
5)Use of contraindicated medications (strong inducers/inhibitors of CYP 3A4/5, P-glycoprotein) 
 
Measured [-180, 0] in prescription claims 
 
Strong CYP3A4 Inhibitors/Inducers 
Inhibitors: Ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir 
Inducers: Rifampin, rifampicin/rifampin, phenytoin, carbamazepine 
 
P-gp Inhibitors/Inducers 
cobicistat, conivaptan, tipranavir 
 
 
 
 
 
 
 
 
 
https://depts.washington.edu/anticoag/home/ 
content/apixaban 
 
 
 
 
 
6) Pregnancy 
Measured [-180, 0] in any diagnosis position and inpatient and outpatient care setting 
 
Pregnancy 
See "Pregnancy" Sheet 
 
 
 
7) Active malignancy, defined as a) diagnosed with cancer within the past 6 months; or b) recurrent, regionally 
advanced or metastatic disease; or c) currently receiving treatment or have received any treatment for cancer during 
the 6 months prior to randomization; or d) a hematologic malignancy not in complete remission 
Measured [-180, 0] in any diagnosis position in an inpatient or outpatient setting 
 
Cancer 
ICD-9 Diagnosis: 140.x-209.x (except 209.4x, 209.5x, 209.6x) 
ICD-10 Diagnosis: C00.x-C96, D45 
For full list, see "Cancer Sheet" 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8) Weight > 120 kg 
 
Measured [-180,0] in any diagnosis position in an inpatient or outpatient setting: 
 
Bypass Surgery 
HCPCS: 43659, 43999, 43842, S2082, 43644, 43645, 43770, 43843, 43845, 43846, 43847 
ICD-9 Procedure: 43.89, 44.69, 44.31, 44.39, 44.95, 45.51, 45.91, 43.82, 44.38, 44.68 
ICD-10 Procedure: 0D160JB, 0D160KL, 0D160Z9, 0D164JL, 0D1687L, 0D168JB, 0D168Z9, 0D168ZL, 0D190ZA, 0D194J9, 0D194K9, 0D194ZA, 0D198K9, 0D198ZA, 0D1A0JB, 0D1A0ZB, 0D1A87A, 
0D1A8JB, 0D1A8KA, 0D1A8KB, 0D1B4JB, 0D1B4KB, 0D1B8JB, 0D760DZ, 0DB63Z3, 0DB67ZZ, 0DB90ZZ, 0DM64ZZ, 0DN67ZZ, 0DQ64ZZ, 0DV60CZ, 0DV63CZ, 0D16079, 0D1607A, 0D1607L, 
0D160ZL, 0D164J9, 0D164KA, 0D164KL, 0D1687A, 0D168J9, 0D168ZA, 0D190K9, 0D190KB, 0D19479, 0D1947B, 0D194JA, 0D194KB, 0D1987A, 0D198ZB, 0D1A07A, 0D1A0KB, 0D1A47A, 
0D1A4KA, 0D1A4ZB, 0D1A8ZA, 0D1A8ZB, 0D1B0JB, 0D763DZ, 0D764ZZ, 0DB60Z3, 0DB67Z3, 0DB68Z3, 0DQ68ZZ, 0DU64KZ, 0DU677Z, 0DU67KZ, 0DU687Z, 0DU68JZ, 0DU68KZ, 0DV63ZZ, 
0DV64CZ, 0DV64DZ, 0D164Z9, 0D168JL, 0D168KA, 0D168KB, 0D168ZB, 0D190Z9, 0D1947A, 0D194KA, 0D194ZB, 0D1987B, 0D1A07B, 0D1A0JA, 0D1A4JA, 0D1A4KB, 0D763ZZ, 0D764DZ, 
0DB63ZZ, 0DBB0ZZ, 0DF67ZZ, 0DF68ZZ, 0DN60ZZ, 0DQ60ZZ, 0DU60KZ, 0DU647Z, 0DU64JZ, 0DV60ZZ, 0DV64ZZ, 0D1607B, 0D160JL, 0D160K9, 0D160KA, 0D164JB, 0D1687B, 0D1907B, 0D190J9, 
0D190JB, 0D190ZB, 0D194Z9, 0D198J9, 0D198KA, 0D1A0ZA, 0D1A47B, 0D1A4JB, 0D1A4ZA, 0D1A8JA, 0D1B47B, 0D1B4ZB, 0D1B8KB, 0D1B8ZB, 0D760ZZ, 0DB64Z3, 0DM60ZZ, 0DN63ZZ, 
0DN64ZZ, 0DN68ZZ, 0DU607Z, 0DU60JZ, 0DV60DZ, 0DV63DZ, 0D160J9, 0D160JA, 0D160KB, 0D160ZA, 0D160ZB, 0D16479, 0D1647A, 0D1647B, 0D1647L, 0D164JA, 0D164K9, 0D164KB, 
0D164ZA, 0D164ZB, 0D164ZL, 0D16879, 0D168JA, 0D168K9, 0D168KL, 0D19079, 0D1907A, 0D190JA, 0D190KA, 0D194JB, 0D19879, 0D198JA, 0D198JB, 0D198KB, 0D198Z9, 0D1A0KA, 0D1A87B, 
0D1A8ZH, 0D1B07B, 0D1B0KB, 0D1B0ZB, 0D1B87B, 0D1B8ZH, 0DB60ZZ, 0DB80ZZ, 0DF60ZZ, 0DF63ZZ, 0DF64ZZ, 0DQ63ZZ, 0DQ67ZZ, 0DU67JZ, 0DV67ZZ, 0DV68ZZ 
 
Obesity 
ICD-9 Diagnosis: 539.89, 649.1, V85.36, V85.41, V85.42, 649.10, 649.11, 649.20, 649.23, V85.37, V85.44, 278.01, 278.03, 539, 649.13, 649.14, 649.2, 649.22, 649.24, V85.31, V85.34, V85.35, 
V85.43, 278.0, 278.00, 539.09, 539.8, 539.81, 649.12, 649.21, V85.38, V85.39, 539.0, 539.01, V85.30, V85.32, V85.33, V85.45 
ICD-10 Diagnosis: O99.215, Z68.41, O99.210, O99.214, O99.844, Z68.35, Z68.38, Z68.43, Z68.45, O99.845, Z68.32, Z68.33, Z68.36, O99.212, O99.841, O99.842, Z68.34, Z68.37, Z68.42, 
O99.211, O99.213, O99.840, O99.843, Z68.30, Z68.31, Z68.39, Z68.44 
 
Weight Loss and Appetite Supressors 
                                                                                                                                                        
FENFLURAMINE HCL, DIETHYLPROPION HCL, PHENDIMETRAZINE TARTRATE, PHENTERMINE HCL 
 
 
 
 
 
 
 
 
 
Appendix A 

12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9) Other Heart Conditions 
Measured [-180, 0] in any diagnosis position and inpatient and outpatient care setting 
 
Mitral Stenosis 
ICD-9 Diagnosis: 394.0 
ICD-10 Diagnosis: I05.0 
 
Mitral Rheumatic Insufficiency 
ICD-9 Diagnosis: 394.1 
ICD-10 Diagnosis: I05.1 
 
Mitral Stenosis with Insufficiency 
ICD-9 Diagnosis: 394.2 
ICD-10 Diagnosis: I05.2 
 
Other and Unspecified Mitral Valve Disorders 
ICD-9 Diagnosis: 394.9 
ICD-10 Diagnosis: I05.9, I05.8 
 
Prosthetic Heart Valve 
ICD-9 Diagnosis: V43.3 
ICD-10 Diagnosis: Z95.2 
 
 
 
 
 
 
 
 
Appendix A 

 
Information from Trial 
 
Trial Name: COBRRA - AF https://clinicaltrials.gov/ct2/show/NCT04642430 
NCT: NCT04642430 
Therapeutic Area: Cardiology 
 
RCT Category: Equivalence/Superiority 
Brand Name: Eliquis and Xarelto 
Generic Name: Apixaban and Rivaroxaban 
Sponsor: Ottwa Hospital Research Institute 
Year: 2020 - Present 
Measurable Endpoint: Major Bleeding and Clinically Relevant Non-Major Bleeding 
Exposure: Apixaban 
Comparator: Rivaroxaban 
 
Populuation: Men and women ages 18 and older presenting with AF 
No. of Patients: 3,018  
Power: TBD 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A 

ICD-9 Dx 
336.1 
363.61 
363.62 
376.32 
377.42 
379.23 
431 
432 
432 
432.1 
432.9 
719.1 
719.11 
719.12 
719.14 
719.15 
719.17 
719.19 
729.92 
852 
852 
852.01 
852.03 
852.05 
852.06 
852.09 
852.1 
852.11 
852.12 
852.15 
852.19 
852.2 
852.22 
852.25 
852.3 
852.3 
852.31 
852.32 
852.33 
852.34 
852.35 
852.42 
852.43 
852.45 
852.49 
852.54 
853 
853 
853.01 
853.03 
853.04 
853.05 
853.1 
853.11 
853.12 
853.13 
853.14 
853.15 
866.02 
VASCULAR MYELOPATHIES 
CHOROIDAL HEMORRHAGE UNSPECIFIED 
EXPULSIVE CHOROIDAL HEMORRHAGE 
ORBITAL HEMORRHAGE 
HEMORRHAGE IN OPTIC NERVE SHEATHS 
VITREOUS HEMORRHAGE 
INTRACEREBRAL HEMORRHAGE 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE 
NONTRAUMATIC EXTRADURAL HEMORRHAGE 
SUBDURAL HEMORRHAGE 
UNSPECIFIED INTRACRANIAL HEMORRHAGE 
HEMARTHROSIS 
HERARTHROSIS INVOLVING SHOULDER REGION 
HEMARTHORSIS INVOLVING UPPER ARM 
HEMARTHROSIS INVOLVING HAND 
HEMARTHROSIS INVOLVING PELVIC REGION AND THIGH 
HEMARTHROSIS INVOLVING ANKLE AND FOOT 
HEMARTHROSIS INVOLVING MULTIPLE SITES 
NONTRAUMATIC HEMATOMA OF SOFT TISSUE 
SUBARACHNOID SUBDURAL AND EXTRADURAL HEMORRHAGE FOLLOWING INJURY 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE (1 - 24 HOURS) LOSS OF CONSCIOUSNESS) 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN 1 HOUR) LOSS OF CONSCIOUSNESS 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-24 HOURS) LOSS OF CONSCIOUSNESS-EXISTING CONSCIOUS LEVEL 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED( MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
LACERATION OF KIDNEY WITHOUT OPEN WOUND INTO CAVITY 
Appendix A 

HEMORRHAGIC CHOROIDAL DETACH 
HEMOPERICARDIUM 
SUBARACHNOID HEMORRHAGE 
HEMOPERITONEUM (NONTRAUMATIC) 
HEMARTHROSIS SITE UNSPECIFIED 
HEMARTHROSIS INVOLVING FOREARM 
HEMARTHROSIS INVOLVING LOWER LEG 
HEMARTHROSIS INVOLVING OTHER SPECIFIED SITES 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION 
SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION 
EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION 
OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED 
HEMATOMA OF KIDNEY WITHOUT RUPTURE OF CAPSULE WITHOUT OPEN WOUND INTO CAVITY 
HEMATOMA OF KIDNEY WITHOUT RUPTURE OF CAPSULE WITH OPEN WOUND INTO CAVITY 
LACERATION OF KIDNEY WITH OPEN WOUND INTO CAVIT 
of Inpatient Confinement with the following attributes: 
is any of: { "99.05", "99.03", "99.04", "99.06" } 
TRANSFUSION OF PLATELETS 
OTHER TRANSFUSION OF WHOLE BLOOD 
TRANSFUSION OF PACKED CELLS 
TRANSFUSION OF COAGULATION FACTORS 
363.72 
423 
430 
568.81 
719.1 
719.13 
719.16 
719.18 
852 
852.02 
852.04 
852.1 
852.13 
852.14 
852.16 
852.2 
852.21 
852.23 
852.24 
852.26 
852.29 
852.36 
852.39 
852.4 
852.4 
852.41 
852.44 
852.46 
852.5 
852.5 
852.51 
852.52 
852.53 
852.55 
852.56 
852.59 
853 
853.02 
853.06 
853.09 
853.1 
853.16 
853.19 
866.01 
866.11 
866.12 
 
The occurrence
Procedure 
Code (Any 
Confinement 
Position) 
99.05 
99.03 
99.04 
99.06 
AND 
ICD-9 Dx 
Appendix A 

455.1 INTERNAL THROMBOSED HEMORRHOIDS 
455.7 UNSPECIFIED THROMBOSED HEMORRHOIDS 
455.8 UNSPECIFIED HEMORRHOIDS WITH OTHER COMPLICATION 
455.9 RESIDUAL HEMORRHOIDAL SKIN TAGS 
459 HEMORRHAGE UNSPECIFIED 
530.1 ESOPHAGITIS 
530.1  ESOPHAGITIS UNSPECIFIED 
530.13 EOSINOPHILIC ESOPHAGITIS 
530.19 OTHER ESOPHAGITIS 
530.7 GASTROESOPHAGEAL LACERATION-HEMORRHAGE SYNDROME 
530.82 ESOPHAGEAL HEMORRHAGE 
531 ACUTE GASTRIC ULCER WITH HEMORRHAGE 
531.01 ACUTE GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION 
531.2 ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
531.21 ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
531.3 ACUTE GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
531.4 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 
531.5 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH PERFORATION 
531.6 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
531.61 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
531.7 CHRONIC GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
531.9 GASTRIC ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
532 ACUTE DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 
532.01 ACUTE DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION 
532.1 ACUTE DUODENAL ULCER WITH PERFORATION 
532.3 ACUTE DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
532.4 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE 
532.41 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION 
532.5 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH PERFORATION 
532.9 DUODENAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
533.1 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH PERFORATION 
533.2 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION 
533.21 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
533.4 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION 
533.41 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION 
533.5 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH PERFORATION 
533.6 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION 
533.9 PEPTIC ULCER OF UNSPECIFIED SITE UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
534 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE 
534.2 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION 
534.21 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
534.4 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE 
534.4 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 
534.6 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION 
534.6 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
534.9 GASTROJEJUNAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
535.11 ATROPHIC GASTRITIS WITH HEMORRHAGE 
535.31 ALCOHOLIC GASTRITIS WITH HEMORRHAGE 
535.4 OTHER SPECIFIED GASTRITIS (WITHOUT HEMORRHAGE) 
535.51 UNSPECIFIED GASTRITIS AND GASTRODUODENITIS WITH HEMORRHAGE 
535.61 DUODENITIS WITH HEMORRHAGE 
562.01 DIVERTICULITIS OF SMALL INTESTINE (WITHOUT HEMORRHAGE) 
562.03 DIVERTICULITIS OF SMALL INTESTINE WITH HEMORRHAGE 
562.11 DIVERTICULITIS OF COLON (WITHOUT HEMORRHAGE) 
562.12 DIVERTICULOSIS OF COLON WITH HEMORRHAGE 
569.85 ANGIODYSPLASIA OF INTESTINE WITH HEMORRHAGE 
578.1 BLOOD IN STOOL 
599.71 GROSS HEMATURIA 
623.8 OTHER SPECIFIED NONINFLAMMATORY DISORDERS OF VAGINA 
626.8 OTHER DISORDERS OF MENSTRUATION AND OTHER ABNORMAL BLEEDING FROM FEMALE GENITAL TRACT 
Appendix A 

784.7 EPISTAXIS 
784.8 HEMORRHAGE FROM THROAT 
786.3 HEMOPTYSIS 
786.39 OTHER HEMOPTYSIS 
280 IRON DEFICIENCY ANEMIA SECONDARY TO BLOOD LOSS (CHRONIC) 
285.1  ACUTE POSTHEMORRHAGIC ANEMIA 
455.2  INTERNAL HEMORRHOIDS WITH OTHER COMPLICATION 
455.4 EXTERNAL THROMBOSED HEMORRHOIDS 
455.5 EXTERNAL HEMORRHOIDS WITH OTHER COMPLICATION 
455.6 UNSPECIFIED HEMORRHOIDS  WITHOUT COMPLICATION 
456 ESOPHAGEAL VARICES WITH BLEEDING 
456.2 ESOPHAGEAL VARICES IN DISEASES CLASSIFIED ELSEWHERE WITH BLEEDING 
530.11 REFLUX ESOPHAGITIS 
530.12 ACUTE ESOPHAGITIS 
531 ACUTE GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 
531.1 ACUTE GASTRIC ULCER WITH PERFORATION 
531.2 ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION 
531.4 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE 
531.41 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION 
531.6 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION 
532 ACUTE DUODENAL ULCER WITH HEMORRHAGE 
532.2 ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION 
532.2 ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
532.21 ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
532.4 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 
532.6 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION 
532.6 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
532.61 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
532.7 CHRONIC DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
533 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE 
533 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION 
533.01 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION 
533.2 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
533.3 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT MENTION OF HEMORRHAGE AND PERFORATION 
533.4 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE 
533.6 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
533.61 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
533.7 CHRONIC PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
534 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 
534.01 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION 
534.1 ACUTE GASTROJEJUNAL ULCER WITH PERFORATION 
534.2 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
534.3 ACUTE GASTROJEJUNAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
534.41 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION 
534.5 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH PERFORATION 
534.61 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
534.7 CHRONIC GASTROJEJUNAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
535 ACUTE GASTRITIS (WITHOUT HEMORRHAGE) 
535.01 ACUTE GASTRITIS WITH HEMORRHAGE 
535.1 ATROPHIC GASTRITIS (WITHOUT HEMORRHAGE) 
535.2 GASTRIC MUCOSAL HYPERTROPHY (WITHOUT HEMORRHAGE) 
535.21 GASTRIC MUCOSAL HYPERTROPHY WITH HEMORRHAGE 
535.3  ALCOHOLIC GASTRITIS (WITHOUT HEMORRHAGE) 
535.41 OTHER SPECIFIED GASTRITIS WITH HEMORRHAGE 
535.5 UNSPECIFIED GASTRITIS AND GASTRODUODENITIS (WITHOUT HEMORRHAGE) 
535.6 DUODENITIS (WITHOUT HEMORRHAGE) 
537.83 ANGIODYSPLASIA OF STOMACH AND DUODENUM WITH HEMORRHAGE 
562 DIVERTICULOSIS OF SMALL INTESTINE (WITHOUT HEMORRHAGE) 
562.02 DIVERTICULOSIS OF SMALL INTESTINE WITH HEMORRHAGE 
562.1 DIVERTICULOSIS OF COLON (WITHOUT HEMORRHAGE) 
Appendix A 

DIVERTICULITIS OF COLON WITH HEMORRHAGE 
HEMORRHAGE OF RECTUM AND ANUS 
HEMATEMESIS 
HEMORRHAGE OF GASTROINTESTINAL TRACT UNSPECIFIED 
VASCULAR DISORDERS OF KIDNEY 
HEMATURIA UNSPECIFIED 
VAGINAL HEMATOMA 
METRORRHAGIA 
HEMOPTYSIS UNSPECIFIED 
ACUTE IDIOPATHIC PULMONARY HEMORRHAGE IN INFANTS 
Other vascular myelopathies 
Hemorrhage of left orbit 
Hemorrhage of unspecified orbit 
Unspecified choroidal hemorrhage 
Unspecified choroidal hemorrhage, right eye 
Unspecified choroidal hemorrhage, bilateral 
Expulsive choroidal hemorrhage, left eye 
Expulsive choroidal hemorrhage, bilateral 
Hemorrhagic choroidal detachment, right eye 
Hemorrhagic choroidal detachment, unspecified eye 
Vitreous hemorrhage 
Vitreous hemorrhage, unspecified eye 
Vitreous hemorrhage, right eye 
Vitreous hemorrhage, bilateral 
Hemorrhage in optic nerve sheath, left eye 
Hemorrhage in optic nerve sheath, bilateral 
Hemorrhage in optic nerve sheath, unspecified eye 
Nontraumatic subarachnoid hemorrhage from carotid siphon and bifurcation 
Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation 
Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation 
Nontraumatic subarachnoid hemorrhage from middle cerebral artery 
Nontraumatic subarachnoid hemorrhage from right middle cerebral artery 
Nontraumatic subarachnoid hemorrhage from right posterior communicating artery 
Nontraumatic subarachnoid hemorrhage from basilar artery 
Nontraumatic subarachnoid hemorrhage from right vertebral artery 
Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery 
Other nontraumatic subarachnoid hemorrhage 
Nontraumatic intracerebral hemorrhage in hemisphere, subcortical 
Nontraumatic intracerebral hemorrhage in hemisphere, unspecified 
Nontraumatic intracerebral hemorrhage in brain stem 
Nontraumatic intracerebral hemorrhage, intraventricular 
Nontraumatic intracerebral hemorrhage, multiple localized 
Other nontraumatic intracerebral hemorrhage 
Other and unspecified nontraumatic intracranial hemorrhage 
Nontraumatic subdural hemorrhage 
Nontraumatic subdural hemorrhage, unspecified 
Nontraumatic acute subdural hemorrhage 
Nontraumatic subacute subdural hemorrhage 
Nontraumatic intracranial hemorrhage, unspecified 
Hemoperitoneum 
Hemarthrosis 
Hemarthrosis, shoulder 
Hemarthrosis, left shoulder 
Hemarthrosis, unspecified shoulder 
Hemarthrosis, right elbow 
Hemarthrosis, unspecified elbow 
Hemarthrosis, wrist 
Hemarthrosis, unspecified wrist 
Hemarthrosis, hip 
562.13 
569.3 
578 
578.9 
593.81 
599.7 
623.6 
626.6 
786.3 
786.31 
ICD-10 Dx 
G95.19 
H05.232 
H05.239 
H31.30 
H31.301 
H31.303 
H31.312 
H31.313 
H31.411 
H31.419 
H43.1 
H43.10 
H43.11 
H43.13 
H47.022 
H47.023 
H47.029 
I60.0 
I60.00 
I60.01 
I60.1 
I60.11 
I60.31 
I60.4 
I60.51 
I60.7 
I60.8 
I61.0 
I61.2 
I61.3 
I61.5 
I61.6 
I61.8 
I62 
I62.0 
I62.00 
I62.01 
I62.02 
I62.9 
K66.1 
M25.0 
M25.01 
M25.012 
M25.019 
M25.021 
M25.029 
M25.03 
M25.039 
M25.05 
Appendix A 

M25.051 
M25.052 
M25.06 
M25.061 
M25.07 
M25.071 
M25.073 
M25.074 
M25.075 
M25.08 
M79.81 
S06.4 
S06.4X 
S06.4X0 
S06.4X0D 
S06.4X1A 
S06.4X2S 
S06.4X3 
S06.4X3A 
S06.4X4 
S06.4X4A 
S06.4X5D 
S06.4X5S 
S06.4X6D 
S06.4X7 
S06.4X7A 
S06.4X9 
S06.4X9A 
S06.5 
S06.5X 
S06.5X0 
S06.5X2 
S06.5X2A 
S06.5X3A 
S06.5X3D 
S06.5X3S 
S06.5X4S 
S06.5X5 
S06.5X5A 
S06.5X5S 
S06.5X6A 
S06.5X6D 
S06.5X6S 
S06.5X8 
S06.5X9A 
S06.5X9D 
S06.5X9S 
S06.6X 
S06.6X0 
S06.6X0A 
S06.6X0D 
S06.6X1 
S06.6X1A 
S06.6X1S 
S06.6X2D 
S06.6X3D 
S06.6X4 
S06.6X4A 
S06.6X4S 
S06.6X5 
Hemarthrosis, right hip 
Hemarthrosis, left hip 
Hemarthrosis, knee 
Hemarthrosis, right knee 
Hemarthrosis, ankle and foot 
Hemarthrosis, right ankle 
Hemarthrosis, unspecified ankle 
Hemarthrosis, right foot 
Hemarthrosis, left foot 
Hemarthrosis, other specified site 
Nontraumatic hematoma of soft tissue 
Epidural hemorrhage 
Epidural hemorrhage 
Epidural hemorrhage without loss of consciousness 
Epidural hemorrhage without loss of consciousness, subsequent encounter 
Epidural hemorrhage with loss of consciousness of 30 minutes or less, initial encounter 
Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela 
Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes 
Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, initial encounter 
Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours 
Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, initial encounter 
Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, subsequent encounter 
Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela 
Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, subsequent encounter 
Epidural hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness 
Epidural hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, initial encounter 
Epidural hemorrhage with loss of consciousness of unspecified duration 
Epidural hemorrhage with loss of consciousness of unspecified duration, initial encounter 
Traumatic subdural hemorrhage 
Traumatic subdural hemorrhage 
Traumatic subdural hemorrhage without loss of consciousness 
Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes 
Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, initial encounter 
Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, initial encounter 
Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, subsequent encounter 
Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela 
Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela 
Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level 
Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, initial encounter 
Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela 
Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, initial encounter 
Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, subsequent encounter 
Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela 
Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to other cause before regaining consciousness 
Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, initial encounter 
Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, subsequent encounter 
Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, sequela 
Traumatic subarachnoid hemorrhage 
Traumatic subarachnoid hemorrhage without loss of consciousness 
Traumatic subarachnoid hemorrhage without loss of consciousness, initial encounter 
Traumatic subarachnoid hemorrhage without loss of consciousness, subsequent encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less 
Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less, initial encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less, sequela 
Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes, subsequent encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, subsequent encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours 
Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours, initial encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela 
Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level 
Appendix A 

S06.6X5S 
S06.6X6 
S06.6X6A 
S06.6X6S 
S06.6X7 
S06.6X8A 
S06.6X9S 
S26.0 
S26.01 
S26.01XA 
S26.020 
S26.020A 
S26.021D 
S26.021S 
S26.022 
S26.022D 
S26.09 
S26.09XD 
S26.09XS 
S37.01 
S37.011D 
S37.011S 
S37.012A 
S37.012D 
S37.012S 
S37.02 
S37.021 
S37.021D 
S37.021S 
S37.022D 
S37.022S 
S37.029 
S37.031A 
S37.031D 
S37.032 
S37.032D 
S37.032S 
S37.039 
S37.039D 
S37.04 
S37.041 
S37.041A 
S37.041D 
S37.041S 
S37.042A 
S37.042D 
S37.042S 
S37.051 
S37.051A 
S37.051S 
S37.052S 
S37.059D 
S37.059S 
S37.061S 
S37.062 
S37.062S 
S37.069A 
S37.069S 
H05.23 
H05.231 
Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela 
Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving 
Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, initial encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela 
Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness 
Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, initial encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration, sequela 
Injury of heart with hemopericardium 
Contusion of heart with hemopericardium 
Contusion of heart with hemopericardium, initial encounter 
Mild laceration of heart with hemopericardium 
Mild laceration of heart with hemopericardium, initial encounter 
Moderate laceration of heart with hemopericardium, subsequent encounter 
Moderate laceration of heart with hemopericardium, sequela 
Major laceration of heart with hemopericardium 
Major laceration of heart with hemopericardium, subsequent encounter 
Other injury of heart with hemopericardium 
Other injury of heart with hemopericardium, subsequent encounter 
Other injury of heart with hemopericardium, sequela 
Minor contusion of kidney 
Minor contusion of right kidney, subsequent encounter 
Minor contusion of right kidney, sequela 
Minor contusion of left kidney, initial encounter 
Minor contusion of left kidney, subsequent encounter 
Minor contusion of left kidney, sequela 
Major contusion of kidney 
Major contusion of right kidney 
Major contusion of right kidney, subsequent encounter 
Major contusion of right kidney, sequela 
Major contusion of left kidney, subsequent encounter 
Major contusion of left kidney, sequela 
Major contusion of unspecified kidney 
Laceration of right kidney, unspecified degree, initial encounter 
Laceration of right kidney, unspecified degree, subsequent encounter 
Laceration of left kidney, unspecified degree 
Laceration of left kidney, unspecified degree, subsequent encounter 
Laceration of left kidney, unspecified degree, sequela 
Laceration of unspecified kidney, unspecified degree 
Laceration of unspecified kidney, unspecified degree, subsequent encounter 
Minor laceration of kidney 
Minor laceration of right kidney 
Minor laceration of right kidney, initial encounter 
Minor laceration of right kidney, subsequent encounter 
Minor laceration of right kidney, sequela 
Minor laceration of left kidney, initial encounter 
Minor laceration of left kidney, subsequent encounter 
Minor laceration of left kidney, sequela 
Moderate laceration of right kidney 
Moderate laceration of right kidney, initial encounter 
Moderate laceration of right kidney, sequela 
Moderate laceration of left kidney, sequela 
Moderate laceration of unspecified kidney, subsequent encounter 
Moderate laceration of unspecified kidney, sequela 
Major laceration of right kidney, sequela 
Major laceration of left kidney 
Major laceration of left kidney, sequela 
Major laceration of unspecified kidney, initial encounter 
Major laceration of unspecified kidney, sequela 
Hemorrhage of orbit 
Hemorrhage of right orbit 
Appendix A 

H05.233 
H31.302 
H31.309 
H31.31 
H31.311 
H31.319 
H31.41 
H31.412 
H31.413 
H43.12 
H47.02 
H47.021 
I23.0 
I31.2 
I60 
I60.02 
I60.10 
I60.12 
I60.2 
I60.3 
I60.30 
I60.32 
I60.5 
I60.50 
I60.52 
I60.6 
I60.9 
I61 
I61.1 
I61.4 
I61.9 
I62.03 
I62.1 
M25.00 
M25.011 
M25.02 
M25.022 
M25.031 
M25.032 
M25.04 
M25.041 
M25.042 
M25.049 
M25.059 
M25.062 
M25.069 
M25.072 
M25.076 
S06.4X0A 
S06.4X0S 
S06.4X1 
S06.4X1D 
S06.4X1S 
S06.4X2 
S06.4X2A 
S06.4X2D 
S06.4X3D 
S06.4X3S 
S06.4X4D 
S06.4X4S 
Hemorrhage of bilateral orbit 
Unspecified choroidal hemorrhage, left eye 
Unspecified choroidal hemorrhage, unspecified eye 
Expulsive choroidal hemorrhage 
Expulsive choroidal hemorrhage, right eye 
Expulsive choroidal hemorrhage, unspecified eye 
Hemorrhagic choroidal detachment 
Hemorrhagic choroidal detachment, left eye 
Hemorrhagic choroidal detachment, bilateral 
Vitreous hemorrhage, left eye 
Hemorrhage in optic nerve sheath 
Hemorrhage in optic nerve sheath, right eye 
Hemopericardium as current complication following acute myocardial infarction 
Hemopericardium, not elsewhere classified 
Nontraumatic subarachnoid hemorrhage 
Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation 
Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery 
Nontraumatic subarachnoid hemorrhage from left middle cerebral artery 
Nontraumatic subarachnoid hemorrhage from anterior communicating artery 
Nontraumatic subarachnoid hemorrhage from posterior communicating artery 
Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery 
Nontraumatic subarachnoid hemorrhage from left posterior communicating artery 
Nontraumatic subarachnoid hemorrhage from vertebral artery 
Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery 
Nontraumatic subarachnoid hemorrhage from left vertebral artery 
Nontraumatic subarachnoid hemorrhage from other intracranial arteries 
Nontraumatic subarachnoid hemorrhage, unspecified 
Nontraumatic intracerebral hemorrhage 
Nontraumatic intracerebral hemorrhage in hemisphere, cortical 
Nontraumatic intracerebral hemorrhage in cerebellum 
Nontraumatic intracerebral hemorrhage, unspecified 
Nontraumatic chronic subdural hemorrhage 
Nontraumatic extradural hemorrhage 
Hemarthrosis, unspecified joint 
Hemarthrosis, right shoulder 
Hemarthrosis, elbow 
Hemarthrosis, left elbow 
Hemarthrosis, right wrist 
Hemarthrosis, left wrist 
Hemarthrosis, hand 
Hemarthrosis, right hand 
Hemarthrosis, left hand 
Hemarthrosis, unspecified hand 
Hemarthrosis, unspecified hip 
Hemarthrosis, left knee 
Hemarthrosis, unspecified knee 
Hemarthrosis, left ankle 
Hemarthrosis, unspecified foot 
Epidural hemorrhage without loss of consciousness, initial encounter 
Epidural hemorrhage without loss of consciousness, sequela 
Epidural hemorrhage with loss of consciousness of 30 minutes or less 
Epidural hemorrhage with loss of consciousness of 30 minutes or less, subsequent encounter 
Epidural hemorrhage with loss of consciousness of 30 minutes or less, sequela 
Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes 
Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, initial encounter 
Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, subsequent encounter 
Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, subsequent encounter 
Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela 
Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, subsequent encounter 
Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela 
Appendix A 

S06.4X5 
S06.4X5A 
S06.4X6 
S06.4X6A 
S06.4X6S 
S06.4X8 
S06.4X8A 
S06.4X9D 
S06.4X9S 
S06.5X0A 
S06.5X0D 
S06.5X0S 
S06.5X1 
S06.5X1A 
S06.5X1D 
S06.5X1S 
S06.5X2D 
S06.5X2S 
S06.5X3 
S06.5X4 
S06.5X4A 
S06.5X4D 
S06.5X5D 
S06.5X6 
S06.5X7 
S06.5X7A 
S06.5X8A 
S06.5X9 
S06.6 
S06.6X0S 
S06.6X1D 
S06.6X2 
S06.6X2A 
S06.6X2S 
S06.6X3 
S06.6X3A 
S06.6X3S 
S06.6X4D 
S06.6X5A 
S06.6X5D 
S06.6X6D 
S06.6X7A 
S06.6X8 
S06.6X9 
S06.6X9A 
S06.6X9D 
S26.00 
S26.00XA 
S26.00XD 
S26.00XS 
S26.01XD 
S26.01XS 
S26.02 
S26.020D 
S26.020S 
S26.021 
S26.021A 
S26.022A 
S26.022S 
S26.09XA 
Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level 
Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, initial encounter 
Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving 
Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, initial encounter 
Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela 
Epidural hemorrhage with loss of consciousness of any duration with death due to other causes prior to regaining consciousness 
Epidural hemorrhage with loss of consciousness of any duration with death due to other causes prior to regaining consciousness, initial encounter 
Epidural hemorrhage with loss of consciousness of unspecified duration, subsequent encounter 
Epidural hemorrhage with loss of consciousness of unspecified duration, sequela 
Traumatic subdural hemorrhage without loss of consciousness, initial encounter 
Traumatic subdural hemorrhage without loss of consciousness, subsequent encounter 
Traumatic subdural hemorrhage without loss of consciousness, sequela 
Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less 
Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less, initial encounter 
Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less, subsequent encounter 
Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less, sequela 
Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, subsequent encounter 
Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela 
Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes 
Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours 
Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours, initial encounter 
Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours, subsequent encounter 
Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, subsequent encounter 
Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving 
Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to brain injury before regaining consciousness 
Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to brain injury before regaining consciousness, initial encounter 
Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to other cause before regaining consciousness, initial encounter 
Traumatic subdural hemorrhage with loss of consciousness of unspecified duration 
Traumatic subarachnoid hemorrhage 
Traumatic subarachnoid hemorrhage without loss of consciousness, sequela 
Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less, subsequent encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes 
Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes, initial encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela 
Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes 
Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, initial encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela 
Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours, subsequent encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, initial encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, subsequent encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, subsequent encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, initial encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to other cause prior to regaining consciousness 
Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration 
Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration, initial encounter 
Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration, subsequent encounter 
Unspecified injury of heart with hemopericardium 
Unspecified injury of heart with hemopericardium, initial encounter 
Unspecified injury of heart with hemopericardium, subsequent encounter 
Unspecified injury of heart with hemopericardium, sequela 
Contusion of heart with hemopericardium, subsequent encounter 
Contusion of heart with hemopericardium, sequela 
Laceration of heart with hemopericardium 
Mild laceration of heart with hemopericardium, subsequent encounter 
Mild laceration of heart with hemopericardium, sequela 
Moderate laceration of heart with hemopericardium 
Moderate laceration of heart with hemopericardium, initial encounter 
Major laceration of heart with hemopericardium, initial encounter 
Major laceration of heart with hemopericardium, sequela 
Other injury of heart with hemopericardium, initial encounter 
Appendix A 

Minor contusion of right kidney 
Minor contusion of right kidney, initial encounter 
Minor contusion of left kidney 
Minor contusion of unspecified kidney 
Minor contusion of unspecified kidney, initial encounter 
Minor contusion of unspecified kidney, subsequent encounter 
Minor contusion of unspecified kidney, sequela 
Major contusion of right kidney, initial encounter 
Major contusion of left kidney 
Major contusion of left kidney, initial encounter 
Major contusion of unspecified kidney, initial encounter 
Major contusion of unspecified kidney, subsequent encounter 
Major contusion of unspecified kidney, sequela 
Laceration of kidney, unspecified degree 
Laceration of right kidney, unspecified degree 
Laceration of right kidney, unspecified degree, sequela 
Laceration of left kidney, unspecified degree, initial encounter 
Laceration of unspecified kidney, unspecified degree, initial encounter 
Laceration of unspecified kidney, unspecified degree, sequela 
Minor laceration of left kidney 
Minor laceration of unspecified kidney 
Minor laceration of unspecified kidney, initial encounter 
Minor laceration of unspecified kidney, subsequent encounter 
Minor laceration of unspecified kidney, sequela 
Moderate laceration of kidney 
Moderate laceration of right kidney, subsequent encounter 
Moderate laceration of left kidney 
Moderate laceration of left kidney, initial encounter 
Moderate laceration of left kidney, subsequent encounter 
Moderate laceration of unspecified kidney 
Moderate laceration of unspecified kidney, initial encounter 
Major laceration of kidney 
Major laceration of right kidney 
Major laceration of right kidney, initial encounter 
Major laceration of right kidney, subsequent encounter 
Major laceration of left kidney, initial encounter 
Major laceration of left kidney, subsequent encounter 
Major laceration of unspecified kidney 
Major laceration of unspecified kidney, subsequent encounter 
of Inpatient Confinement with the following attributes: 
is any of: { "30 30   ", "30 30   ", "30 30   ", "30 30   ", "30 30   ", "30 30V ", "30 30   ", "30 33   ", "30 33   ", "30 33   ", "30 33   ", "30 40   ", "30 40   ", "30 40   ", "30 40   ", "30 43L ", "30 43    ", "30 43   ", "30 43   ", "30 43    ", "30 30   ", 
"30 30L ", "30 30 ", "30 33 ", "30 33L ", "30 33 ", "30 33 ", "30 33V ", "30 33 ", "30 40L ", "30 40 ", "30 40 ", "30 40 ", "30 40V ", "30 40 ", "30 43 ", "30 43 ", "30 43 ", "30 43 ", "30 43V " } 
Iron deficiency anemia secondary to blood loss (chronic) 
Acute posthemorrhagic anemia 
Secondary esophageal varices with bleeding 
Esophagitis 
Eosinophilic esophagitis 
Other esophagitis 
Esophagitis, unspecified 
Gastro-esophageal reflux disease with esophagitis 
Ulcer of esophagus with bleeding 
Acute gastric ulcer with perforation 
Acute gastric ulcer with both hemorrhage and perforation 
Chronic or unspecified gastric ulcer with hemorrhage 
Chronic or unspecified gastric ulcer with perforation 
S37.011 
S37.011A 
S37.012 
S37.019 
S37.019A 
S37.019D 
S37.019S 
S37.021A 
S37.022 
S37.022A 
S37.029A 
S37.029D 
S37.029S 
S37.03 
S37.031 
S37.031S 
S37.032A 
S37.039A 
S37.039S 
S37.042 
S37.049 
S37.049A 
S37.049D 
S37.049S 
S37.05 
S37.051D 
S37.052 
S37.052A 
S37.052D 
S37.059 
S37.059A 
S37.06 
S37.061 
S37.061A 
S37.061D 
S37.062A 
S37.062D 
S37.069 
S37.069D 
 
The occurrence
Procedure 
Code (Any 
Confinement 
Position) 
AND 
D50.0 
D62 
I85.11 
K20 
K20.0 
K20.8 
K20.9 
K21.0 
K22.11 
K25.1 
K25.2 
K25.4 
K25.5 
Appendix A 

K26.2 
K26.4 
K26.6 
K27.4 
K27.5 
K27.6 
K28.1 
K28.2 
K29.31 
K29.91 
K57.11 
K57.21 
K57.51 
K57.53 
K57.93 
K62.5 
K64.1 
K64.3 
K64.9 
K92.0 
K92.1 
N89.7 
N92.1 
N93.8 
R04.0 
R31.0 
R31.9 
R58 
I85.01 
K22.6 
K25.0 
K25.6 
K26.0 
K26.1 
K26.5 
K27.0 
K27.1 
K27.2 
K28.0 
K28.4 
K28.5 
K28.6 
K29.01 
K29.21 
K29.41 
K29.51 
K29.61 
K29.71 
K29.81 
K31.811 
K55.21 
K57.01 
K57.31 
K57.41 
K57.81 
K57.91 
K64.0 
K64.2 
K64.4 
K64.5 
Acute duodenal ulcer with both hemorrhage and perforation 
Chronic or unspecified duodenal ulcer with hemorrhage 
Chronic or unspecified duodenal ulcer with both hemorrhage and perforation 
Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage 
Chronic or unspecified peptic ulcer, site unspecified, with perforation 
Chronic or unspecified peptic ulcer, site unspecified, with both hemorrhage and perforation 
Acute gastrojejunal ulcer with perforation 
Acute gastrojejunal ulcer with both hemorrhage and perforation 
Chronic superficial gastritis with bleeding 
Gastroduodenitis, unspecified, with bleeding 
Diverticulosis of small intestine without perforation or abscess with bleeding 
Diverticulitis of large intestine with perforation and abscess with bleeding 
Diverticulosis of both small and large intestine without perforation or abscess with bleeding 
Diverticulitis of both small and large intestine without perforation or abscess with bleeding 
Diverticulitis of intestine, part unspecified, without perforation or abscess with bleeding 
Hemorrhage of anus and rectum 
Second degree hemorrhoids 
Fourth degree hemorrhoids 
Unspecified hemorrhoids 
Hematemesis 
Melena 
Hematocolpos 
Excessive and frequent menstruation with irregular cycle 
Other specified abnormal uterine and vaginal bleeding 
Epistaxis 
Gross hematuria 
Hematuria, unspecified 
Hemorrhage, not elsewhere classified 
Esophageal varices with bleeding 
Gastro-esophageal laceration-hemorrhage syndrome 
Acute gastric ulcer with hemorrhage 
Chronic or unspecified gastric ulcer with both hemorrhage and perforation 
Acute duodenal ulcer with hemorrhage 
Acute duodenal ulcer with perforation 
Chronic or unspecified duodenal ulcer with perforation 
Acute peptic ulcer, site unspecified, with hemorrhage 
Acute peptic ulcer, site unspecified, with perforation 
Acute peptic ulcer, site unspecified, with both hemorrhage and perforation 
Acute gastrojejunal ulcer with hemorrhage 
Chronic or unspecified gastrojejunal ulcer with hemorrhage 
Chronic or unspecified gastrojejunal ulcer with perforation 
Chronic or unspecified gastrojejunal ulcer with both hemorrhage and perforation 
Acute gastritis with bleeding 
Alcoholic gastritis with bleeding 
Chronic atrophic gastritis with bleeding 
Unspecified chronic gastritis with bleeding 
Other gastritis with bleeding 
Gastritis, unspecified, with bleeding 
Duodenitis with bleeding 
Angiodysplasia of stomach and duodenum with bleeding 
Angiodysplasia of colon with hemorrhage 
Diverticulitis of small intestine with perforation and abscess with bleeding 
Diverticulosis of large intestine without perforation or abscess with bleeding 
Diverticulitis of both small and large intestine with perforation and abscess with bleeding 
Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding 
Diverticulosis of intestine, part unspecified, without perforation or abscess with bleeding 
First degree hemorrhoids 
Third degree hemorrhoids 
Residual hemorrhoidal skin tags 
Perianal venous thrombosis 
Appendix A 

K64.8 
K92.2 
N89.8 
N93.9 
R04.1 
R04.2 
Other hemorrhoids 
Gastrointestinal hemorrhage, unspecified 
Other specified noninflammatory disorders of vagina 
Abnormal uterine and vaginal bleeding, unspecified 
Hemorrhage from throat 
Hemoptysis 
Appendix A 

Inpatient, Any Diagnosis: ICD-9 Codes 
280.0 - IRON DEFICIENCY ANEMIA SECONDARY TO BLOOD LOSS (CHRONIC) 
455.7 - UNSPECIFIED THROMBOSED HEMORRHOIDS 
459.0 - HEMORRHAGE UNSPECIFIED 
530.10 - ESOPHAGITIS UNSPECIFIED 
530.13 - EOSINOPHILIC ESOPHAGITIS 
531.0 - ACUTE GASTRIC ULCER WITH HEMORRHAGE 
531.1 - ACUTE GASTRIC ULCER WITH PERFORATION 
531.2 - ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION 
531.20 - ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
531.3 - ACUTE GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
531.4 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE 
531.6 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION 
531.61 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
531.9 - GASTRIC ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
532.0 - ACUTE DUODENAL ULCER WITH HEMORRHAGE 
532.00 - ACUTE DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 
532.01 - ACUTE DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION 
532.2 - ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION 
532.20 - ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
532.3 - ACUTE DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
532.4 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE 
532.41 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION 
532.5 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH PERFORATION 
532.61 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
533.0 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE 
533.00 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION 
533.01 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION 
533.1 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH PERFORATION 
533.2 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION 
533.20 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
533.3 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT MENTION OF HEMORRHAGE AND PERFORATION 
533.6 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION 
533.60 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
533.7 - CHRONIC PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
534.00 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 
534.01 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION 
534.20 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
534.3 - ACUTE GASTROJEJUNAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
534.40 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 
534.41 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION 
534.61 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
534.7 - CHRONIC GASTROJEJUNAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
534.9 - GASTROJEJUNAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
535.00 - ACUTE GASTRITIS (WITHOUT HEMORRHAGE) 
535.01 - ACUTE GASTRITIS WITH HEMORRHAGE 
535.10 - ATROPHIC GASTRITIS (WITHOUT HEMORRHAGE) 
535.20 - GASTRIC MUCOSAL HYPERTROPHY (WITHOUT HEMORRHAGE) 
Appendix A 

535.21 - GASTRIC MUCOSAL HYPERTROPHY WITH HEMORRHAGE 
535.31 - ALCOHOLIC GASTRITIS WITH HEMORRHAGE 
535.40 - OTHER SPECIFIED GASTRITIS (WITHOUT HEMORRHAGE) 
535.41 - OTHER SPECIFIED GASTRITIS WITH HEMORRHAGE 
562.00 - DIVERTICULOSIS OF SMALL INTESTINE (WITHOUT HEMORRHAGE) 
562.01 - DIVERTICULITIS OF SMALL INTESTINE (WITHOUT HEMORRHAGE) 
562.03 - DIVERTICULITIS OF SMALL INTESTINE WITH HEMORRHAGE 
562.11 - DIVERTICULITIS OF COLON (WITHOUT HEMORRHAGE) 
562.13 - DIVERTICULITIS OF COLON WITH HEMORRHAGE 
569.85 - ANGIODYSPLASIA OF INTESTINE WITH HEMORRHAGE 
578.0 - HEMATEMESIS 
578.1 - BLOOD IN STOOL 
578.9 - HEMORRHAGE OF GASTROINTESTINAL TRACT UNSPECIFIED 
593.81 - VASCULAR DISORDERS OF KIDNEY 
599.70 - HEMATURIA UNSPECIFIED 
599.71 - GROSS HEMATURIA 
623.6 - VAGINAL HEMATOMA 
626.6 - METRORRHAGIA 
784.7 - EPISTAXIS 
784.8 - HEMORRHAGE FROM THROAT 
786.31 - ACUTE IDIOPATHIC PULMONARY HEMORRHAGE IN INFANTS 
285.1 - ACUTE POSTHEMORRHAGIC ANEMIA 
455.1 - INTERNAL THROMBOSED HEMORRHOIDS 
455.2 - INTERNAL HEMORRHOIDS WITH OTHER COMPLICATION 
455.4 - EXTERNAL THROMBOSED HEMORRHOIDS 
455.5 - EXTERNAL HEMORRHOIDS WITH OTHER COMPLICATION 
455.6 - UNSPECIFIED HEMORRHOIDS WITHOUT COMPLICATION 
455.8 - UNSPECIFIED HEMORRHOIDS WITH OTHER COMPLICATION 
455.9 - RESIDUAL HEMORRHOIDAL SKIN TAGS 
456.0 - ESOPHAGEAL VARICES WITH BLEEDING 
456.20 - ESOPHAGEAL VARICES IN DISEASES CLASSIFIED ELSEWHERE WITH BLEEDING 
530.1 - ESOPHAGITIS 
530.11 - REFLUX ESOPHAGITIS 
530.12 - ACUTE ESOPHAGITIS 
530.19 - OTHER ESOPHAGITIS 
530.7 - GASTROESOPHAGEAL LACERATION-HEMORRHAGE SYNDROME 
530.82 - ESOPHAGEAL HEMORRHAGE 
531.00 - ACUTE GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 
531.01 - ACUTE GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION 
531.21 - ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
531.40 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 
531.41 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION 
531.5 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH PERFORATION 
531.60 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
531.7 - CHRONIC GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
532.1 - ACUTE DUODENAL ULCER WITH PERFORATION 
532.21 - ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
532.40 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 
Appendix A 

532.6 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION 
532.60 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
532.7 - CHRONIC DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
532.9 - DUODENAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
533.21 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
533.4 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE 
533.40 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION 
533.41 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION 
533.5 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH PERFORATION 
533.61 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
533.9 - PEPTIC ULCER OF UNSPECIFIED SITE UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 
534.0 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE 
534.1 - ACUTE GASTROJEJUNAL ULCER WITH PERFORATION 
534.2 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION 
534.21 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 
534.4 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE 
534.5 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH PERFORATION 
534.6 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION 
534.60 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 
535.11 - ATROPHIC GASTRITIS WITH HEMORRHAGE 
535.30 - ALCOHOLIC GASTRITIS (WITHOUT HEMORRHAGE) 
535.50 - UNSPECIFIED GASTRITIS AND GASTRODUODENITIS (WITHOUT HEMORRHAGE) 
535.51 - UNSPECIFIED GASTRITIS AND GASTRODUODENITIS WITH HEMORRHAGE 
535.60 - DUODENITIS (WITHOUT HEMORRHAGE) 
535.61 - DUODENITIS WITH HEMORRHAGE 
537.83 - ANGIODYSPLASIA OF STOMACH AND DUODENUM WITH HEMORRHAGE 
562.02 - DIVERTICULOSIS OF SMALL INTESTINE WITH HEMORRHAGE 
562.10 - DIVERTICULOSIS OF COLON (WITHOUT HEMORRHAGE) 
562.12 - DIVERTICULOSIS OF COLON WITH HEMORRHAGE 
569.3 - HEMORRHAGE OF RECTUM AND ANUS 
623.8 - OTHER SPECIFIED NONINFLAMMATORY DISORDERS OF VAGINA 
626.8 - OTHER DISORDERS OF MENSTRUATION AND OTHER ABNORMAL BLEEDING FROM FEMALE GENITAL TRACT 
786.3 - HEMOPTYSIS 
786.30 - HEMOPTYSIS UNSPECIFIED 
786.39 - OTHER HEMOPTYSIS 
285.9 - ANEMIA UNSPECIFIED 
790.92 - ABNORMAL COAGULATION PROFILE 
363.63 - CHOROIDAL RUPTURE 
626.2 - EXCESSIVE OR FREQUENT MENSTRUATION 
372.72 - CONJUNCTIVAL HEMORRHAGE 
 
Inpatient, Any Diagnosis: ICD-10 Codes 
D50.0 - Iron deficiency anemia secondary to blood loss (chronic) 
D62 - Acute posthemorrhagic anemia 
I85.01 - Esophageal varices with bleeding 
I85.11 - Secondary esophageal varices with bleeding 
K20.0 - Eosinophilic esophagitis 
K20.8 - Other esophagitis 
Appendix A 

K22.11 - Ulcer of esophagus with bleeding 
K22.6 - Gastro-esophageal laceration-hemorrhage syndrome 
K25.0 - Acute gastric ulcer with hemorrhage 
K25.1 - Acute gastric ulcer with perforation 
K25.2 - Acute gastric ulcer with both hemorrhage and perforation 
K25.4 - Chronic or unspecified gastric ulcer with hemorrhage 
K25.5 - Chronic or unspecified gastric ulcer with perforation 
K26.1 - Acute duodenal ulcer with perforation 
K26.2 - Acute duodenal ulcer with both hemorrhage and perforation 
K26.4 - Chronic or unspecified duodenal ulcer with hemorrhage 
K27.1 - Acute peptic ulcer, site unspecified, with perforation 
K27.2 - Acute peptic ulcer, site unspecified, with both hemorrhage and perforation 
K27.5 - Chronic or unspecified peptic ulcer, site unspecified, with perforation 
K27.6 - Chronic or unspecified peptic ulcer, site unspecified, with both hemorrhage and perforation 
K28.0 - Acute gastrojejunal ulcer with hemorrhage 
K28.4 - Chronic or unspecified gastrojejunal ulcer with hemorrhage 
K28.6 - Chronic or unspecified gastrojejunal ulcer with both hemorrhage and perforation 
K29.01 - Acute gastritis with bleeding 
K29.31 - Chronic superficial gastritis with bleeding 
K29.41 - Chronic atrophic gastritis with bleeding 
K29.51 - Unspecified chronic gastritis with bleeding 
K29.71 - Gastritis, unspecified, with bleeding 
K57.11 - Diverticulosis of small intestine without perforation or abscess with bleeding 
K57.21 - Diverticulitis of large intestine with perforation and abscess with bleeding 
K57.41 - Diverticulitis of both small and large intestine with perforation and abscess with bleeding 
K57.51 - Diverticulosis of both small and large intestine without perforation or abscess with bleeding 
K57.81 - Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding 
K57.91 - Diverticulosis of intestine, part unspecified, without perforation or abscess with bleeding 
K57.93 - Diverticulitis of intestine, part unspecified, without perforation or abscess with bleeding 
K62.5 - Hemorrhage of anus and rectum 
K64.0 - First degree hemorrhoids 
K64.5 - Perianal venous thrombosis 
K64.8 - Other hemorrhoids 
K64.9 - Unspecified hemorrhoids 
K92.0 - Hematemesis 
K92.2 - Gastrointestinal hemorrhage, unspecified 
N89.7 - Hematocolpos 
N93.8 - Other specified abnormal uterine and vaginal bleeding 
R04.2 - Hemoptysis 
R31.0 - Gross hematuria 
K20 - Esophagitis 
K20.9 - Esophagitis, unspecified 
K21.0 - Gastro-esophageal reflux disease with esophagitis 
K25.6 - Chronic or unspecified gastric ulcer with both hemorrhage and perforation 
K26.0 - Acute duodenal ulcer with hemorrhage 
K26.5 - Chronic or unspecified duodenal ulcer with perforation 
K26.6 - Chronic or unspecified duodenal ulcer with both hemorrhage and perforation 
K27.0 - Acute peptic ulcer, site unspecified, with hemorrhage 
Appendix A 

K27.4 - Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage 
K28.1 - Acute gastrojejunal ulcer with perforation 
K28.2 - Acute gastrojejunal ulcer with both hemorrhage and perforation 
K28.5 - Chronic or unspecified gastrojejunal ulcer with perforation 
K29.21 - Alcoholic gastritis with bleeding 
K29.61 - Other gastritis with bleeding 
K29.81 - Duodenitis with bleeding 
K29.91 - Gastroduodenitis, unspecified, with bleeding 
K31.811 - Angiodysplasia of stomach and duodenum with bleeding 
K55.21 - Angiodysplasia of colon with hemorrhage 
K57.01 - Diverticulitis of small intestine with perforation and abscess with bleeding 
K57.31 - Diverticulosis of large intestine without perforation or abscess with bleeding 
K57.53 - Diverticulitis of both small and large intestine without perforation or abscess with bleeding 
K64.1 - Second degree hemorrhoids 
K64.2 - Third degree hemorrhoids 
K64.3 - Fourth degree hemorrhoids 
K64.4 - Residual hemorrhoidal skin tags 
K92.1 - Melena 
N89.8 - Other specified noninflammatory disorders of vagina 
N93.9 - Abnormal uterine and vaginal bleeding, unspecified 
R04.0 - Epistaxis 
R04.1 - Hemorrhage from throat 
R58 - Hemorrhage, not elsewhere classified 
D64.9 - Anemia, unspecified 
R79.1 - Abnormal coagulation profile 
H11.30 - Conjunctival hemorrhage, unspecified eye 
H11.31 - Conjunctival hemorrhage, right eye 
H11.32 - Conjunctival hemorrhage, left eye 
H11.33 - Conjunctival hemorrhage, bilateral 
H31.321 - Choroidal rupture, right eye 
H31.322 - Choroidal rupture, left eye 
H31.323 - Choroidal rupture, bilateral 
H31.329 - Choroidal rupture, unspecified eye 
N92.1 - Excessive and frequent menstruation with irregular cycle 
R31.1 - Benign essential microscopic hematuria 
R31.2 - Other microscopic hematuria 
R31.29 - Other microscopic hematuria 
N92.0 - Excessive and frequent menstruation with regular cycle 
R31.21 - Asymptomatic microscopic hematuria 
R31.9 - Hematuria, unspecified 
 
Appendix A 

Procedure Codes Description 
CPT-4 codes 
1960 
Anesthesia for vaginal delivery only 
1961 
Anesthesia for cesarean delivery only 
1962 
Anesthesia for urgent hysterectomy following delivery 
1963 
Anesthesia for cesarean hysterectomy w/o any labor analgesia/anesthesia care 
1967 
Neuraxial labor analgesia/anesthesia, planned vaginal delivery 
1968 
Anesthesia for cesarean delivery following neuraxial labor analgesia/anesthesia 
1969 
Anes for cesarean hysterectomy following neuraxial labor analgesia/anesthesia 
59050 
Fetal monitoring in labor, physician w/written report; s & i 
59051 
Fetal monitoring in labor, physician w/written report; intrepretation only 
59400 
ROUTINE TOTAL OBSTETRIC CARE including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care. 
59409 
Vaginal delivery only (w/wo episiotomy &/or forceps) 
59410 
Vaginal delivery only (w/wo episiotomy &/or forceps); w/postpartum care 
59412 
Ext cephalic version, w/wo tocolysis 
59414 
Delivery of placenta (separate proc) 
59430 
Postpartum care only 
59510 
Routine obstetric care w/antepartum care, cesarean delivery, & postpartum care 
59514 
Cesarean delivery only 
59515 
Cesarean delivery only; w/postpartum care 
59525 
Subtotal/total hysterectomy after cesarean delivery 
59610 
Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care, after previous cesarean delivery 
59612 
Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps) 
59614 
Vaginal delivery only, previous cesarean delivery w/postpartum care 
59618 
Routine obstetric care including antepartum care, cesarean delivery, and postpartum care, following attempted vaginal delivery after previous cesarean delivery 
59620 
Cesarean delivery after failed vaginal delivery, previous cesarean delivery 
59622 
Cesarean delivery after failed vaginal delivery, previous cesarean delivery; w/postpartum care 
99436 
Attendance at delivery, at request of delivering physician, & stabilization of newborn 
99440 
Newborn resuscitation 
 
ICD-9 procedure 
codes 
 
72.xx 
Forceps, vacuum, & breech 
73.xx 
Other including manual delivery 
74xx 
Cesarean section 
75.4x 
Manual removal of placenta 
ICD-10 
procedure 
codes 
 
Normal 
Delivery 
10E0X22 
Delivery of Products of Conception, External Approach 
C-Section 
10D0020 
Extraction of Products of Conception, High, Open Approach 
10D0021 
Extraction of Products of Conception, Low, Open Approach 
10D0022 
Extraction of Products of Conception, Extraperitoneal, Open Approach 
Other assisted delivery (forceps, vacuum, internal version, other) 
10D0723 
Extraction of Products of Conception, Low Forceps, Via Natural or Artificial Opening 
10D0724 
Extraction of Products of Conception, Mid Forceps, Via Natural or Artificial Opening 
10D0725 
Extraction of Products of Conception, High Forceps, Via Natural or Artificial Opening 
10D0726 
Extraction of Products of Conception, Vacuum, Via Natural or Artificial Opening 
10D0727 
Extraction of Products of Conception, Internal Version, Via Natural or Artificial Opening 
10D0728 
Extraction of Products of Conception, Other, Via Natural or Artificial Opening 
ICD-9 code 
Definition  
Gestational Age 
Weeks 
Days 
765.21 
Less than 24 c 24 
168 
765.22 
24 completed weeks of gestation 
765.23 
25-26 comple 26 
182 
765.24 
27-28 comple 28 
196 
765.25 
29-30 comple 30 
210 
765.26 
31-32 comple 32 
224 
765.27 
33-34 comple 34 
238 
765.28 
35-36 comple 36 
252 
ICD-10 code 
Definition  
Gestational Age 
Appendix A 

Weeks 
Extreme imm 23 
Extreme imm 23 
Extreme imm 24 
Extreme imm 25 
Extreme imm 26 
Extreme imm 27 
Preterm new 28 
Preterm new 29 
Preterm new 30 
Preterm new 31 
Preterm new 32 
Preterm new 33 
Preterm new 34 
Preterm new 35 
Preterm new 36 
Days 
161 
161 
168 
175 
182 
189 
196 
203 
210 
217 
224 
231 
238 
245 
252 
P07.21 
P07.22 
P07.23 
P07.24 
P07.25 
P07.26 
P07.31 
P07.32 
P07.33 
P07.34 
P07.35 
P07.36 
P07.37 
P07.38 
P07.39 
Codes indicating extreme prematurity 
ICD-9 code 
Definition  
Gestational Age 
Weeks 
Disorders rela 28 
Days 
196 
765.0 
765.00 
765.01 
765.02 
765.03 
765.04 
765.05 
765.06 
765.07 
765.08 
Extreme immaturity, unspecified [weight] 
Extreme immaturity, less than 500 grams 
Extreme immaturity, 500-749 grams 
Extreme immaturity, 750-999 grams 
Extreme immaturity, 1,000-1,249 grams 
Extreme immaturity, 1,250-1,499 grams 
Extreme immaturity, 1,500-1,749 grams 
Extreme immaturity, 1,750-1,999 grams 
Extreme immaturity, 2,000-2,499 grams 
ICD-10 code 
Definition  
Gestational Age 
Weeks 
Extreme imm 28 
Days 
196 
P07.2 
P07.20 
O42.012 
Extreme immaturity of newborn, unspecified weeks of gestation 
Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, second trimester 
Other preterm 
codes 
ICD-9 code 
Definition  
Gestational Age 
Weeks 
Disorders rela 35 
Days 
245 
765.1 
765.10 
765.11 
765.12 
765.13 
765.14 
765.15 
765.16 
765.17 
765.18 
644.21 
Other preterm infants, unspecified [weight] 
Other preterm infants, less than 500 grams 
Other preterm infants, 500-749 grams 
Other preterm infants, 750-999 grams 
Other preterm infants, 1,000-1,249 grams 
Other preterm infants, 1,250-1,499 grams 
Other preterm infants, 1,500-1,749 grams 
Other preterm infants, 1,750-1,999 grams 
Other preterm infants, 2,000-2,499 grams 
Onset of delivery before 37 completed weeks of gestation 
ICD-10 code 
Definition  
Gestational Age 
Weeks 
Disorders of n 35 
Days 
245 
P05.01 
P05.02 
P05.03 
P05.04 
P05.05 
P05.06 
P05.07 
P05.11 
P05.12 
P05.13 
P05.14 
Disorders of newborn related to slow fetal growth and fetal malnutrition, 500-749 grams 
Disorders of newborn related to slow fetal growth and fetal malnutrition, 750-999 grams 
Disorders of newborn related to slow fetal growth and fetal malnutrition, 1000-1249 grams 
Disorders of newborn related to slow fetal growth and fetal malnutrition, 1250-1499 grams 
Disorders of newborn related to slow fetal growth and fetal malnutrition, 1500-1749 grams 
Disorders of newborn related to slow fetal growth and fetal malnutrition, 1750-1999 grams 
Newborn small for gestational age, less than 500 grams 
Newborn small for gestational age, 500-749 grams 
Newborn small for gestational age, 750-999 grams 
Newborn small for gestational age, 1000-1249 grams 
 
 
 
 
 
 
Appendix A 

P05.15 
P05.16 
P05.17 
P07.0 
P07.00 
P07.01 
P07.02 
P07.03 
P07.1 
P07.10 
P07.14 
P07.15 
P07.16 
P07.17 
P07.3 
P07.30 
060.1 
O42.01 
O42.019 
O42.013 
Newborn small for gestational age, 1250-1499 grams 
Newborn small for gestational age, 1500-1749 grams 
Newborn small for gestational age, 1750-1999 grams 
Extremely low birth weight newborn 
Extremely low birth weight newborn, unspecified weight 
Extremely low birth weight newborn, less than 500 grams 
Extremely low birth weight newborn, 500-749 grams 
Extremely low birth weight newborn, 750-999 grams 
Other low birth weight newborn 
Other low birth weight newborn, unspecified weight 
Other low birth weight newborn,1000-1249 grams 
Other low birth weight newborn,1250-1499 grams 
Other low birth weight newborn,1500-1749 grams 
Other low birth weight newborn,1750-1999 grams 
Preterm [premature] newborn [other] 
Preterm newborn, unspecified weeks of gestation 
Preterm labor with preterm delivery 
Preterm premature rupture of membranes, onset of labor within 24 hours of rupture 
Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, unspecified trimester 
Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, third trimester 
644.2 
644.20 
644.21 
776.6 
362.20 
362.22 
362.23 
362.24 
362.25 
362.26 
362.27 
early onset of delivery 
Early onset of delivery, unspecified as to episode of care or not applicable 
Early onset of delivery, delivered, with or without mention of antepartum condition 
anemia of prematurity 
retinopathy of prematurity, unspecified 
retinopathy of prematurity, stage 0 
retinopathy of prematurity, stage 1 
retinopathy of prematurity, stage 2 
retinopathy of prematurity, stage 3 
retinopathy of prematurity, stage 4 
retinopathy of prematurity, stage 5 
CPT 
49491 
49492 
67229 
836 
repair, initial inguinal hernia, preterm infant (younger than 37 weeks gestation at birth), performed from birth up to 50 weeks postconception 
repair, initial inguinal hernia, preterm infant (younger than 37 weeks gestation at birth), performed from birth up to 50 weeks postconception 
treatment of extensive or progressive retinopathy, 1 or more sessions; preterm infant (less than 37 weeks gestation at birth), performed from 
anesthesia for hernia repairs in the lower abdomen not otherwise specified, infants younger than 37 weeks gestational age at birth 
ICD-10 code 
Definition 
H35.1 
P61.2 
Retinopathy of prematurity 
Anemia of prematurity 
V27.2 
V27.3 
V27.4 
V27.5 
V27.6 
V31 
V32 
V33 
V34 
V35 
V36 
V37 
651 
651.0 x 
651.1 x 
651.2 x 
651.3 x 
651.4 x 
651.5 x 
651.6 x 
651.7 x 
651.8 x 
651.9 x 
Twins both liveborn 
Mother with twins one liveborn and one stillborn 
Mother with twins both stillborn 
Other multiple birth, all liveborn 
Other multiple birth, some liveborn 
Twin, mate liveborn 
Twin birth mate stillborn 
Twin, unspecified 
Other multiple, mates all liveborn 
Other multiple birth (three or more) mates all stillborn 
Other multiple, mates live- and stillborn 
Other multiple, unspecified 
Multiple gestation 
Twin Pregnancy 
Triplet pregnancy 
Quadruplet pregnancy 
Twin pregnancy with fetal loss and retention of one fetus 
Triplet pregnancy with fetal loss and retention of one or more fetus(es) 
Quadruplet pregnancy with fetal loss and retention of one or more fetus(es) 
Other multiple pregnancy with fetal loss and retention of one or more fetus(es) 
Multiple gestation following (elective) fetal reduction 
Other specified multiple gestation 
Unspecified multiple gestation 
 
 
 
Appendix A 

652.6x 
660.5x 
662.3x 
761.5x 
Multiple gestation with malpresentation of one fetus or more 
Locked Twins 
Delayed delivery of second twin, triplet, etc. 
Multiple pregnancy 
ICD10 Code 
Description 
030xxxx 
031xxxx 
043.02 
063.2 
237.2 
237.3 
237.5 
237.50 
237.51 
237.52 
237.53 
237.54 
237.59 
237.6 
237.60 
237.61 
237.62 
237.63 
237.64 
237.69 
238.3 
238.30 
238.31 
238.4 
238.5 
238.6 
238.61 
238.62 
238.63 
238.64 
238.65 
238.66 
238.68 
238.69 
238.7 
238.8 
P01.5 
Multiple gestation 
Complications specific to multiple gestation 
Fetus-to-fetus placental transfusion syndrome 
Delayed delivery of second twin, triplet, etc. 
Twins, both liveborn 
Twins, one liveborn and one stillborn 
Other multiple births, all liveborn 
Multiple births, unspecified, all liveborn 
Triplets, all liveborn 
Quadruplets, all liveborn 
Quintuplets, all liveborn 
Sextuplets, all liveborn 
Other multiple births, all liveborn 
Other multiple births, some liveborn 
Multiple births, unspecified, some liveborn 
Triplets, some liveborn 
Quadruplets, some liveborn 
Quintuplets, some liveborn 
Sextuplets, some liveborn 
Other multiple births, some liveborn 
Twin liveborn infant, born in hospital 
Twin liveborn infant, delivered vaginally 
Twin liveborn infant, delivered by cesarean 
Twin liveborn infant, born outside hospital 
Twin liveborn infant, unspecified as to place of birth 
Other multiple liveborn infant, born in hospital 
Triplet liveborn infant, delivered vaginally 
Triplet liveborn infant, delivered by cesarean 
Quadruplet liveborn infant, delivered vaginally 
Quadruplet liveborn infant, delivered by cesarean 
Quintuplet liveborn infant, delivered vaginally 
Quintuplet liveborn infant, delivered by cesarean 
Other multiple liveborn infant, delivered vaginally 
Other multiple liveborn infant, delivered by cesarean 
Other multiple liveborn infant, born outside hospital 
Other multiple liveborn infant, unspecified as to place of birth 
Newborn affected by multiple pregnancy 
645 
645.1 
645.10 
645.11 
645.13 
645.2 
645.20 
645.21 
645.23 
766.2 
766.21 
766.22 
Late Pregnancy 
Post term pregnancy 
Post term pregnancy, unspecified as to episode of care or not applicable 
Post term pregnancy, delivered, with or without mention of antepartum condition 
Post term pregnancy, antepartum condition or complication 
Prolonged pregnancy 
Prolonged pregnancy, unspecified as to episode of care or not applicable 
Prolonged pregnancy, delivered, with or without mention of antepartum condition 
Prolonged pregnancy, antepartum condition or complication 
Late infant, not 'heavy-for-dates' 
Post-term infant 
Prolonged gestation of infant 
048 
048.0 
048.1 
P08.2 
P08.21 
P08.22 
23A.41 
23A.42 
Late pregnancy 
Post-term pregnancy 
Prolonged pregnancy 
Late newborn, not heavy for gestational age 
Post-term newborn 
Prolonged gestation of newborn 
41 weeks gestation of pregnancy 
42 weeks gestation of pregnancy 
 
 
Appendix A 

23A.49 
Greater than 42 weeks gestation of pregnancy 
ICD-10 CODES 
INDICATING 
PREGNANCY 
Dx codes: 
009.XY2 Supervision of high risk pregnancy {if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O10 Pre-existing hypertension complicating pregnancy, childbirth and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
011 Pre-existing hypertension with pre-eclampsia {if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O12 Gestational [pregnancy-induced] edema and proteinuria without hypertension (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O13 Gestational [pregnancy-induced] hypertension without significant proteinuria (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O14 Pre-eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O15 Eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O16 Unspecified maternal hypertension (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O20 Hemorrhage in early pregnancy 
O21 Excessive vomiting in pregnancy (last digit refers to first/second/third/unspecified trimester) 
O22 Venous complications and hemorrhoids in pregnancy 
O23 Infections of genitourinary tract in pregnancy (last digit refers to first/second/third/unspecified trimester) 
O24 Diabetes mellitus in pregnancy, childbirth, and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O25 Malnutrition in pregnancy, childbirth and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O26 Maternal care for other conditions predominantly related to pregnancy (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O28 Abnormal findings on antenatal screening of mother 
O29 Complications of anesthesia during pregnancy (last digit refers to first/second/third/unspecified trimester) 
O30 Multiple gestation (last digit refers to first/second/third/unspecified trimester) 
O31 Complications specific to multiple gestation (certain digit refers to first/second/third/unspecified trimester) 
O32 Maternal care for malpresentation of fetus 
O33 Maternal care for disproportion 
O34 Maternal care for abnormality of pelvic organs (most codes indicate first/second/third/unspecified trimester) 
035 Maternal care for known or suspected fetal abnormality and damage 
O36 Maternal care for other fetal problems (codes indicate first/second/third/unspecified trimester) 
O40 Polyhydramnios (codes indicate first/second/third/unspecified trimester) 
O41 Other disorders of amniotic fluid and membranes (codes indicate first/second/third/unspecified trimester) 
042.1 Premature rupture of membranes, onset of labor more than 24 hours following rupture 
042.9 Premature rupture of membranes, unspecified as to length of time between rupture and onset of labor 
043 Placental disorders {last digit refers to first/second/third/unspecified trimester) 
O44 Placenta previa (last digit refers to first/second/third/unspecified trimester) 
O45 Premature separation of placenta (last digit refers to first/second/third/unspecified trimester) 
O46 Antepartum hemorrhage, not elsewhere classified (last digit refers to first/second/third/unspecified trimester) 
047 False labor 
O60.0 Preterm labor without delivery 
O61 Failed induction of labor 
071.0 Rupture of uterus {spontaneous) before onset of labor 
072 Postpartum hemorrhage 
72.2 Delayed and secondary postpartum hemorrhage 
72.3 Postpartum coagulation defects 
O73 Retained placenta and membranes, without hemorrhage 
O75 Other complications of labor and delivery, not elsewhere classified 
094 Sequelae of complication of pregnancy, childbirth, and the puerperium 
098 Maternal infectious and parasitic diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium {if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing) 
099 0ther maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium {if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing) 
09A Maternal malignant neoplasms, traumatic in uries and abuse classifiable elsewhere but complicating pregnancy, childbirth and the puerperium {if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing) 
232.01 Encounter for pregnancy test - result positive 
233 Pregnant state 
234 Encounter for supervision of normal pregnancy 
236 Encounter for antenatal screening of mother 
239 Encounter for maternal postpartum care and examination 
239.1 Encounter for care and examination of lactating mother 
239.2 Encounter for routine postpartum follow-up 
23A Weeks of gestation 
Proc codes: 
102 Change 
109 Drainage 
10H Insertion 
10J Inspection 
10P Removal 
10Q Repair 
 
 
 
 
Appendix A 

10S Reposition 
10Y Transplantation 
ries) 
 
Use the following codes only if the last digit indicates childbirth or puerperium or labor 
O10 Pre-existing hypertension complicating pregnancy, childbirth and the puerperium 
011 Pre-existing hypertension with pre-eclampsia 
O12 Gestational [pregnancy-induced] edema and proteinuria without hypertension 
O13 Gestational [pregnancy-induced] hypertension without significant proteinuria 
O14 Pre-eclampsia 
O15 Eclampsia 
O16 Unspecified maternal hypertension 
024 Diabetes mellitus in pregnancy, childbirth, and the puerperium 
025 Malnutrition in pregnancy, childbirth and the puerperium 
O26 Maternal care for other conditions predominantly related to pregnancy 
042.0 Premature rupture of membranes, onset of labor within 24 hours of rupture, except 042.011 {first trimester) 
O48 Late pregnancy 
O60.1 Preterm labor with preterm delivery 
O60.2 Term delivery with preterm labor 
O62 Abnormalities of forces of labor 
O63 Long labor 
O64 Obstructed labor due to malposition and malpresentation of fetus 
O65 Obstructed labor due to maternal pelvic abnormality 
O66 Other obstructed labor 
O67 Labor and delivery complicated by intrapartum hemorrhage, not elsewhere classified 
O68 Labor and delivery complicated by abnormality of fetal acid-base balance 
O69 Labor and delivery complicated by umbilical cord complications 
O70 Perineal laceration during delivery 
71.1 Rupture of uterus during labor 
71.2 Postpartum inversion of uterus 
71.3 0bstetric laceration of cervix 
71.4 0bstetric high vaginal laceration alone 
72.0 Third-stage hemorrhage 
72.1 0ther immediate postpartum hemorrhage 
O74 Complications of anesthesia during labor and delivery 
O76 Abnormality in fetal heart rate and rhythm complicating labor and delivery 
O77 Other fetal stress complicating labor and delivery 
O80 Encounter for full-term uncomplicated delivery 
O82 Encounter for cesarean delivery without indication 
098 Maternal infectious and parasitic diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium {if last digit indicates childbirth or puerperium) 
099 0ther maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium {if last digit indicates childbirth or puerperium) 
09A Maternal malignant neoplasms, traumatic in uries and abuse classifiable elsewhere but complicating pregnancy, childbirth and the puerperium {if last digit indicates childbirth or puerperium) 
237 0utcome of delivery {For livebirth cohort, exclude 237.1, 237.4, 237.7 - all stillbirth codes) 
238 Liveborn infants according to place of birth and type of delivery 
239.0 Encounter for care and examination of mother immediately after delivery 
ICD-10 CODES INDICATING PREGNANCY WITH ABORTIVE/NON-LIVE BIRTH OUTCOMES 
Dx codes: 
 
O00-O08 Pregnancy with abortive outcome 
Proc codes: 
10A Abortion 
10D1729 Manual Extraction of Products of Conception, Retained, Via Natural or Artificial 0pening 
10D1722 Extraction of Products of Conception, Retained, Via Natural or Artificial 0pening 
10D1829 Manual Extraction of Products of Conception, Retained, Via Natural or Artificial 0pening Endoscopic 
10D1822 Extraction of Products of Conception, Retained, Via Natural or Artificial 0pening Endoscopic 
CY 
10D2722 Extraction of Products of Conception, Ectopic, Via Natural or Artificial 0pening 
10D2822 Extraction of Products of Conception, Ectopic, Via Natural or Artificial 0pening Endoscopic 
10S2 Reposition Products of Conception, Ectopic 
10T Resection {Ectopic) 
ICD-10 CODES INDICATING ECTOPIC PREGNAN
ICD-10 CODES INDICATING DELIVERY (diagnostic codes that were not considered in the algorithm to identify delive 
Dx codes: 
Appendix A 

Dialysis Codes 
 
Codes include: 
- ICD9 prox codes: 
39.95, Hemodialysis 
54.98, Peritoneal dialysis 
- ICD9 dx codes: 
585.5x, Chronic kidney disease, Stage V (for ESRD with no mention of dialysis) 
585.6x, End stage renal disease (for ESRD with dialysis) 
V56.0x, encounter for dialysis NOS 
V56.8x, encounter for peritoneal dialysis 
V45.1x, renal dialysis status 
- CPT4 codes: 
90957, 90960, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 4 or more face-to-face physician 
visits per month 
90958, 90961, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 2-3 face-to-face physician visits 
90959, 90962, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 1 face-to-face physician visit per 
90920, 90921, ESRD related services per full month; for patients 12-19 and twenty years of age and over 
90924, 90925, ESRD related services (less than full month), per day; for patients 12-19 and twenty years of age and over 
90935, Hemodialysis procedure with single physician evaluation 
90937, Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription 
90945, Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement 
therapies), with single physician evaluation 
90947, Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement 
therapies) requiring repeated physician evaluations, with or without substantial revision of dialysis prescription 
90965, 90966, ESRD related services for home dialysis per full month, for patients 12-19 and 20 years of age and older 
90969, 90970, ESRD related services for dialysis less than a full month of service, per day; for patients 12-19 and 20 years of age and 
90989, Dialysis training, patient, including helper where applicable, any mode, completed course 
90993, Dialysis training, patient, including helper where applicable, any mode, course not completed, per training session 
90999, Unlisted dialysis procedure, inpatient or outpatient 
99512, Home visit for hemodialysis 
- HCPCS codes: 
G0257, Unscheduled or emergency dialysis treatment for ESRD patient in a hospital outpatient dept. that is not certified as an ESRD 
Appendix A 

G0314, G0317, ESRD related services during the course of treatment, for patients 12-19 and 20 yrs of age an over to include monitoring 
for the adequacy of nutrition, etc. w/4 or more physician visit per month 
G0315, G0318, ESRD related services during the course of treatment, for patients 12-19 and 20yrs of age and over to include 
monitoring for the adequacy of nutrition, etc. w/2 or 3 physician visit per month 
G0316, G0319, ESRD related services during the course of treatment, for patients 12-19 and 20 yrs of age and over to include 
monitoring for the adequacy of nutrition, etc. w/1 physician visit per month 
G0322, G0323, ESRD related services for home dialysis patients per full month: for patients 12-19 and 20 yrs of age and over to include 
monitoring for adequacy of nutrition and etc. 
G0326, G0327, ESRD related services for home dialysis (less than full month), per day; for patients 12-19 and 20 yrs of age and over 
S9335, Home therapy, hemodialysis; administrative services, professional pharmacy services, care coordination, and all necessary 
supplies and equipment (drugs and nursing services coded separately), per diem 
S9339, Home therapy, peritoneal dialysis, administrative services, care coordination and all necessary supplies and equipment, per 
OR 
Kidney transplant, defined as either 1 inpatient or 1 outpatient code 
Codes include: 
-ICD9 dx codes: 
V42.0x, Kidney transplant status 
996.81 Complications of transplanted kidney 
-ICD9 prox codes: 
55.6x, Transplant of kidney (Exclude 55.61) 
- CPT4 codes: 
50360, Renal allotransplantation, implantation, graft, w/o donor & recipient nephrectomy 
50365, Renal allotransplantation, implantation, graft, w/ donor & recipient nephrectomy 
 
Appendix A 

Liver Bypass ICD-10 Procedure Codes 
06100Z5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein, Open Approach 
0610496 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
06104K5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
06104Z5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein, Percutaneous Endoscopic Approach 
06104ZY - Bypass Inferior Vena Cava to Lower Vein, Percutaneous Endoscopic Approach 
061107B - Bypass Splenic Vein to Left Renal Vein with Autologous Tissue Substitute, Open Approach 
0611099 - Bypass Splenic Vein to Right Renal Vein with Autologous Venous Tissue, Open Approach 
06110AY - Bypass Splenic Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 
06110J9 - Bypass Splenic Vein to Right Renal Vein with Synthetic Substitute, Open Approach 
0611479 - Bypass Splenic Vein to Right Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
061147Y - Bypass Splenic Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
06114J9 - Bypass Splenic Vein to Right Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
06120ZY - Bypass Gastric Vein to Lower Vein, Open Approach 
06140AY - Bypass Hepatic Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 
061507Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 
061509Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Open Approach 
061549Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
06154AY - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
061647Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
061709Y - Bypass Colic Vein to Lower Vein with Autologous Venous Tissue, Open Approach 
061807Y - Bypass Portal Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 
061809B - Bypass Portal Vein to Left Renal Vein with Autologous Venous Tissue, Open Approach 
061809Y - Bypass Portal Vein to Lower Vein with Autologous Venous Tissue, Open Approach 
06180J9 - Bypass Portal Vein to Right Renal Vein with Synthetic Substitute, Open Approach 
06180Z9 - Bypass Portal Vein to Right Renal Vein, Open Approach 
0618479 - Bypass Portal Vein to Right Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
061849B - Bypass Portal Vein to Left Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
06184AB - Bypass Portal Vein to Left Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
06184JB - Bypass Portal Vein to Left Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
06184ZB - Bypass Portal Vein to Left Renal Vein, Percutaneous Endoscopic Approach 
06190ZY - Bypass Right Renal Vein to Lower Vein, Open Approach 
061947Y - Bypass Right Renal Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
061949Y - Bypass Right Renal Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
Appendix A 

061B0ZY - Bypass Left Renal Vein to Lower Vein, Open Approach 
061B4AY - Bypass Left Renal Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
061B4KY - Bypass Left Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
061J09Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Venous Tissue, Open Approach 
061J0KY - Bypass Left Hypogastric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 
06L30ZZ - Occlusion of Esophageal Vein, Open Approach 
061007Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Tissue Substitute, Open Approach 
06100A5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Arterial Tissue, Open Approach 
06100J5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Synthetic Substitute, Open Approach 
06100K6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Nonautologous Tissue Substitute, Open Approach 
06110JB - Bypass Splenic Vein to Left Renal Vein with Synthetic Substitute, Open Approach 
06110KB - Bypass Splenic Vein to Left Renal Vein with Nonautologous Tissue Substitute, Open Approach 
06114JY - Bypass Splenic Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
061207Y - Bypass Gastric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 
061407Y - Bypass Hepatic Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 
061409Y - Bypass Hepatic Vein to Lower Vein with Autologous Venous Tissue, Open Approach 
061449Y - Bypass Hepatic Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
06144AY - Bypass Hepatic Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
06150KY - Bypass Superior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 
06154ZY - Bypass Superior Mesenteric Vein to Lower Vein, Percutaneous Endoscopic Approach 
061607Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 
06160ZY - Bypass Inferior Mesenteric Vein to Lower Vein, Open Approach 
06164AY - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
061749Y - Bypass Colic Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
06174AY - Bypass Colic Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
06174KY - Bypass Colic Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
0618099 - Bypass Portal Vein to Right Renal Vein with Autologous Venous Tissue, Open Approach 
06180K9 - Bypass Portal Vein to Right Renal Vein with Nonautologous Tissue Substitute, Open Approach 
06184J9 - Bypass Portal Vein to Right Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
06184JY - Bypass Portal Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
06184Z9 - Bypass Portal Vein to Right Renal Vein, Percutaneous Endoscopic Approach 
061909Y - Bypass Right Renal Vein to Lower Vein with Autologous Venous Tissue, Open Approach 
061J4JY - Bypass Left Hypogastric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
06L34CZ - Occlusion of Esophageal Vein with Extraluminal Device, Percutaneous Endoscopic Approach 
Appendix A 

0610075 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Tissue Substitute, Open Approach 
06100A6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Arterial Tissue, Open Approach 
06100K5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Nonautologous Tissue Substitute, Open Approach 
06100KY - Bypass Inferior Vena Cava to Lower Vein with Nonautologous Tissue Substitute, Open Approach 
06100ZY - Bypass Inferior Vena Cava to Lower Vein, Open Approach 
061049Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
06104A5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
06104A6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
06104JY - Bypass Inferior Vena Cava to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
06104Z6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein, Percutaneous Endoscopic Approach 
061107Y - Bypass Splenic Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 
06110KY - Bypass Splenic Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 
06110ZB - Bypass Splenic Vein to Left Renal Vein, Open Approach 
061149Y - Bypass Splenic Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
06114A9 - Bypass Splenic Vein to Right Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
06114AB - Bypass Splenic Vein to Left Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
06114AY - Bypass Splenic Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
06114ZB - Bypass Splenic Vein to Left Renal Vein, Percutaneous Endoscopic Approach 
06140KY - Bypass Hepatic Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 
06140ZY - Bypass Hepatic Vein to Lower Vein, Open Approach 
06144ZY - Bypass Hepatic Vein to Lower Vein, Percutaneous Endoscopic Approach 
06150AY - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 
06150ZY - Bypass Superior Mesenteric Vein to Lower Vein, Open Approach 
061609Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Open Approach 
061649Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
06164JY - Bypass Inferior Mesenteric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
06164KY - Bypass Inferior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
06164ZY - Bypass Inferior Mesenteric Vein to Lower Vein, Percutaneous Endoscopic Approach 
06170KY - Bypass Colic Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 
061807B - Bypass Portal Vein to Left Renal Vein with Autologous Tissue Substitute, Open Approach 
06180JB - Bypass Portal Vein to Left Renal Vein with Synthetic Substitute, Open Approach 
06180KY - Bypass Portal Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 
06180ZY - Bypass Portal Vein to Lower Vein, Open Approach 
061847Y - Bypass Portal Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
Appendix A 

06184DY - Bypass Portal Vein to Lower Vein with Intraluminal Device, Percutaneous Endoscopic Approach 
06184KY - Bypass Portal Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
06190AY - Bypass Right Renal Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 
06194JY - Bypass Right Renal Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
061B07Y - Bypass Left Renal Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 
061B0AY - Bypass Left Renal Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 
061B4ZY - Bypass Left Renal Vein to Lower Vein, Percutaneous Endoscopic Approach 
061J07Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 
061J4ZY - Bypass Left Hypogastric Vein to Lower Vein, Percutaneous Endoscopic Approach 
06L33DZ - Occlusion of Esophageal Vein with Intraluminal Device, Percutaneous Approach 
06L34DZ - Occlusion of Esophageal Vein with Intraluminal Device, Percutaneous Endoscopic Approach 
0610096 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Venous Tissue, Open Approach 
061009Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Venous Tissue, Open Approach 
06100Z6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein, Open Approach 
0610476 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
06104AY - Bypass Inferior Vena Cava to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
06104J5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
06104J6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
06104KY - Bypass Inferior Vena Cava to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
06110JY - Bypass Splenic Vein to Lower Vein with Synthetic Substitute, Open Approach 
06110K9 - Bypass Splenic Vein to Right Renal Vein with Nonautologous Tissue Substitute, Open Approach 
06110ZY - Bypass Splenic Vein to Lower Vein, Open Approach 
0611499 - Bypass Splenic Vein to Right Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
06114JB - Bypass Splenic Vein to Left Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
06114K9 - Bypass Splenic Vein to Right Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
06114KB - Bypass Splenic Vein to Left Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
06114KY - Bypass Splenic Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
06114Z9 - Bypass Splenic Vein to Right Renal Vein, Percutaneous Endoscopic Approach 
06114ZY - Bypass Splenic Vein to Lower Vein, Percutaneous Endoscopic Approach 
06120KY - Bypass Gastric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 
061247Y - Bypass Gastric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
061249Y - Bypass Gastric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
06124AY - Bypass Gastric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
06150JY - Bypass Superior Mesenteric Vein to Lower Vein with Synthetic Substitute, Open Approach 
Appendix A 

06154JY - Bypass Superior Mesenteric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
06160KY - Bypass Inferior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 
061747Y - Bypass Colic Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
06174ZY - Bypass Colic Vein to Lower Vein, Percutaneous Endoscopic Approach 
0618079 - Bypass Portal Vein to Right Renal Vein with Autologous Tissue Substitute, Open Approach 
06180AY - Bypass Portal Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 
06180JY - Bypass Portal Vein to Lower Vein with Synthetic Substitute, Open Approach 
06180KB - Bypass Portal Vein to Left Renal Vein with Nonautologous Tissue Substitute, Open Approach 
06180ZB - Bypass Portal Vein to Left Renal Vein, Open Approach 
06183DY - Bypass Portal Vein to Lower Vein with Intraluminal Device, Percutaneous Approach 
061847B - Bypass Portal Vein to Left Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
0618499 - Bypass Portal Vein to Right Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
06184AY - Bypass Portal Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
06184K9 - Bypass Portal Vein to Right Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
06184ZY - Bypass Portal Vein to Lower Vein, Percutaneous Endoscopic Approach 
061907Y - Bypass Right Renal Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 
06194ZY - Bypass Right Renal Vein to Lower Vein, Percutaneous Endoscopic Approach 
061B0JY - Bypass Left Renal Vein to Lower Vein with Synthetic Substitute, Open Approach 
061B0KY - Bypass Left Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 
061B47Y - Bypass Left Renal Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
061B4JY - Bypass Left Renal Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
061J0AY - Bypass Left Hypogastric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 
061J0ZY - Bypass Left Hypogastric Vein to Lower Vein, Open Approach 
061J47Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
06L30CZ - Occlusion of Esophageal Vein with Extraluminal Device, Open Approach 
06L30DZ - Occlusion of Esophageal Vein with Intraluminal Device, Open Approach 
06L33CZ - Occlusion of Esophageal Vein with Extraluminal Device, Percutaneous Approach 
06L33ZZ - Occlusion of Esophageal Vein, Percutaneous Approach 
0610076 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Tissue Substitute, Open Approach 
0610095 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Venous Tissue, Open Approach 
06100AY - Bypass Inferior Vena Cava to Lower Vein with Autologous Arterial Tissue, Open Approach 
06100J6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Synthetic Substitute, Open Approach 
06100JY - Bypass Inferior Vena Cava to Lower Vein with Synthetic Substitute, Open Approach 
0610475 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
Appendix A 

061047Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
0610495 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
06104K6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
0611079 - Bypass Splenic Vein to Right Renal Vein with Autologous Tissue Substitute, Open Approach 
061109B - Bypass Splenic Vein to Left Renal Vein with Autologous Venous Tissue, Open Approach 
061109Y - Bypass Splenic Vein to Lower Vein with Autologous Venous Tissue, Open Approach 
06110A9 - Bypass Splenic Vein to Right Renal Vein with Autologous Arterial Tissue, Open Approach 
06110AB - Bypass Splenic Vein to Left Renal Vein with Autologous Arterial Tissue, Open Approach 
06110Z9 - Bypass Splenic Vein to Right Renal Vein, Open Approach 
061147B - Bypass Splenic Vein to Left Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
061149B - Bypass Splenic Vein to Left Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
061209Y - Bypass Gastric Vein to Lower Vein with Autologous Venous Tissue, Open Approach 
06120AY - Bypass Gastric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 
06120JY - Bypass Gastric Vein to Lower Vein with Synthetic Substitute, Open Approach 
06124JY - Bypass Gastric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
06124KY - Bypass Gastric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
06124ZY - Bypass Gastric Vein to Lower Vein, Percutaneous Endoscopic Approach 
06140JY - Bypass Hepatic Vein to Lower Vein with Synthetic Substitute, Open Approach 
061447Y - Bypass Hepatic Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
06144JY - Bypass Hepatic Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
06144KY - Bypass Hepatic Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
061547Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 
06154KY - Bypass Superior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
06160AY - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 
06160JY - Bypass Inferior Mesenteric Vein to Lower Vein with Synthetic Substitute, Open Approach 
061707Y - Bypass Colic Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 
06170AY - Bypass Colic Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 
06170JY - Bypass Colic Vein to Lower Vein with Synthetic Substitute, Open Approach 
06170ZY - Bypass Colic Vein to Lower Vein, Open Approach 
06174JY - Bypass Colic Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 
06180A9 - Bypass Portal Vein to Right Renal Vein with Autologous Arterial Tissue, Open Approach 
06180AB - Bypass Portal Vein to Left Renal Vein with Autologous Arterial Tissue, Open Approach 
061849Y - Bypass Portal Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
06184A9 - Bypass Portal Vein to Right Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
Appendix A 

06184KB - Bypass Portal Vein to Left Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
06190JY - Bypass Right Renal Vein to Lower Vein with Synthetic Substitute, Open Approach 
06190KY - Bypass Right Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 
06194AY - Bypass Right Renal Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
06194KY - Bypass Right Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
061B09Y - Bypass Left Renal Vein to Lower Vein with Autologous Venous Tissue, Open Approach 
061B49Y - Bypass Left Renal Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
061J0JY - Bypass Left Hypogastric Vein to Lower Vein with Synthetic Substitute, Open Approach 
061J49Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 
061J4AY - Bypass Left Hypogastric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 
061J4KY - Bypass Left Hypogastric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 
06L34ZZ - Occlusion of Esophageal Vein, Percutaneous Endoscopic Approach 
 
Appendix A 

Procedure Codes Description  
CPT-4 codes  
1960  
Anesthesia for vaginal delivery only  
1961  
Anesthesia for cesarean delivery only  
1962  
Anesthesia for urgent hysterectomy following delivery  
1963  
Anesthesia for cesarean hysterectomy w/o any labor analgesia/anesthesia care 1967 
 
                                                                                                            
Neuraxial labor analgesia/anesthesia, planned vaginal delivery  
1968  
Anesthesia for cesarean delivery following neuraxial labor analgesia/anesthesia 1969 
 
                                                                                                               
Anes for cesarean hysterectomy following neuraxial labor analgesia/anesthesia 59050  
                                                                                                                    
Fetal monitoring in labor, physician w/written report; s & i  
59051  
Fetal monitoring in labor, physician w/written report; intrepretation only  
59400  
ROUTINE TOTAL OBSTETRIC CARE including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care. 59409 
 
                                                                                                                                                                                                                    
Vaginal delivery only (w/wo episiotomy &/or forceps)  
59410  
Vaginal delivery only (w/wo episiotomy &/or forceps); w/postpartum care 59412 
 
                                                                                                               
Ext cephalic version, w/wo tocolysis  
59414  
Delivery of placenta (separate  proc)  
59430  
Postpartum care only  
59510  
Routine obstetric care w/antepartum care, cesarean delivery, & postpartum care 59514 
 
                                                                                                               
Cesarean delivery only  
59515  
Cesarean delivery only; w/postpartum care  
59525  
Subtotal/total hysterectomy after cesarean delivery  
59610  
Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care, after previous cesarean delivery 59612                                                                                                                                                                      
Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps)  
59614  
Vaginal delivery only, previous cesarean delivery w/postpartum care  
 
ICD-9 procedure 
codes  
 
72. x  
Forceps, vacuum, & breech  
73. x  
Other including manual delivery  
74xx  
Cesarean section  
75.4x  
Manual removal of placenta  
ICD-10 
procedure 
codes  
 
Normal 
Delivery  
10E0XZZ 
Delivery of Products of Conception, External Approach  
C-Section  
10D00Z0 
Extraction of Products of Conception, High, Open Approach  
10D00Z1 
Extraction of Products of Conception, Low, Open Approach  
10D00Z2 
Extraction of Products of Conception, Extraperitoneal, Open Approach  
Other assisted delivery (forceps, vacuum, internal version, other)  
10D07Z3 
Extraction of Products of Conception, Low Forceps, Via Natural or Artificial Opening 10D07Z4
 
                                                                                                                       
Extraction of Products of Conception, Mid Forceps, Via Natural or Artificial Opening 10D07Z5
 
                                                                                                                       
Extraction of Products of Conception, High Forceps, Via Natural or Artificial Opening 10D07Z6
 
                                                                                                                       
Extraction of Products of Conception, Vacuum, Via Natural or Artificial Opening 10D07Z7 
                                                                                                                       
f
f C
f
O
10 0
8
ICD-9 code  
Definition   Gestational Age  
  
  
Weeks  
Days  
765.21  
Less than 24 c 24  
168  
765.22  
24 completed weeks of gestation  
765.23  
25-26 comple 26  
182  
765.24  
27-28 comple 28  
196  
765.25  
29-30 comple 30  
210  
765.26  
31-32 comple 32  
224  
765.27  
33-34 comple 34  
238  
765.28  
35-36 comple 36  
252  
ICD-10 code  
Definition   Gestational Age  

 P07.2
1 P07.2
2 P07.2
3 P07.2
4 P07.2
5 P07.2
6 P07.3
1 P07.3
2 P07.3
3 P07.3
4 P07.3
5 P07.3
6 P07.3
7 P07.3
8 P07.3
9  
  
Weeks  
Days 
161  
161  
168  
175  
182  
189  
196  
203  
210  
217  
224  
231  
238  
245  
252  
Extreme imm 23 Extreme 
imm 23 Extreme 
imm 24 Extreme 
imm 25 Extreme 
imm 26 Extreme 
imm 27 Preterm 
new 28 Preterm 
new 29 Preterm 
new 30 Preterm 
new 31 Preterm 
new 32 Preterm 
new 33 Preterm 
new 34 Preterm 
new 35 Preterm 
new 36  
Codes indicating extreme prematurity  
ICD-9 code  
Definition   Gestational Age  
 765.
0  
765.00 
765.01 
765.02 
765.03 
765.04 
765.05 
765.06 
765.07 
765.08 
  
Weeks  
Days 
196  
Disorders rela 28  
Extreme immaturity, unspecified [weight] Extreme 
immaturity, less than 500 grams Extreme 
immaturity, 500-749 grams Extreme 
immaturity, 750-999 grams Extreme 
immaturity, 1,000-1,249 grams Extreme 
immaturity, 1,250-1,499 grams Extreme 
immaturity, 1,500-1,749 grams Extreme 
immaturity, 1,750-1,999 grams Extreme 
immaturity, 2,000-2,499 grams  
ICD-10 code  
Definition   Gestational Age  
 P07.2 
P07.20  
O42.012  
  
Weeks  
Days 
196  
Extreme imm 28  
Extreme immaturity of newborn, unspecified weeks of gestation  
Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, second trimester  
Other preterm 
codes  
ICD-9 code  
Definition   Gestational Age  
 765.
1  
765.10 
765.11 
765.12 
765.13 
765.14 
765.15 
765.16 
765.17 
765.18 
644.21  
  
Weeks  
Days 
245  
Disorders rela 35  
Other preterm infants, unspecified [weight] Other 
preterm infants, less than 500 grams Other 
preterm infants, 500-749 grams Other 
preterm infants, 750-999 grams Other 
preterm infants, 1,000-1,249 grams Other 
preterm infants, 1,250-1,499 grams Other 
preterm infants, 1,500-1,749 grams Other 
preterm infants, 1,750-1,999 grams Other 
preterm infants, 2,000-2,499 grams  
Onset of delivery before 37 completed weeks of gestation  
ICD-10 code  
Definition   Gestational Age  
  
P05.01 
P05.02 
P05.03 
P05.04 
P05.05 
P05.06 
P05.07 
P05.11 
P05.12 
P05.13 
P05.14  
  
Weeks  
Days 
245  
Disorders of n 35  
Disorders of newborn related to slow fetal growth and fetal malnutrition, 500-749 grams Disorders 
of newborn related to slow fetal growth and fetal malnutrition, 750-999 grams Disorders 
of newborn related to slow fetal growth and fetal malnutrition, 1000-1249 grams Disorders 
of newborn related to slow fetal growth and fetal malnutrition, 1250-1499 grams Disorders 
of newborn related to slow fetal growth and fetal malnutrition, 1500-1749 grams Disorders 
of newborn related to slow fetal growth and fetal malnutrition, 1750-1999 grams Newborn 
small for gestational age, less than 500 grams  
Newborn small for gestational age, 500-749 grams Newborn 
small for gestational age, 750-999 grams Newborn 
small for gestational age, 1000-1249 grams  
 
 
 
 
 
 

P05.15 P0
P07.00 P0
O60.1 O42
Newborn small for gestational age, 1250-1499 grams Newborn 
small for gestational age, 1500-1749 grams Newborn 
small for gestational age, 1750-1999 grams Extremely 
low birth weight newborn  
Extremely low birth weight newborn, unspecified weight Extremely 
low birth weight newborn, less than 500 grams Extremely 
low birth weight newborn, 500-749 grams Extremely 
low birth weight newborn, 750-999 grams Other 
low birth weight newborn  
Other low birth weight newborn, unspecified weight Other 
low birth weight newborn,1000-1249 grams Other 
low birth weight newborn,1250-1499 grams Other 
low birth weight newborn,1500-1749 grams Other 
low birth weight newborn,1750-1999 grams Preterm 
[premature] newborn [other]  
Preterm newborn, unspecified weeks of gestation Preterm 
labor with preterm delivery  
Preterm premature rupture of membranes, onset of labor within 24 hours of rupture 
Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, unspecified trimester 
Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, third trimester  
644.2  
644.20  
644.21  
776.6  
362.20  
362.22  
362.23  
362.24  
362.25  
362.26  
362.27  
early onset of delivery  
Early onset of delivery, unspecified as to episode of care or not applicable  
Early onset of delivery, delivered, with or without mention of antepartum condition anemia 
of prematurity  
retinopathy of prematurity, unspecified retinopathy 
of prematurity, stage   0 retinopathy 
of prematurity, stage   1 retinopathy 
of prematurity, stage   2 retinopathy 
of prematurity, stage   3 retinopathy 
of prematurity, stage   4 retinopathy 
of prematurity, stage 5  
  
repair, initial inguinal hernia, preterm infant (younger than 37 weeks gestation at birth), performed from birth up to 50 weeks postconception repair, 
initial inguinal hernia, preterm infant (younger than 37 weeks gestation at birth), performed from birth up to 50 weeks postconception treatment 
of extensive or progressive retinopathy, 1 or more sessions; preterm infant (less than 37 weeks gestation at birth), performed from anesthesia 
for hernia repairs in the lower abdomen not otherwise specified, infants younger than 37 weeks gestational age at birth  
CPT  
49491  
49492  
67229  
836  
ICD-10 code  
Definition  
  
Retinopathy of prematurity Anemia 
of prematurity  
 H35.
1 P61.
2  
V27.2 
V27.3 
V27.4 
V27.5  
V27.6 
V31 V
32 V33
 V34 V
35 V36
 V37 6
51  
651.0 x  
651.1 x  
651.2 x  
651.3 x  
651.4 x  
651.5 x  
651.6 x  
651.7 x  
651.8 x  
651.9 x  
Twins both liveborn  
Mother with twins one liveborn and one stillborn  Mother 
with twins both stillborn  
Other multiple birth, all liveborn Other 
multiple birth, some liveborn Twin, 
mate liveborn  
Twin birth mate stillborn  Twin, 
unspecified  
Other multiple, mates all liveborn  
Other multiple birth (three or more) mates all stillborn  Other 
multiple, mates live- and stillborn  
Other multiple, unspecified Multiple 
gestation  
Twin Pregnancy Triplet 
pregnancy Quadruplet 
pregnancy  
Twin pregnancy with fetal loss and retention of one fetus 
Triplet pregnancy with fetal loss and retention of one or more fetus(es) Quadruplet 
pregnancy with fetal loss and retention of one or more fetus(es) Other 
multiple pregnancy with fetal loss and retention of one or more fetus(es) Multiple 
gestation following (elective) fetal reduction  
Other specified multiple gestation Unspecified 
multiple gestation  
 
 
 

652.6x  
660.5x  
662.3x  
761.5x  
Multiple gestation with malpresentation of one fetus or more Locked 
Twins  
Delayed delivery of second twin, triplet, 
etc. Multiple pregnancy  
ICD10 Code   
Description  
O30xxxx 
O31xxxx 
O43.02 
O63.2 
Z37.2 
Z37.3 
Z37.5 
Z37.50 
Z37.51 
Z37.52 
Z37.53 
Z37.54 
Z37.59 
Z37.6 
Z37.60 
Z37.61 
Z37.62 
Z37.63 
Z37.64 
Z37.69 
Z38.3 
Z38.30 
Z38.31 
Z38.4 
Z38.5 
Z38.6 
Z38.61 
Z38.62 
Z38.63 
Z38.64 
Z38.65 
Z38.66 
Z38.68 
Z38.69 
Z38.7 
Z38.8 
P01.5 
Multiple gestation  
Complications specific to multiple gestation Fetus-to-fetus 
placental transfusion syndrome Delayed 
delivery of second twin, triplet, etc. Twins, 
both liveborn  
Twins, one liveborn and one stillborn Other 
multiple births, all liveborn Multiple 
births, unspecified, all liveborn Triplets, 
all liveborn  
Quadruplets, al liveborn Quintuplets, 
all 
liveborn Sextuplets, 
all liveborn  
Other multiple births, all liveborn Other 
multiple births, some liveborn  
Multiple births, unspecified, some liveborn Triplets, 
some liveborn  
Quadruplets, some liveborn Quintuplets, 
some 
liveborn Sextuplets, 
some liveborn  
Other multiple births, some liveborn Twin 
liveborn infant, born in hospital Twin 
liveborn infant, delivered vaginally  
Twin liveborn infant, delivered by cesarean Twin 
liveborn infant, born outside hospital  
Twin liveborn infant, unspecified as to place of birth Other 
multiple liveborn infant, born in hospital Triplet 
liveborn infant, delivered vaginally  
Triplet liveborn infant, delivered by cesarean Quadruplet 
liveborn infant, delivered vaginally Quadruplet 
liveborn infant, delivered by cesarean Quintuplet 
liveborn infant, delivered vaginally Quintuplet 
liveborn infant, delivered by cesarean Other 
multiple liveborn infant, delivered vaginally Other 
multiple liveborn infant, delivered by cesarean Other 
multiple liveborn infant, born outside hospital  
Other multiple liveborn infant, unspecified as to place of birth Newborn 
affected by multiple pregnancy  
 64
5  
645.1  
645.10  
645.11  
645.13  
645.2  
645.20  
645.21  
645.23  
766.2  
766.21  
766.22  
  
Late Pregnancy  
Post term pregnancy  
Post term pregnancy, unspecified as to episode of care or not applicable  
Post term pregnancy, delivered, with or without mention of antepartum condition Post 
term pregnancy, antepartum condition or complication  
Prolonged pregnancy  
Prolonged pregnancy, unspecified as to episode of care or not applicable Prolonged 
pregnancy, delivered, with or without mention of antepartum condition Prolonged 
pregnancy, antepartum condition or complication  
Late infant, not 'heavy-for-dates' Post-term 
infant  
Prolonged gestation of infant  
O48 
O48.0 
O48.1 
P08.2 
P08.21 
P08.22 
Z3A.41 
Z3A.42 
Late pregnancy  
Post-term pregnancy Prolonged 
pregnancy  
Late newborn, not heavy for gestational age Post-term 
newborn  
Prolonged gestation of newborn 41 
weeks gestation of pregnancy 42 
weeks gestation of pregnancy  
 
 

Z3A.49 
Greater than 42 weeks gestation of pregnancy  
ICD-10 CODES 
INDICATING 
PREGNANCY  
Dx codes:  
O09.XYZ Supervision of high risk pregnancy (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O10 Pre-existing hypertension complicating pregnancy, childbirth and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)  
O11 Pre-existing hypertension with pre-eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 
O12 Gestational [pregnancy-induced] edema and proteinuria without hypertension (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O13 
Gestational [pregnancy-induced] hypertension without significant proteinuria (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O14 
Pre-eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)  
O15 Eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)  
O16 Unspecified maternal hypertension (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O20 
Hemorrhage in early pregnancy  
O21 Excessive vomiting in pregnancy (last digit refers to first/second/third/unspecified trimester) O22 
Venous complications and hemorrhoids in pregnancy  
O23 Infections of genitourinary tract in pregnancy (last digit refers to first/second/third/unspecified trimester)  
O24 Diabetes mellitus in pregnancy, childbirth, and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O25 
Malnutrition in pregnancy, childbirth and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period)  
O26 Maternal care for other conditions predominantly related to pregnancy (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O28 
Abnormal findings on antenatal screening of mother  
O29 Complications of anesthesia during pregnancy (last digit refers to first/second/third/unspecified trimester) O30 
Multiple gestation (last digit refers to first/second/third/unspecified trimester)  
O31 Complications specific to multiple gestation (certain digit refers to first/second/third/unspecified trimester) O32 
Maternal care for malpresentation of fetus  
O33 Maternal care for disproportion  
O34 Maternal care for abnormality of pelvic organs (most codes indicate first/second/third/unspecified trimester)  
O35 Maternal care for known or suspected fetal abnormality and damage 
O36 Maternal care for other fetal problems (codes indicate first/second/third/unspecified trimester) O40 
Polyhydramnios (codes indicate first/second/third/unspecified trimester)  
O41 Other disorders of amniotic fluid and membranes (codes indicate first/second/third/unspecified trimester)  
O42.1 Premature rupture of membranes, onset of labor more than 24 hours following rupture 
O42.9 Premature rupture of membranes, unspecified as to length of time between rupture and onset of labor 
O43 Placental disorders (last digit refers to first/second/third/unspecified trimester) 
O44 Placenta previa (last digit refers to first/second/third/unspecified trimester)  
O45 Premature separation of placenta (last digit refers to first/second/third/unspecified trimester)  
O46 Antepartum hemorrhage, not elsewhere classified (last digit refers to first/second/third/unspecified trimester)  
O47 False labor 
O60.0 Preterm labor without delivery O61 
Failed induction of labor  
O71.0 Rupture of uterus (spontaneous) before onset of labor 
O72 Postpartum hemorrhage 
O72.2 Delayed and secondary postpartum hemorrhage 
O72.3 Postpartum coagulation defects 
O73 Retained placenta and membranes, without hemorrhage  
O75 Other complications of labor and delivery, not elsewhere classified  
O94 Sequelae of complication of pregnancy, childbirth, and the puerperium 
O98 Maternal infectious and parasitic diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing) 
O99 Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing) 
O9A Maternal malignant neoplasms, traumatic injuries and abuse classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing) 
Z32.01 Encounter for pregnancy test - result positive 
Z33 Pregnant state 
Z34 Encounter for supervision of normal pregnancy 
Z36 Encounter for antenatal screening of mother 
Z39 Encounter for maternal postpartum care and examination 
Z39.1 Encounter for care and examination of lactating mother 
Z39.2 Encounter for routine postpartum follow-up 
Z3A Weeks of gestation 
Proc codes:  
102 Change 
109 Drainage 
10H Insertion 
10J Inspection 
10P Removal 
10Q Repair 
 
 
 
 

10S Reposition 
10Y Transplantation 
ries)  
 
Use the following codes only if the last digit indicates childbirth or puerperium or labor O10 
Pre-existing hypertension complicating pregnancy, childbirth and the puerperium O11 
Pre-existing hypertension with pre-eclampsia 
O12 Gestational [pregnancy-induced] edema and proteinuria without hypertension O13 
Gestational [pregnancy-induced] hypertension without significant proteinuria O14 
Pre-eclampsia  
O15 Eclampsia  
O16 Unspecified maternal hypertension  
O24 Diabetes mellitus in pregnancy, childbirth, and the puerperium 
O25 Malnutrition in pregnancy, childbirth and the puerperium 
O26 Maternal care for other conditions predominantly related to pregnancy  
O42.0 Premature rupture of membranes, onset of labor within 24 hours of rupture, except 042.011 (first trimester) 
O48 Late pregnancy  
O60.1 Preterm labor with preterm delivery O60.2 
Term delivery with preterm labor O62 
Abnormalities of forces of labor  
O63 Long labor  
O64  Obstructed labor due to malposition and malpresentation of 
fetus O65  Obstructed labor due to maternal pelvic abnormality  
O66  Other obstructed labor  
O67  Labor and delivery complicated by intrapartum hemorrhage, not elsewhere 
classified O68  Labor and delivery complicated by abnormality of fetal acid-base balance  
O69  Labor and delivery complicated by umbilical cord 
complications O70  Perineal laceration during delivery  
O71.1 Rupture of uterus during labor 
O71.2 Postpartum inversion of uterus 
O71.3 Obstetric laceration of cervix 
O71.4 Obstetric high vaginal laceration alone 
O72.0 Third-stage hemorrhage 
O72.1 Other immediate postpartum hemorrhage 
O74 Complications of anesthesia during labor and delivery  
O76  Abnormality in fetal heart rate and rhythm complicating labor and 
delivery O77  Other fetal stress complicating labor and delivery  
O80  Encounter for full-term uncomplicated 
delivery O82  Encounter for cesarean delivery without 
indication  
O98 Maternal infectious and parasitic diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates childbirth or puerperium) 
O99 Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates childbirth or puerperium) 
O9A Maternal malignant neoplasms, traumatic injuries and abuse classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates childbirth or puerperium) 
Z37 Outcome of delivery (For livebirth cohort, exclude Z37.1, Z37.4, Z37.7 - all stillbirth codes) 
Z38 Liveborn infants according to place of birth and type of delivery 
ICD-10 CODES INDICATING PREGNANCY WITH ABORTIVE/NON-LIVE BIRTH OUTCOMES  
Dx codes:  
 
O00-O08  Pregnancy with abortive outcome  
Proc codes:  
10A Abortion 
10D17Z9 Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening 
10D17ZZ Extraction of Products of Conception, Retained, Via Natural or Artificial Opening 
10D18Z9 Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening Endoscopic 
10D18ZZ Extraction of Products of Conception, Retained, Via Natural or Artificial Opening Endoscopic 
CY  
10D27ZZ Extraction of Products of Conception, Ectopic, Via Natural or Artificial Opening 
10D28ZZ Extraction of Products of Conception, Ectopic, Via Natural or Artificial Opening Endoscopic 
10S2 Reposition Products of Conception, Ectopic 
10T Resection (Ectopic) 
ICD-10 CODES INDICATING ECTOPIC PREGNAN
ICD-10 CODES INDICATING DELIVERY (diagnostic codes that were not considered in the algorithm to identify delive 
Dx codes:  

Unmatched 
Optum 
MarketScan 
Medicare 
Pooled 
Variable 
Number of patients 
Rivaroxaban 
39,574 
Apixaban 
72,261 
St. Diff 
Rivaroxaban 
41,932 
Apixaban 
49,503 
St. Diff 
Rivaroxaban 
148,933 
Apixaban 
176,546 
St. Diff 
Rivaroxaban 
230,439 
Apixaban 
298,310 
St. Diff 
Age 
...mean (sd) 
71.62 (10.97) 
74.33 (10.14) 
-0.26 
66.38 (12.81) 
65.00 [58.00, 
76.00] 
68.13 (13.18) 
-0.13 
76.19 (8.31) 
76.00 [70.00, 
82.00] 
77.68 (8.32) 
77.00 [72.00, 
84.00] 
-0.18 
73.62 (9.75) 
75.28 (9.73) 
-0.17 
...median [IQR] 
73.00 [66.00, 80.00] 
75.00 [68.00, 82.00] 
-0.19 
67.00 [59.00, 79.00] -0.15 
-0.12 
73.48 (9.75) 
74.86 (9.73) 
-0.14 
Age categories 
11,181 (4.9%) 
24,474 (10.6%) 
10,856 (3.6%) 
27,186 (9.1%) 
...18 - 54; n (%) 
...55 - 64; n (%) 
2,971 (7.5%) 
5,841 (14.8%) 
3,087 (4.3%) 
7,454 (10.3%) 
0.14 
0.14 
6,634 (15.8%) 
14,308 (34.1%) 
6,712 (13.6%) 
16,051 (32.4%) 
0.06 
0.04 
1,576 (1.1%) 
4,325 (2.9%) 
1,057 (0.6%) 
3,681 (2.1%) 
0.05 
0.05 
0.06 
0.05 
...65 - 74; n (%) 
13,453 (34.0%) 
22,947 (31.8%) 
0.05 
8,881 (21.2%) 
9,746 (19.7%) 
0.04 
59,453 (39.9%) 
61,457 (34.8%) 
0.11 
-0.13 
81,787 (35.5%) 
94,150 (31.6%) 
0.08 
...>= 75; n (%) 
17,309 (43.7%) 
38,773 (53.7%) 
-0.20 
12,109 (28.9%) 
16,994 (34.3%) 
-0.12 
83,579 (56.1%) 
110,351 (62.5%) 
112,997 (49.0%) 
166,118 (55.7%) -0.13 
Calendar Year 
...2012-2013; n (%) 
...2014; n (%) 
...2015; n (%) 
4,197 (10.6%) 
4,602 (11.6%) 
4,140 (10.5%) 
867 (1.2%) 
2,864 (4.0%) 
4,852 (6.7%) 
0.41 
0.29 
0.14 
9,233 (22.0%) 
9,189 (21.9%) 
5,973 (14.2%) 
2,364 (4.8%) 
5,504 (11.1%) 
6,793 (13.7%) 
25,035 (16.8%) 
31,251 (21.0%) 
28,517 (19.1%) 
6,172 (3.5%) 
22,092 (12.5%) 
38,857 (22.0%) 
45,042 (19.5%) 
38,630 (16.8%) 
30,460 (10.2%) 
50,502 (16.9%) 
0.01 
-0.07 
0.00 
...2016; n (%) 
...2017; n (%) 
4,683 (11.8%) 
6,255 (15.8%) 
7,836 (10.8%) 
11,432 (15.8%) 
0.03 
0.00 
5,979 (14.3%) 
4,651 (11.1%) 
9,613 (19.4%) 
8,328 (16.8%) 
29,375 (19.7%) 
34,755 (23.3%) 
54,270 (30.7%) 
55,155 (31.2%) 
40,037 (17.4%) 
45,661 (19.8%) 
71,719 (24.0%) 
74,915 (25.1%) 
-0.16 
-0.13 
-0.15 
-0.21 
-0.13 
10,686 (4.6%) 
9,185 (4.0%) 
2,733 (1.2%) 
24,376 (8.2%) 
27,560 (9.2%) 
9,375 (3.1%) 
...2018; n (%) 
...2019; n (%) 
...2020; n (%) 
6,939 (17.5%) 
6,025 (15.2%) 
2,733 (6.9%) 
16,269 (22.5%) 
18,766 (26.0%) 
9,375 (13.0%) 
-0.13 
-0.27 
-0.20 
3,747 (8.9%) 
3,160 (7.5%) 
0 (0.0%) 
8,107 (16.4%) 
8,794 (17.8%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0.00 
0.00 
0.00 
0.00 
Race 
...White; n (%) 
...Asian; n (%) 
...Black; n (%) 
...Hispanic; n (%) 
...North American Native; n (%) 
...Other; n (%) 
...Unknown/Missing; n (%) 
30,226 (76.4%) 
1,106 (2.8%) 
3,074 (7.8%) 
3,338 (8.4%) 
0 (0.0%) 
0 (0.0%) 
1,830 (4.6%) 
54,845 (75.9%) 
1,674 (2.3%) 
6,306 (8.7%) 
5,831 (8.1%) 
0 (0.0%) 
0 (0.0%) 
3,605 (5.0%) 
0.01 
0.03 
-0.03 
0.01 
0.00 
0.00 
-0.02 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
135,426 (90.9%) 
2,255 (1.5%) 
5,771 (3.9%) 
1,831 (1.2%) 
488 (0.3%) 
1,695 (1.1%) 
1,467 (1.0%) 
162,189 (91.9%) 
2,276 (1.3%) 
6,463 (3.7%) 
1,723 (1.0%) 
394 (0.2%) 
1,871 (1.1%) 
1,630 (0.9%) 
-0.04 
0.02 
0.01 
0.02 
0.02 
0.00 
0.01 
165,652 (71.9%) 
3,361 (1.5%) 
8,845 (3.8%) 
5,169 (2.2%) 
488 (0.2%) 
1,695 (0.7%) 
3,297 (1.4%) 
217,034 (72.8%) -0.02 
3,950 (1.3%) 
12,769 (4.3%) 
7,554 (2.5%) 
394 (0.1%) 
1,871 (0.6%) 
5,235 (1.8%) 
0.02 
-0.03 
-0.02 
0.03 
0.01 
-0.03 
Gender 
...Males; n (%) 
...Females; n (%) 
22,017 (55.6%) 
17,557 (44.4%) 
35,331 (48.9%) 
36,930 (51.1%) 
0.13 
-0.13 
25,981 (62.0%) 
15,951 (38.0%) 
28,450 (57.5%) 
21,053 (42.5%) 
0.09 
-0.09 
69,102 (46.4%) 
79,831 (53.6%) 
74,655 (42.3%) 
101,891 (57.7%) 
0.08 
-0.08 
117,100 (50.8%) 
113,339 (49.2%) 
138,436 (46.4%) 0.09 
159,874 (53.6%) -0.09 
Region 
...Northeast; n (%) 
...South; n (%) 
...Midwest; n (%) 
...West; n (%) 
...Unknown+missing; n (%) 
5,135 (13.0%) 
15,708 (39.7%) 
8,152 (20.6%) 
10,532 (26.6%) 
47 (0.1%) 
8,428 (11.7%) 
31,239 (43.2%) 
14,311 (19.8%) 
18,224 (25.2%) 
59 (0.1%) 
0.04 
-0.07 
0.02 
0.03 
0.00 
9,129 (21.8%) 
15,396 (36.7%) 
11,112 (26.5%) 
5,984 (14.3%) 
311 (0.7%) 
10,796 (21.8%) 
19,405 (39.2%) 
12,993 (26.2%) 
6,136 (12.4%) 
173 (0.3%) 
0.00 
-0.05 
0.01 
0.06 
0.06 
28,936 (19.4%) 
58,960 (39.6%) 
33,349 (22.4%) 
27,511 (18.5%) 
177 (0.1%) 
33,847 (19.2%) 
75,552 (42.8%) 
37,469 (21.2%) 
29,543 (16.7%) 
135 (0.1%) 
0.01 
-0.07 
0.03 
0.05 
0.00 
43,200 (18.7%) 
90,064 (39.1%) 
52,613 (22.8%) 
44,027 (19.1%) 
535 (0.2%) 
53,071 (17.8%)  0.02 
126,196 (42.3%) -0.07 
64,773 (21.7%) 
53,903 (18.1%) 
367 (0.1%) 
0.03 
0.03 
0.03 
Combined comorbidity score, 180 days 
1.84 (1.83) 
1.17 (1.83) 
2.14 (2.04) 
1.83 (2.04) 
...mean (sd) 
2.18 (2.11) 
2.63 (2.37) 
-0.20 
1.53 (1.58) 
1.80 (1.80) 
-0.16 
1.83 (1.81) 
2.04 (1.95) 
-0.11 
-0.53 
-0.15 
-0.34 
...median [IQR] 
2.00 [1.00, 3.00] 
2.00 [1.00, 4.00] 
0.00 
1.00 [0.00, 2.00] 
1.00 [0.00, 3.00] 
0.00 
1.00 [0.00, 3.00] 
2.00 [1.00, 3.00] 
Lifestyle Factors 
42,207 (18.3%) 
63,027 (21.1%) 
Lifestyle - Smoking ; n (%) 
7,264 (18.4%) 
16,958 (23.5%) 
-0.13 
3,833 (9.1%) 
5,125 (10.4%) 
-0.04 
31,110 (20.9%) 
40,944 (23.2%) 
-0.06 
-0.07 
Lifestyle - Drug abuse or dependence; n (%) 
Lifestyle - Alcohol abuse or dependence ; n (%) 
635 (1.6%) 
942 (2.4%) 
1,364 (1.9%) 
1,620 (2.2%) 
-0.02 
0.01 
301 (0.7%) 
789 (1.9%) 
479 (1.0%) 
879 (1.8%) 
-0.03 
0.01 
930 (0.6%) 
1,437 (1.0%) 
1,139 (0.6%) 
1,907 (1.1%) 
0.00 
-0.01 
1,866 (0.8%) 
3,168 (1.4%) 
2,982 (1.0%) 
4,406 (1.5%) 
-0.02 
-0.01 
2,433 (1.1%) 
8,688 (3.8%) 
5,295 (2.3%) 
1,563 (0.7%) 
2,224 (1.0%) 
2,485 (1.1%) 
53,863 (23.4%) 
183,583 (79.7%) 
119,427 (51.8%) 
4,851 (2.1%) 
4,669 (2.0%) 
8,208 (3.6%) 
7,199 (3.1%) 
54,774 (23.8%) 
2,337 (1.0%) 
13,796 (6.0%) 
23,513 (10.2%) 
338 (0.1%) 
8,647 (3.8%) 
6,868 (3.0%) 
5,558 (2.4%) 
41,789 (18.1%) 
14,534 (6.3%) 
147,362 (63.9%) 
16,844 (7.3%) 
68,662 (29.8%) 
71,846 (31.2%) 
53,521 (23.2%) 
26,244 (11.4%) 
154,666 (67.1%) 
48,281 (21.0%) 
9,908 (4.3%) 
12,453 (5.4%) 
116,527 (50.6%) 
10,050 (4.4%) 
89,021 (38.6%) 
18,485 (8.0%) 
14,903 (6.5%) 
35,362 (15.3%) 
3,528 (1.2%) 
13,093 (4.4%) 
10,257 (3.4%) 
1,407 (0.5%) 
2,371 (0.8%) 
4,240 (1.4%) 
68,887 (23.1%) 
DM - Diabetic Retinopathy; n (%) 
DM - Diabetic Neuropathy; n (%) 
DM - Diabetic Nephropathy; n (%) 
DM - Diabetes with peripheral circulatory disorders; n (%) 
DM - Diabetes with peripheral circulatory disorders and lower extremity amputation; n (%) 
DM - Diabetes with unspecified complications; n (%) 
DM - Diabetes mellitus without mention of complications; n (%) 
CV - Hypertension; n (%) 
CV - Hyperlipidemia; n (%) 
CV -Acute MI; n (%) 
CV - ACS/unstable angina; n (%) 
CV - Old MI; n (%) 
CV - Stable angina; n (%) 
CV - Coronary atherosclerosis and other forms of chronic ischemic heart disease; n (%) 
CV - Other atherosclerosis; n (%) 
CV - Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA; n (%) 
CV - Ischemic stroke; n (%) 
CV - Hemorrhagic stroke; n (%) 
CV - TIA; n (%) 
CV - Other cerebrovascular disease; n (%) 
CV - Late effects of cerebrovascular disease; n (%) 
CV - Heart failure (CHF); n (%) 
CV - Peripheral Vascular Disease (PVD) or PVD Surgery; n (%) 
CV - Other cardiac dysrhythmia; n (%) 
CV - Cardiac conduction disorders; n (%) 
CV - Other CVD; n (%) 
CV Medications - ACE inhibitors; n (%) 
CV Medications - ARBs; n (%) 
CV Medications - Alpha blockers; n (%) 
CV Medications - Beta blockers; n (%) 
CV Medications - Loop Diuretics; n (%) 
CV Medications - Other diuretics; n (%) 
CV Medications - Use of nitrates; n (%) 
CV Medications - Use of statins; n (%) 
CV Medications - Use of other lipid-lowering drugs; n (%) 
CV Medications - calcium channel blockers; n (%) 
Other Comorbidity - Osteoporosis; n (%) 
Other Comorbidity - Dementia; n (%) 
605 (1.5%) 
2,112 (5.3%) 
1,839 (4.6%) 
237 (0.6%) 
400 (1.0%) 
613 (1.5%) 
9,234 (23.3%) 
30,179 (76.3%) 
22,249 (56.2%) 
867 (2.2%) 
879 (2.2%) 
1,608 (4.1%) 
1,611 (4.1%) 
9,721 (24.6%) 
401 (1.0%) 
2,438 (6.2%) 
3,999 (10.1%) 
82 (0.2%) 
1,479 (3.7%) 
1,318 (3.3%) 
1,121 (2.8%) 
8,081 (20.4%) 
2,975 (7.5%) 
31,139 (78.7%) 
3,467 (8.8%) 
13,558 (34.3%) 
12,072 (30.5%) 
8,626 (21.8%) 
4,439 (11.2%) 
25,750 (65.1%) 
7,758 (19.6%) 
1,689 (4.3%) 
1,781 (4.5%) 
19,481 (49.2%) 
1,491 (3.8%) 
14,755 (37.3%) 
3,078 (7.8%) 
2,747 (6.9%) 
1,277 (1.8%) 
4,428 (6.1%) 
4,384 (6.1%) 
219 (0.3%) 
559 (0.8%) 
1,427 (2.0%) 
17,107 (23.7%) 
58,264 (80.6%) 
42,515 (58.8%) 
2,489 (3.4%) 
2,265 (3.1%) 
3,799 (5.3%) 
3,872 (5.4%) 
20,300 (28.1%) 
694 (1.0%) 
5,874 (8.1%) 
10,074 (13.9%) 
276 (0.4%) 
3,583 (5.0%) 
3,880 (5.4%) 
3,137 (4.3%) 
18,051 (25.0%) 
6,179 (8.6%) 
67,495 (93.4%) 
8,478 (11.7%) 
28,521 (39.5%) 
22,048 (30.5%) 
16,995 (23.5%) 
8,629 (11.9%) 
49,038 (67.9%) 
16,454 (22.8%) 
3,660 (5.1%) 
3,976 (5.5%) 
38,574 (53.4%) 
2,508 (3.5%) 
28,557 (39.5%) 
7,053 (9.8%) 
6,824 (9.4%) 
16,582 (22.9%) 
-0.02 
-0.03 
-0.07 
0.04 
0.02 
-0.04 
-0.01 
338 (0.8%) 
1,314 (3.1%) 
658 (1.6%) 
246 (0.6%) 
317 (0.8%) 
489 (1.2%) 
8,582 (20.5%) 
27,872 (66.5%) 
19,838 (47.3%) 
789 (1.9%) 
767 (1.8%) 
756 (1.8%) 
1,167 (2.8%) 
8,115 (19.4%) 
361 (0.9%) 
1,003 (2.4%) 
3,344 (8.0%) 
34 (0.1%) 
1,408 (3.4%) 
923 (2.2%) 
630 (1.5%) 
6,103 (14.6%) 
1,711 (4.1%) 
25,395 (60.6%) 
2,711 (6.5%) 
12,470 (29.7%) 
12,189 (29.1%) 
9,120 (21.7%) 
3,771 (9.0%) 
27,693 (66.0%) 
6,412 (15.3%) 
1,526 (3.6%) 
1,561 (3.7%) 
18,597 (44.4%) 
1,972 (4.7%) 
15,341 (36.6%) 
1,699 (4.1%) 
1,496 (3.6%) 
6,361 (15.2%) 
493 (1.0%) 
1,911 (3.9%) 
1,260 (2.5%) 
217 (0.4%) 
311 (0.6%) 
804 (1.6%) 
10,171 (20.5%) 
35,203 (71.1%) 
24,998 (50.5%) 
1,344 (2.7%) 
1,230 (2.5%) 
1,138 (2.3%) 
1,781 (3.6%) 
10,947 (22.1%) 
359 (0.7%) 
1,429 (2.9%) 
5,013 (10.1%) 
92 (0.2%) 
1,972 (4.0%) 
1,671 (3.4%) 
1,071 (2.2%) 
8,903 (18.0%) 
2,377 (4.8%) 
40,703 (82.2%) 
4,261 (8.6%) 
16,958 (34.3%) 
14,397 (29.1%) 
11,351 (22.9%) 
4,739 (9.6%) 
33,905 (68.5%) 
8,884 (17.9%) 
2,269 (4.6%) 
2,176 (4.4%) 
23,729 (47.9%) 
2,064 (4.2%) 
18,852 (38.1%) 
2,302 (4.7%) 
2,445 (4.9%) 
8,489 (17.1%) 
-0.02 
-0.04 
-0.06 
0.03 
0.02 
-0.03 
0.00 
-0.10 
-0.06 
-0.05 
-0.05 
-0.04 
-0.05 
-0.07 
0.02 
-0.03 
-0.07 
-0.03 
-0.03 
-0.07 
-0.05 
-0.09 
-0.03 
1,490 (1.0%) 
5,262 (3.5%) 
2,798 (1.9%) 
1,080 (0.7%) 
1,507 (1.0%) 
1,383 (0.9%) 
36,047 (24.2%) 
125,532 (84.3%) 
77,340 (51.9%) 
3,195 (2.1%) 
3,023 (2.0%) 
5,844 (3.9%) 
4,421 (3.0%) 
36,938 (24.8%) 
1,575 (1.1%) 
10,355 (7.0%) 
16,170 (10.9%) 
222 (0.1%) 
5,760 (3.9%) 
4,627 (3.1%) 
3,807 (2.6%) 
27,605 (18.5%) 
9,848 (6.6%) 
90,828 (61.0%) 
10,666 (7.2%) 
42,634 (28.6%) 
47,585 (32.0%) 
35,775 (24.0%) 
18,034 (12.1%) 
101,223 (68.0%) 
34,111 (22.9%) 
6,693 (4.5%) 
9,111 (6.1%) 
78,449 (52.7%) 
6,587 (4.4%) 
58,925 (39.6%) 
13,708 (9.2%) 
10,660 (7.2%) 
20,911 (14.0%) 
1,758 (1.0%) 
6,754 (3.8%) 
4,613 (2.6%) 
971 (0.5%) 
1,501 (0.9%) 
2,009 (1.1%) 
41,609 (23.6%) 
151,441 (85.8%) 
94,591 (53.6%) 
5,006 (2.8%) 
4,598 (2.6%) 
7,866 (4.5%) 
6,189 (3.5%) 
47,627 (27.0%) 
1,739 (1.0%) 
14,101 (8.0%) 
23,347 (13.2%) 
448 (0.3%) 
8,392 (4.8%) 
7,613 (4.3%) 
5,928 (3.4%) 
37,843 (21.4%) 
12,738 (7.2%) 
135,567 (76.8%) 
15,813 (9.0%) 
57,463 (32.5%) 
56,121 (31.8%) 
43,883 (24.9%) 
20,939 (11.9%) 
123,946 (70.2%) 
44,427 (25.2%) 
8,786 (5.0%) 
12,068 (6.8%) 
96,679 (54.8%) 
7,477 (4.2%) 
70,935 (40.2%) 
17,868 (10.1%) 
15,257 (8.6%) 
19,911 (11.3%) 
0.00 
-0.02 
-0.05 
0.03 
0.01 
-0.02 
0.01 
-0.04 
-0.03 
-0.05 
-0.04 
-0.03 
-0.03 
-0.05 
0.01 
-0.04 
-0.07 
-0.04 
-0.04 
-0.06 
-0.05 
-0.07 
-0.02 
-0.01 
-0.03 
-0.07 
0.03 
0.02 
-0.03 
0.01 
244,908 (82.1%) -0.06 
162,104 (54.3%) -0.05 
-0.05 
-0.07 
-0.06 
-0.06 
-0.06 
-0.08 
0.00 
-0.07 
8,839 (3.0%) 
8,093 (2.7%) 
12,803 (4.3%) 
11,842 (4.0%) 
78,874 (26.4%) 
2,792 (0.9%) 
21,404 (7.2%) 
38,434 (12.9%) 
816 (0.3%) 
13,947 (4.7%) 
13,164 (4.4%) 
10,136 (3.4%) 
64,797 (21.7%) 
21,294 (7.1%) 
243,765 (81.7%) 
28,552 (9.6%) 
102,942 (34.5%) 
92,566 (31.0%) 
72,229 (24.2%) 
34,307 (11.5%) 
-0.06 
-0.05 
-0.04 
-0.05 
-0.06 
0.01 
-0.05 
-0.08 
-0.04 
-0.04 
-0.07 
-0.06 
-0.09 
-0.03 
-0.04 
-0.06 
-0.08 
-0.04 
-0.10 
-0.08 
-0.10 
0.00 
-0.03 
-0.02 
-0.05 
-0.07 
-0.05 
-0.04 
-0.07 
0.02 
-0.03 
-0.03 
-0.06 
-0.05 
-0.07 
-0.08 
0.00 
-0.02 
0.01 
-0.05 
-0.05 
-0.02 
-0.03 
-0.04 
0.01 
-0.01 
-0.03 
-0.05 
0.08 
-0.08 
0.00 
-0.04 
-0.02 
-0.06 
-0.08 
-0.04 
-0.05 
-0.08 
0.02 
-0.05 
-0.07 
-0.09 
-0.06 
0.00 
-0.02 
0.00 
206,889 (69.4%) -0.05 
69,765 (23.4%) 
14,715 (4.9%) 
18,220 (6.1%) 
-0.06 
-0.03 
-0.03 
158,982 (53.3%) -0.05 
12,049 (4.0%)   0.02 
118,344 (39.7%) -0.02 
27,223 (9.1%) 
24,526 (8.2%) 
44,982 (15.1%) 
-0.04 
-0.07 
0.01 
Other Comorbidity - Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland ; n ( 8,090 (20.4%) 
-0.10 
-0.11 
-0.41 
-0.35 
-0.49 
-0.43 
-0.11 
-0.10 
-0.12 
-0.10 
Comorbidities 
 
 
 
 
 
 
 
 
 
 
 
-0.26 
-0.18 
-0.14 
-0.17 
-0.23 
-0.31 
 
 
 
 
0.26 
0.23 
0.29 
 
 
 
 
 
 
 
 
 
 
 

Other Comorbidity - Edema; n (%) 
Other Comorbidity - Depression; n (%) 
Other Comorbidity - Anxiety; n (%) 
Other Comorbidity - Pneumonia; n (%) 
Other Comorbidity - COPD; n (%) 
Other Comorbidity - Asthma; n (%) 
Other Comorbidity - Acute renal disease; n (%) 
Other Comorbidity CKD Stage 1; n (%) 
Other Comorbidity - CKD Stage 2; n (%) 
Other Comorbidity - CKD Stage 3; n (%) 
Other Comorbidity - Occurrence of chronic renal insufficiency w/o CKD ; n (%) 
Other Comorbidity - Occurrence of miscellaneous renal insufficiency; n (%) 
Other Comorbidity - Hypertensive nephropathy; n (%) 
Other Comorbidity - Obstructive sleep apnea; n (%) 
Other Comorbidity - Osteoarthritis; n (%) 
Other Comorbidity - Other arthritis, arthropathies and musculoskeletal pain; n (%) 
Other Comorbidity - Dorsopathies; n (%) 
Other Comorbidity - Fractures; n (%) 
Other Comorbidity - Falls; n (%) 
Other Comorbidity - Sleep Disorder; n (%) 
Other Comorbidity - Delirium; n (%) 
Other Comorbidity - Psychosis; n (%) 
4,035 (10.2%) 
3,332 (8.4%) 
4,297 (10.9%) 
2,458 (6.2%) 
5,572 (14.1%) 
2,490 (6.3%) 
1,850 (4.7%) 
136 (0.3%) 
867 (2.2%) 
3,551 (9.0%) 
1,824 (4.6%) 
2,103 (5.3%) 
2,884 (7.3%) 
4,313 (10.9%) 
8,123 (20.5%) 
15,178 (38.4%) 
8,826 (22.3%) 
1,798 (4.5%) 
2,265 (5.7%) 
2,301 (5.8%) 
953 (2.4%) 
468 (1.2%) 
8,491 (11.8%) 
6,763 (9.4%) 
9,395 (13.0%) 
6,015 (8.3%) 
11,986 (16.6%) 
4,912 (6.8%) 
5,496 (7.6%) 
265 (0.4%) 
1,858 (2.6%) 
8,834 (12.2%) 
4,451 (6.2%) 
4,886 (6.8%) 
7,839 (10.8%) 
7,717 (10.7%) 
16,520 (22.9%) 
29,550 (40.9%) 
17,719 (24.5%) 
3,589 (5.0%) 
5,681 (7.9%) 
2,499 (3.5%) 
2,815 (3.9%) 
911 (1.3%) 
-0.05 
-0.04 
-0.06 
-0.08 
-0.07 
-0.02 
 -0.12 
 
-0.02 
-0.03 
 -0.10 
 
-0.07 
-0.06 
 -0.12 
 
0.01 
-0.06 
-0.05 
-0.05 
-0.02 
-0.09 
 0.11 
 
-0.09 
-0.01 
2,909 (6.9%) 
2,627 (6.3%) 
3,242 (7.7%) 
2,008 (4.8%) 
3,710 (8.8%) 
2,347 (5.6%) 
1,224 (2.9%) 
61 (0.1%) 
281 (0.7%) 
1,276 (3.0%) 
863 (2.1%) 
1,364 (3.3%) 
1,129 (2.7%) 
5,200 (12.4%) 
6,591 (15.7%) 
14,428 (34.4%) 
8,294 (19.8%) 
1,485 (3.5%) 
834 (2.0%) 
3,477 (8.3%) 
596 (1.4%) 
352 (0.8%) 
3,989 (8.1%) 
3,222 (6.5%) 
4,742 (9.6%) 
2,892 (5.8%) 
4,984 (10.1%) 
2,880 (5.8%) 
2,272 (4.6%) 
84 (0.2%) 
485 (1.0%) 
2,358 (4.8%) 
1,459 (2.9%) 
2,249 (4.5%) 
2,361 (4.8%) 
6,858 (13.9%) 
7,983 (16.1%) 
17,421 (35.2%) 
10,115 (20.4%) 
1,806 (3.6%) 
1,462 (3.0%) 
2,600 (5.3%) 
1,051 (2.1%) 
356 (0.7%) 
-0.05 
-0.01 
-0.07 
-0.04 
-0.04 
-0.01 
-0.09 
-0.03 
-0.03 
-0.09 
-0.05 
-0.06 
 -0.11 
 
-0.04 
-0.01 
-0.02 
-0.01 
-0.01 
-0.06 
 0.12 
 
-0.05 
0.01 
11,693 (7.9%) 
12,001 (8.1%) 
12,625 (8.5%) 
9,669 (6.5%) 
20,527 (13.8%) 
9,009 (6.0%) 
6,220 (4.2%) 
278 (0.2%) 
1,473 (1.0%) 
7,918 (5.3%) 
5,890 (4.0%) 
6,344 (4.3%) 
8,281 (5.6%) 
9,174 (6.2%) 
31,918 (21.4%) 
54,846 (36.8%) 
30,828 (20.7%) 
7,167 (4.8%) 
2,974 (2.0%) 
8,065 (5.4%) 
3,460 (2.3%) 
2,692 (1.8%) 
14,969 (8.5%) 
14,544 (8.2%) 
16,289 (9.2%) 
13,219 (7.5%) 
25,900 (14.7%) 
11,077 (6.3%) 
10,592 (6.0%) 
319 (0.2%) 
2,126 (1.2%) 
13,220 (7.5%) 
8,882 (5.0%) 
8,864 (5.0%) 
13,721 (7.8%) 
11,567 (6.6%) 
38,031 (21.5%) 
65,149 (36.9%) 
38,050 (21.6%) 
8,538 (4.8%) 
4,471 (2.5%) 
7,074 (4.0%) 
5,237 (3.0%) 
2,582 (1.5%) 
-0.02 
0.00 
-0.02 
-0.04 
-0.03 
-0.01 
-0.08 
0.00 
-0.02 
-0.09 
-0.05 
-0.03 
-0.09 
-0.02 
0.00 
0.00 
-0.02 
0.00 
-0.03 
0.07 
-0.04 
0.02 
18,637 (8.1%) 
17,960 (7.8%) 
20,164 (8.8%) 
14,135 (6.1%) 
29,809 (12.9%) 
13,846 (6.0%) 
9,294 (4.0%) 
475 (0.2%) 
2,621 (1.1%) 
12,745 (5.5%) 
8,577 (3.7%) 
9,811 (4.3%) 
12,294 (5.3%) 
18,687 (8.1%) 
46,632 (20.2%) 
84,452 (36.6%) 
47,948 (20.8%) 
10,450 (4.5%) 
6,073 (2.6%) 
13,843 (6.0%) 
5,009 (2.2%) 
3,512 (1.5%) 
27,449 (9.2%) 
24,529 (8.2%) 
30,426 (10.2%) 
22,126 (7.4%) 
42,870 (14.4%) 
18,869 (6.3%) 
18,360 (6.2%) 
668 (0.2%) 
4,469 (1.5%) 
24,412 (8.2%) 
14,792 (5.0%) 
15,999 (5.4%) 
23,921 (8.0%) 
26,142 (8.8%) 
62,534 (21.0%) 
-0.04 
-0.01 
-0.05 
-0.05 
-0.04 
-0.01 
 -0.10 
 
0.00 
-0.04 
 -0.11 
 
-0.06 
-0.05 
 -0.11 
 
-0.03 
-0.02 
112,120 (37.6%) -0.02 
65,884 (22.1%) 
13,933 (4.7%) 
11,614 (3.9%) 
12,173 (4.1%) 
9,103 (3.1%) 
3,849 (1.3%) 
-0.03 
-0.01 
-0.07 
0.09 
-0.06 
0.02 
 Procedures 
 
Procedure - Hip Surgery; n (%) 
258 (0.7%) 
327 (0.5%) 
0.03 
272 (0.6%) 
127 (0.3%) 
0.04 
1,111 (0.7%) 
668 (0.4%) 
0.04 
1,641 (0.7%) 
1,122 (0.4%) 
0.04 
 Medications 
 
624 (0.3%) 
162 (0.1%) 
8,496 (3.7%) 
2,534 (1.1%) 
14,296 (6.2%) 
6,685 (2.9%) 
1,878 (0.8%) 
1,315 (0.6%) 
29,237 (12.7%) 
37,826 (16.4%) 
30,905 (13.4%) 
15,834 (6.9%) 
19,910 (8.6%) 
41,367 (18.0%) 
5,223 (2.3%) 
8,460 (3.7%) 
6,381 (2.8%) 
14,257 (6.2%) 
24,419 (10.6%) 
47,447 (20.6%) 
231 (0.1%) 
30,161 (13.1%) 
740 (0.3%) 
54,492 (23.6%) 
41,892 (18.2%) 
46,537 (20.2%) 
1,065 (0.5%) 
7,331 (3.2%) 
27,237 (11.8%) 
9,408 (4.1%) 
774 (0.3%) 
206 (0.1%) 
11,866 (4.0%) 
3,170 (1.1%) 
18,175 (6.1%) 
8,440 (2.8%) 
2,526 (0.8%) 
1,959 (0.7%) 
37,260 (12.5%) 
48,918 (16.4%) 
37,759 (12.7%) 
21,986 (7.4%) 
21,940 (7.4%) 
55,183 (18.5%) 
6,494 (2.2%) 
12,077 (4.0%) 
8,788 (2.9%) 
16,694 (5.6%) 
34,159 (11.5%) 
64,840 (21.7%) 
280 (0.1%) 
39,582 (13.3%) 
1,045 (0.4%) 
65,867 (22.1%) 
56,584 (19.0%) 
62,628 (21.0%) 
1,208 (0.4%) 
9,918 (3.3%) 
36,857 (12.4%) 
11,428 (3.8%) 
DM Medications - Meglitinides; n (%) 
DM Medications - AGIs; n (%) 
DM Medications - Insulin; n (%) 
DM Medications - Glitazones; n (%) 
DM Medications - 1st and 2nd Generation SUs ; n (%) 
DM Medications - DPP-4 Inhibitors; n (%) 
DM Medications - GLP-1 RA; n (%) 
DM Medications - SGLT-2 Inhibitors ; n (%) 
DM Medications - Metformin; n (%) 
DM Medciations - All antidiabetic medications except Insulin; n (%) 
Other Medications - Use of NSAIDs; n (%) 
Other Medications - Use of other hypertension drugs; n (%) 
Other Medications - Digoxin; n (%) 
Other Medications - Use of Anti-arrhythmics; n (%) 
Other Medications - Use of antipsychotics; n (%) 
Other Medications - Use of dementia meds; n (%) 
Other Medications - Use of antiparkinsonian meds; n (%) 
Other Medications - Use of anxiolytics/hypnotics; n (%) 
Other Medications - Use of anticonvulsants; n (%) 
Other Medications - Use of antidepressants; n (%) 
Other Medications - Use of lithium; n (%) 
Other Medications - Use of Benzos; n (%) 
Other Medication - Use of CNS stimulants; n (%) 
Other Medications - Use of opioids; n (%) 
Other Medications - Use of COPD/asthma meds; n (%) 
Other Medications - Use of oral corticosteroids; n (%) 
Other Medications - Use of Sympatomimetic agents; n (%) 
Other Medications - Use of bisphosphonates; n (%) 
Other Medications - Use of thiazide; n (%) 
Other Medications - Use of estrogens, progestins, androgens; n (%) 
82 (0.2%) 
24 (0.1%) 
1,672 (4.2%) 
427 (1.1%) 
2,450 (6.2%) 
1,017 (2.6%) 
380 (1.0%) 
337 (0.9%) 
5,305 (13.4%) 
6,751 (17.1%) 
4,868 (12.3%) 
2,563 (6.5%) 
2,782 (7.0%) 
6,439 (16.3%) 
711 (1.8%) 
1,201 (3.0%) 
938 (2.4%) 
1,964 (5.0%) 
4,174 (10.5%) 
7,779 (19.7%) 
40 (0.1%) 
4,562 (11.5%) 
118 (0.3%) 
8,286 (20.9%) 
6,602 (16.7%) 
7,388 (18.7%) 
207 (0.5%) 
1,255 (3.2%) 
4,300 (10.9%) 
1,333 (3.4%) 
127 (0.2%) 
48 (0.1%) 
3,346 (4.6%) 
755 (1.0%) 
4,496 (6.2%) 
1,789 (2.5%) 
667 (0.9%) 
636 (0.9%) 
9,656 (13.4%) 
12,368 (17.1%) 
8,492 (11.8%) 
5,347 (7.4%) 
4,295 (5.9%) 
12,185 (16.9%) 
1,467 (2.0%) 
2,716 (3.8%) 
1,975 (2.7%) 
3,281 (4.5%) 
8,578 (11.9%) 
15,737 (21.8%) 
62 (0.1%) 
8,618 (11.9%) 
209 (0.3%) 
14,637 (20.3%) 
13,136 (18.2%) 
14,755 (20.4%) 
292 (0.4%) 
2,648 (3.7%) 
8,543 (11.8%) 
2,276 (3.1%) 
0.00 
0.00 
-0.02 
0.01 
0.00 
0.01 
0.01 
0.00 
0.00 
0.00 
0.02 
-0.04 
0.04 
-0.02 
-0.01 
-0.04 
-0.02 
0.02 
-0.04 
-0.05 
0.00 
-0.01 
0.00 
0.01 
-0.04 
-0.04 
0.01 
-0.03 
-0.03 
0.02 
105 (0.3%) 
19 (0.0%) 
1,725 (4.1%) 
491 (1.2%) 
2,195 (5.2%) 
1,326 (3.2%) 
561 (1.3%) 
417 (1.0%) 
5,176 (12.3%) 
6,546 (15.6%) 
5,670 (13.5%) 
2,190 (5.2%) 
3,135 (7.5%) 
8,417 (20.1%) 
540 (1.3%) 
805 (1.9%) 
806 (1.9%) 
2,493 (5.9%) 
3,272 (7.8%) 
7,164 (17.1%) 
35 (0.1%) 
4,763 (11.4%) 
218 (0.5%) 
9,023 (21.5%) 
6,715 (16.0%) 
7,541 (18.0%) 
375 (0.9%) 
768 (1.8%) 
4,137 (9.9%) 
2,202 (5.3%) 
111 (0.2%) 
27 (0.1%) 
2,154 (4.4%) 
536 (1.1%) 
2,581 (5.2%) 
1,571 (3.2%) 
713 (1.4%) 
604 (1.2%) 
6,296 (12.7%) 
7,917 (16.0%) 
6,544 (13.2%) 
2,886 (5.8%) 
3,139 (6.3%) 
9,802 (19.8%) 
716 (1.4%) 
1,121 (2.3%) 
1,036 (2.1%) 
2,780 (5.6%) 
4,291 (8.7%) 
9,240 (18.7%) 
42 (0.1%) 
5,528 (11.2%) 
251 (0.5%) 
9,723 (19.6%) 
8,410 (17.0%) 
9,394 (19.0%) 
426 (0.9%) 
1,035 (2.1%) 
5,433 (11.0%) 
2,415 (4.9%) 
0.02 
-0.04 
-0.01 
0.01 
0.00 
0.00 
-0.01 
-0.02 
-0.01 
-0.01 
0.01 
-0.03 
0.05 
0.01 
-0.01 
-0.03 
-0.01 
0.01 
-0.03 
-0.04 
0.00 
0.01 
0.00 
0.05 
-0.03 
-0.03 
0.00 
-0.02 
-0.04 
0.02 
437 (0.3%) 
119 (0.1%) 
5,099 (3.4%) 
1,616 (1.1%) 
9,651 (6.5%) 
4,342 (2.9%) 
937 (0.6%) 
561 (0.4%) 
18,756 (12.6%) 
24,529 (16.5%) 
20,367 (13.7%) 
11,081 (7.4%) 
13,993 (9.4%) 
26,511 (17.8%) 
3,972 (2.7%) 
6,454 (4.3%) 
4,637 (3.1%) 
9,800 (6.6%) 
16,973 (11.4%) 
32,504 (21.8%) 
156 (0.1%) 
20,836 (14.0%) 
404 (0.3%) 
37,183 (25.0%) 
28,575 (19.2%) 
31,608 (21.2%) 
483 (0.3%) 
5,308 (3.6%) 
18,800 (12.6%) 
5,873 (3.9%) 
536 (0.3%) 
131 (0.1%) 
6,366 (3.6%) 
1,879 (1.1%) 
11,098 (6.3%) 
5,080 (2.9%) 
1,146 (0.6%) 
719 (0.4%) 
21,308 (12.1%) 
28,633 (16.2%) 
22,723 (12.9%) 
13,753 (7.8%) 
14,506 (8.2%) 
33,196 (18.8%) 
4,311 (2.4%) 
8,240 (4.7%) 
5,777 (3.3%) 
10,633 (6.0%) 
21,290 (12.1%) 
39,863 (22.6%) 
176 (0.1%) 
25,436 (14.4%) 
585 (0.3%) 
41,507 (23.5%) 
35,038 (19.8%) 
38,479 (21.8%) 
490 (0.3%) 
6,235 (3.5%) 
22,881 (13.0%) 
6,737 (3.8%) 
0.00 
0.00 
-0.01 
0.00 
0.01 
0.00 
0.00 
0.00 
0.02 
0.01 
0.02 
-0.02 
0.04 
-0.03 
0.02 
-0.02 
-0.01 
0.02 
-0.02 
-0.02 
0.00 
-0.01 
0.00 
0.04 
-0.02 
-0.01 
0.00 
0.01 
-0.01 
0.01 
0.00 
0.00 
-0.02 
0.00 
0.00 
0.01 
0.00 
-0.01 
0.01 
0.00 
0.02 
-0.02 
0.04 
-0.01 
0.01 
-0.02 
-0.01 
0.03 
-0.03 
-0.03 
0.00 
-0.01 
-0.02 
0.04 
-0.02 
-0.02 
0.01 
-0.01 
-0.02 
0.02 
 Healthcare Utilization 
 
HU - Bone mineral density; n (%) 
HU - Occurrence of creatinine tests ordered ; n (%) 
HU - Number of D-dimer tests 
...mean (sd) 
...median [IQR] 
HU - Number of CRP, high-sensitivity CRP tests 
...mean (sd) 
...median [IQR] 
HU - Colonoscopy; n (%) 
HU - Flu vaccine; n (%) 
HU - Mammogram; n (%) 
HU - PSA test or Prostate exam for DRE; n (%) 
HU - Pap smear; n (%) 
HU - Pneumonia vaccine; n (%) 
Frailty Score: Empirical Version 365 days (ICD-9 and ICD-10) V2 
...mean (sd) 
...median [IQR] 
CHADS2 score, 180 days 
...mean (sd) 
...median [IQR] 
HU - Number of Hospitalizations 
...mean (sd) 
...median [IQR] 
HU - Number of hospital days 
...mean (sd) 
...median [IQR] 
HU - Number of Emergency Department (ED) visits 
...mean (sd) 
...median [IQR] 
HU - Number of internal medicine/family medicine visits 
...mean (sd) 
1,408 (3.6%) 
1,968 (5.0%) 
2,795 (3.9%) 
3,659 (5.1%) 
-0.02 
0.00 
635 (1.5%) 
1,800 (4.3%) 
804 (1.6%) 
2,056 (4.2%) 
-0.01 
0.00 
6,141 (4.1%) 
10,228 (6.9%) 
7,455 (4.2%) 
12,445 (7.0%) 
-0.01 
0.00 
8,184 (3.6%) 
13,996 (6.1%) 
11,054 (3.7%) 
18,160 (6.1%) 
-0.01 
0.00 
0.04 (0.21) 
0.00 [0.00, 0.00] 
0.04 (0.22) 
0.00 [0.00, 0.00] 
0.00 
0.00 
0.04 (0.23) 
0.00 [0.00, 0.00] 
0.04 (0.23) 
0.00 [0.00, 0.00] 
0.00 
0.00 
0.04 (0.21) 
0.00 [0.00, 0.00] 
0.04 (0.21) 
0.00 [0.00, 0.00] 
0.00 
0.00 
0.04 (0.21) 
0.00 (0.21) 
0.04 (0.22) 
0.00 (0.22) 
0.00 
0.00 
0.07 (0.38) 
0.00 [0.00, 0.00] 
1,530 (3.9%) 
7,287 (18.4%) 
3,466 (8.8%) 
5,667 (14.3%) 
647 (1.6%) 
7,329 (18.5%) 
0.07 (0.39) 
0.00 [0.00, 0.00] 
2,615 (3.6%) 
12,910 (17.9%) 
6,563 (9.1%) 
8,448 (11.7%) 
1,135 (1.6%) 
16,159 (22.4%) 
0.00 
0.00 
0.02 
0.01 
-0.01 
0.08 
0.00 
-0.10 
0.05 (0.29) 
0.00 [0.00, 0.00] 
1,806 (4.3%) 
5,148 (12.3%) 
2,525 (6.0%) 
5,233 (12.5%) 
1,022 (2.4%) 
3,782 (9.0%) 
0.05 (0.30) 
0.00 [0.00, 0.00] 
2,083 (4.2%) 
6,004 (12.1%) 
3,114 (6.3%) 
5,439 (11.0%) 
1,180 (2.4%) 
6,392 (12.9%) 
0.00 
0.00 
0.00 
0.01 
-0.01 
0.05 
0.00 
 -0.13 
 
0.09 (0.43) 
0.00 [0.00, 0.00] 
6,130 (4.1%) 
48,520 (32.6%) 
15,435 (10.4%) 
19,077 (12.8%) 
3,636 (2.4%) 
32,767 (22.0%) 
0.09 (0.42) 
0.00 [0.00, 0.00] 
6,707 (3.8%) 
58,029 (32.9%) 
18,530 (10.5%) 
19,785 (11.2%) 
4,177 (2.4%) 
0.00 
0.00 
0.02 
-0.01 
0.00 
0.05 
0.00 
0.08 (0.40) 
0.00 (0.40) 
9,466 (4.1%) 
60,955 (26.5%) 
21,426 (9.3%) 
29,977 (13.0%) 
5,305 (2.3%) 
43,878 (19.0%) 
0.08 (0.40) 
0.00 (0.40) 
11,405 (3.8%) 
76,943 (25.8%) 
28,207 (9.5%) 
33,672 (11.3%) 
6,492 (2.2%) 
74,343 (24.9%) 
0.00 
0.00 
0.02 
0.02 
-0.01 
0.05 
0.01 
 -0.14 
 
51,792 (29.3%)   -0.17 
 
0.18 (0.06) 
0.17 (0.06) 
0.19 (0.06) 
0.18 (0.06) 
0.18 (0.06) 
0.17 [0.14, 0.20] 
0.19 (0.06) 
0.18 [0.15, 0.22] 
0.17 (0.05) 
0.16 [0.13, 0.19] 
0.17 (0.05) 
0.16 [0.14, 0.19] 
0.00 
0.00 
0.19 (0.06) 
0.17 [0.14, 0.21] 
0.19 (0.06) 
0.00 
0.18 [0.15, 0.22]  -0.02 
1.35 (1.22) 
1.00 (1.22) 
1.28 (1.18) 
1.00 (1.18) 
1.41 (1.24) 
1.00 [0.00, 2.00] 
1.53 (1.29) 
1.00 [1.00, 2.00] 
-0.09 
0.00 
1.23 (1.19) 
1.00 [0.00, 2.00] 
1.23 (1.24) 
1.00 [0.00, 2.00] 
0.00 
0.00 
1.37 (1.22) 
1.00 [1.00, 2.00] 
1.19 (1.12) 
 0.15 
 
0.06 
0.00 
1.00 [0.00, 2.00] 0.00 
0.34 (0.59) 
0.00 (0.59) 
0.39 (0.63) 
0.00 (0.63) 
0.27 (0.54) 
0.00 [0.00, 0.00] 
0.36 (0.62) 
0.00 [0.00, 1.00] 
 -0.15 
 
0.00 
0.29 (0.50) 
0.00 [0.00, 1.00] 
0.31 (0.51) 
0.00 [0.00, 1.00] 
-0.04 
0.00 
0.37 (0.62) 
0.00 [0.00, 1.00] 
0.42 (0.66) 
-0.08 
-0.08 
0.00 
0.00 [0.00, 1.00] 0.00 
1.40 (4.22) 
0.00 [0.00, 0.00] 
2.11 (5.65) 
0.00 [0.00, 3.00] 
 -0.14 
 
0.00 
1.25 (3.19) 
0.00 [0.00, 2.00] 
1.47 (3.68) 
0.00 [0.00, 2.00] 
-0.06 
0.00 
1.97 (5.34) 
0.00 [0.00, 3.00] 
2.29 (5.31) 
-0.06 
1.74 (4.83) 
0.00 (4.83) 
2.11 (5.16) 
0.00 (5.16) 
-0.07 
0.00 
0.00 [0.00, 3.00] 0.00 
0.77 (1.45) 
0.00 [0.00, 1.00] 
0.91 (1.55) 
0.00 [0.00, 2.00] 
-0.09 
0.00 
0.57 (2.15) 
0.00 [0.00, 0.00] 
0.73 (2.43) 
0.00 [0.00, 0.00] 
-0.07 
0.00 
0.96 (1.68) 
0.00 [0.00, 2.00] 
1.03 (1.66) 
-0.04 
0.86 (1.74) 
0.00 (1.74) 
0.95 (1.79) 
0.00 (1.79) 
-0.05 
0.00 
0.00 [0.00, 2.00] 0.00 
8.84 (12.12) 
9.96 (13.21) 
-0.09 
6.19 (9.18) 
6.51 (9.71) 
-0.03 
7.94 (9.62) 
8.23 (9.78) 
-0.03 
7.78 (10.02) 
8.36 (10.70) 
-0.06 
-0.17 
-0.17 
-0.17 
-0.17 

...median [IQR] 
HU - Number of different/distinct medication prescriptions 
...mean (sd) 
5.00 [2.00, 11.00] 
6.00 [2.00, 13.00] 
-0.08 
4.00 [1.00, 8.00]  4.00 [1.00, 8.00] 
0.00 
5.00 [2.00, 11.00] 5.00 [2.00, 11.00] 0.00 
4.82 (10.02) 
5.08 (10.70) 
-0.03 
8.62 (4.41) 
8.90 (4.44) 
8.27 (4.49) 
8.80 (4.57) 
 -0.12 
 
7.93 (4.40) 
8.28 (4.46) 
-0.08 
8.91 (4.39) 
9.11 (4.38) 
-0.05 
-0.06 
7.82 (4.41) 
8.00 (4.44) 
...median [IQR] 
HU Total N distinct ICD9/ICD10 diagnoses at the 3rd digit level 
...mean (sd) 
8.00 [5.00, 11.00] 
8.00 [5.00, 11.00] 
0.00 
7.00 [5.00, 10.00] 8.00 [5.00, 11.00] 
8.00 [6.00, 11.00] 8.00 [6.00, 12.00] 0.00 
-0.04 
8.26 (9.64) 
11.99 (11.61) 
4.30 (6.67) 
6.85 (8.07) 
8.17 (9.90) 
11.04 (11.08) 
7.48 (9.35) 
10.57 (10.78) 
...median [IQR] 
HU - Number of Office visits 
...mean (sd) 
6.00 [0.00, 12.00] 
9.00 [4.00, 17.00] 
1.00 [0.00, 6.00] 
4.00 [0.00, 10.00] 
5.00 [0.00, 13.00] 9.00 [1.00, 17.00] 
4.44 (9.35) 
8.17 (10.78) 
5.05 (3.75) 
5.15 (3.73) 
-0.03 
4.92 (3.80) 
5.05 (3.82) 
-0.03 
12.51 (11.50) 
12.74 (11.81) 
10.00 [5.00, 
10.00 [5.00, 16.00] 17.00] 
-0.02 
9.85 (9.51) 
9.63 (9.40) 
0.02 
...median [IQR] 
HU - Number of Cardiologist visits 
...mean (sd) 
...median [IQR] 
HU - Number electrocardiograms 
...mean (sd) 
...median [IQR] 
HU - Number of echocardiograms 
...mean (sd) 
...median [IQR] 
HU - Number of neurologist visits 
...mean (sd) 
...median [IQR] 
HU - Fecal occult blood (FOB) test; n (%) 
HU - Number of PT or aPTTt tests 
...mean (sd) 
...median [IQR] 
N of days in database anytime prior 
4.00 [2.00, 7.00] 
4.00 [3.00, 7.00] 
0.00 
4.00 [2.00, 7.00] 
4.00 [2.00, 7.00] 
0.00 
0.00 
7.88 (9.51) 
7.55 (9.40) 
0.03 
4.57 (5.62) 
2.82 (5.62) 
4.92 (5.71) 
3.43 (5.71) 
4.26 (5.03) 
3.00 [1.00, 6.00] 
4.91 (5.46) 
3.00 [1.00, 7.00] 
 -0.12 
 
0.00 
3.11 (4.31) 
2.00 [0.00, 4.00] 
3.40 (4.50) 
2.00 [0.00, 5.00] 
-0.07 
0.00 
5.06 (6.08) 
3.00 [1.00, 7.00] 
5.35 (6.10) 
-0.05 
-0.06 
 -0.11 
 
4.00 [1.00, 7.00]  -0.16 
 
2.18 (2.09) 
1.82 (2.09) 
2.35 (2.19) 
2.00 (2.19) 
2.14 (2.29) 
2.00 [1.00, 3.00] 
2.34 (2.41) 
2.00 [1.00, 3.00] 
-0.09 
0.00 
1.92 (1.99) 
1.00 [1.00, 3.00] 
2.03 (2.01) 
2.00 [1.00, 3.00] 
-0.05 
 -0.50 
 
2.27 (2.06) 
2.00 [1.00, 3.00] 
2.44 (2.15) 
2.00 [1.00, 3.00] 
-0.08 
0.00 
-0.08 
-0.08 
0.94 (1.76) 
0.65 (1.76) 
1.06 (2.01) 
1.00 (2.01) 
1.15 (3.20) 
0.00 [0.00, 1.00] 
1.25 (3.37) 
1.00 [0.00, 1.00] 
-0.03 
 -0.30 
 
0.86 (1.35) 
0.00 [0.00, 1.00] 
0.96 (1.43) 
1.00 [0.00, 1.00] 
-0.07 
 -0.72 
 
0.90 (1.24) 
1.00 [0.00, 1.00] 
1.01 (1.28) 
1.00 [0.00, 2.00] 
-0.09 
0.00 
-0.06 
 -0.19 
 
0.32 (1.69) 
0.00 (1.69) 
7,350 (3.2%) 
0.40 (1.76) 
0.00 (1.76) 
8,909 (3.0%) 
0.32 (1.70) 
0.00 [0.00, 0.00] 
1,505 (3.8%) 
0.42 (1.85) 
0.00 [0.00, 0.00] 
2,236 (3.1%) 
-0.06 
0.00 
0.04 
0.18 (1.09) 
0.00 [0.00, 0.00] 
1,223 (2.9%) 
0.21 (1.16) 
0.00 [0.00, 0.00] 
1,327 (2.7%) 
-0.03 
0.00 
0.01 
0.36 (1.82) 
0.00 [0.00, 0.00] 
4,622 (3.1%) 
0.44 (1.86) 
0.00 [0.00, 0.00] 
5,346 (3.0%) 
-0.04 
0.00 
0.01 
-0.05 
0.00 
0.04 
0.41 (1.20) 
0.00 [0.00, 0.00] 
0.40 (1.14) 
0.00 [0.00, 0.00] 
0.01 
0.00 
0.39 (1.13) 
0.00 [0.00, 0.00] 
0.37 (1.10) 
0.00 [0.00, 0.00] 
0.02 
0.00 
0.34 (1.08) 
0.00 [0.00, 0.00] 
0.33 (0.99) 
0.00 [0.00, 0.00] 
0.01 
0.00 
0.36 (1.11) 
0.00 (1.11) 
0.35 (1.05) 
0.00 (1.05) 
0.01 
0.00 
2,369.06 
(1,488.04) 
2,168.00 
[1,048.00, 
3,668.75] 
...mean (sd) 
1,873.87 (1,373.15) 
1,997.86 (1,480.21) 
-0.09 
2,555.93 (1,598.77) 
-0.12 
767.20 (508.76) 
789.93 (494.30) 
-0.05 
1248.74 (945.52) 1375.59 (1048.57 -0.13 
1,493.00 [717.00, 
2,895.00] 
1,564.00 [756.00, 
3,051.00] 
2,395.00 [1,138.00, 
3,906.00] 
615.00 [465.00, 
863.00] 
658.00 [497.00, 
909.00] 
...median [IQR] 
-0.05 
-0.15 
-0.09 
1048.37 (945.52) 1165.71 (1048.57 -0.12 
Socioeconomic Status Proxy Variables 
SES - Mean Copay for per prescription cost (charges in U.S. $) 
...mean (sd) 
21.67 (29.08) 
20.24 (27.51) 
0.05 
15.18 (20.95) 
10.21 [4.18, 
19.95] 
3,963 (9.5%) 
14.15 (20.04) 
0.05 
115.27 (137.49) 
90.00 [63.00, 
132.00] 
3,567 (2.4%) 
113.78 (113.51) 
90.72 [64.26, 
131.13] 
3,282 (1.9%) 
0.01 
80.98 (111.55) 
74.59 (88.74) 
0.06 
...median [IQR] 
...Missing; n (%) 
SES - Copay: pharmacy cost 
...mean (sd) 
14.16 [6.00, 27.52] 
1,786 (4.5%) 
12.92 [5.39, 25.50] 
2,434 (3.4%) 
0.04 
0.06 
9.68 [3.97, 18.31] 
6,979 (14.1%) 
0.03 
 -0.14 
 
-0.01 
0.03 
62.46 (111.55) 
9,316 (4.0%) 
58.43 (88.74) 
12,695 (4.3%) 
0.04 
-0.02 
203.92 (310.68) 
105.00 [30.00, 
267.78] 
201.17 (313.71) 
101.10 [30.00, 
257.34] 
0.01 
129.33 (193.24) 
66.00 [6.12, 
173.54] 
119.00 (205.46) 
0.05 
159.63 (302.48) 
51.43 [0.00, 
194.68] 
210.89 (354.92) 
97.00 [18.07, 
264.50] 
161.72 (287.23) 
193.29 (324.65) -0.10 
 
...median [IQR] 
SES - Business type: Commercial vs Medicare 
...Commerical; n (%) 
...Medicare; n (%) 
SES - Low income indicator; n (%) 
SES - Urban vs Rural (MSA variable) 
...Urban; n (%) 
...Rural; n (%) 
...Unknown/Missing; n (%) 
SES - Dual Status; n (%) 
SES - Generic name prescription - unique value 
...mean (sd) 
0.01 
55.32 [0.00, 155.54] 0.05 
63.28 (287.23) 
91.08 (324.65)  -0.09 
31,439 (13.6%) 
50,067 (21.7%) 
4,702 (2.0%) 
35,444 (11.9%) 
0.05 
86,320 (28.9%)  -0.17 
 
10,520 (26.6%) 
29,054 (73.4%) 
4,702 (11.9%) 
12,610 (17.5%) 
59,651 (82.5%) 
9,719 (13.4%) 
20,919 (49.9%) 
21,013 (50.1%) 
0 (0.0%) 
22,834 (46.1%) 
26,669 (53.9%) 
0 (0.0%) 
0.08 
-0.08 
0.00 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.04 
-0.05 
9,719 (3.3%) 
-0.08 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0.00 
0.00 
0.00 
0.00 
29,285 (69.8%) 
2,571 (6.1%) 
10,076 (24.0%) 
0 (0.0%) 
30,344 (61.3%) 
5,127 (10.4%) 
14,032 (28.3%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
24,143 (16.2%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
25,715 (14.6%) 
29,285 (12.7%) 
2,571 (1.1%) 
10,076 (4.4%) 
24,143 (10.5%) 
30,344 (10.2%) 
5,127 (1.7%) 
14,032 (4.7%) 
25,715 (8.6%) 
0.08 
-0.05 
-0.01 
0.06 
-0.10 
0.00 
8.27 (4.49) 
8.80 (4.57) 
7.93 (4.40) 
8.28 (4.46) 
-0.08 
8.91 (4.39) 
9.11 (4.38) 
-0.05 
8.62 (4.41) 
8.90 (4.44) 
-0.06 
...median [IQR] 
SES - Brand name prescription - unique value 
...mean (sd) 
8.00 [5.00, 11.00] 
8.00 [5.00, 11.00] 
7.00 [5.00, 10.00] 8.00 [5.00, 11.00] 
8.00 [6.00, 11.00] 
8.00 [6.00, 12.00] 0.00 
7.82 (4.41) 
8.00 (4.44) 
-0.04 
8.35 (4.58) 
8.89 (4.66) 
 -0.12 
 
8.04 (4.50) 
8.39 (4.55) 
-0.08 
9.02 (4.48) 
9.22 (4.47) 
-0.04 
8.73 (4.50) 
9.00 (4.53) 
-0.06 
...median [IQR] 
8.00 [5.00, 11.00] 
8.00 [6.00, 11.00] 
0.00 
7.00 [5.00, 10.00] 8.00 [5.00, 11.00] 
8.00 [6.00, 11.00] 
9.00 [6.00, 12.00] 
7.82 (4.50) 
8.59 (4.53) 
 
-0.17 
-0.22 
-0.22 
-0.23 
-0.12 
 
-0.18 
0.18 
-0.16 
0.22 
-0.22 
-0.16 
-0.14 
 
 
 
 
-0.31 
 
-0.37 
-0.27 
-0.38 
-0.34 
-0.41 
-0.35 
 
-0.28 
-0.23 

  
Optum 
 
  
MarketScan 
 
  
Medicare 
 
  
Pooled 
 
Variable 
Number of patients 
Rivaroxaban 
34,067 
Apixaban 
34,067 
St. Diff 
Rivaroxaban 
Apixaban 
St. Diff 
Rivaroxaban 
Apixaban 
St. Diff 
Rivaroxaban 
184,107 
Apixaban 
184,107 
St. Diff 
30,923 
30,923 
119,117 
119,117 
 Age 
 
...mean (sd) 
...median [IQR] 
72.20 (10.67) 
72.15 (10.83) 
0.004651034 
66.74 (12.85) 
66.58 (13.02) 
0.012369273 
76.50 (8.21) 
76.51 (8.26) 
-0.001214323 
74.07 (9.61) 
73.60 (9.61) 
74.04 (9.71)    0.003105548 
73.43 (9.71)    0.017598108 
73.00 [66.00, 80.00]  73.00 [66.00, 81.00]   0 
65.00 [58.00, 77.00] 64.00 [58.00, 77.00]  0.077307956 
76.00 [71.00, 82.00] 76.00 [70.00, 82.00 -0.061930498 
 Age categories 
 
...18 - 54; n (%) 
...55 - 64; n (%) 
...65 - 74; n (%) 
...>= 75; n (%) 
2,227 (6.5%) 
4,694 (13.8%) 
11,682 (34.3%) 
15,464 (45.4%) 
2,217 (6.5%) 
4,717 (13.8%) 
11,719 (34.4%) 
15,414 (45.2%) 
0 
0 
-0.002105812 
0.004017798 
4,719 (15.3%) 
4,814 (15.6%) 
10,618 (34.3%)    10,666 (34.5%) 
6,320 (20.4%) 
6,291 (20.3%) 
9,266 (30.0%) 
9,152 (29.6%) 
-0.008300494 
-0.004210172 
0.002483849 
0.008745557 
1,010 (0.8%) 
987 (0.8%) 
0 
3,145 (2.6%) 
3,146 (2.6%) 
0 
46,684 (39.2%)     46,637 (39.2%)    0 
68,278 (57.3%)     68,347 (57.4%)    -0.002021967 
7,956 (4.3%) 
8,018 (4.4%)    -0.004902461 
18,457 (10.0%) 
18,529 (10.1%)  -0.00332596 
64,686 (35.1%) 
64,647 (35.1%)  0 
93,008 (50.5%) 
92,913 (50.5%)  0 
 Calendar Year (2014-2020) 
 
...2012-2013; n (%) 
...2014; n (%) 
...2015; n (%) 
...2016; n (%) 
...2017; n (%) 
...2018; n (%) 
...2019; n (%) 
...2020; n (%) 
897 (2.6%) 
2,798 (8.2%) 
3,811 (11.2%) 
4,639 (13.6%) 
6,227 (18.3%) 
6,937 (20.4%) 
6,025 (17.7%) 
2,733 (8.0%) 
867 (2.5%) 
2,787 (8.2%) 
3,804 (11.2%) 
4,689 (13.8%) 
6,247 (18.3%) 
6,984 (20.5%) 
5,990 (17.6%) 
2,699 (7.9%) 
0.006343679 
0 
0 
-0.005816559 
0 
-0.002479326 
0.002622987 
0.003696624 
2,413 (7.8%) 
5,492 (17.8%) 
5,550 (17.9%) 
5,931 (19.2%) 
4,635 (15.0%) 
3,742 (12.1%) 
3,160 (10.2%) 
0 (0.0%) 
2,364 (7.6%) 
5,455 (17.6%) 
5,563 (18.0%) 
5,973 (19.3%) 
4,716 (15.3%) 
3,739 (12.1%) 
3,113 (10.1%) 
0 (0.0%) 
6,280 (5.3%) 
21,548 (18.1%) 
27,718 (23.3%) 
29,239 (24.5%) 
34,332 (28.8%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
6,172 (5.2%) 
21,628 (18.2%) 
27,988 (23.5%) 
29,110 (24.4%) 
34,219 (28.7%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0.005240165 
-0.002605727 
-0.002536376 
-0.008367444 
0 
0.003311376 
0 
-0.002594494 
-0.004723989 
0.002326717 
0.002209474 
0 
0 
0 
29,838 (16.2%) 
37,079 (20.1%) 
39,809 (21.6%) 
45,194 (24.5%) 
10,679 (5.8%) 
9,185 (5.0%) 
2,733 (1.5%) 
29,870 (16.2%) 0 
37,355 (20.3%)  -0.004981432 
39,772 (21.6%)  0 
45,182 (24.5%)  0 
10,723 (5.8%)   0 
9,103 (4.9%)    0.004610229 
2,699 (1.5%)    0 
 Race 
 
...White; n (%) 
...Asian; n (%) 
...Black; n (%) 
...Hispanic; n (%) 
...North American Native; n (%) 
...Other; n (%) 
...Unknown/Missing; n (%) 
25,848 (75.9%) 
925 (2.7%) 
2,747 (8.1%) 
2,931 (8.6%) 
0 (0.0%) 
0 (0.0%) 
1,616 (4.7%) 
25,812 (75.8%) 
948 (2.8%) 
2,755 (8.1%) 
2,919 (8.6%) 
0 (0.0%) 
0 (0.0%) 
1,633 (4.8%) 
0.00233649 
-0.006114921 
0 
0 
0 
0 
-0.004701343 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 
0 
0 
0 
0 
0 
0 
108,611 (91.2%)    108,678 (91.2%)   0 
134,459 (73.0%)     134,490 (73.0%) 0 
1,701 (1.4%) 
4,521 (3.8%) 
1,348 (1.1%) 
335 (0.3%) 
1,333 (1.1%) 
1,268 (1.1%) 
1,711 (1.4%) 
0 
4,509 (3.8%) 
0 
1,318 (1.1%) 
0 
344 (0.3%) 
0 
1,330 (1.1%) 
0 
1,227 (1.0%) 
0.009810761 
2,626 (1.4%) 
7,268 (3.9%) 
4,279 (2.3%) 
335 (0.2%) 
1,330 (0.7%) 
2,884 (1.6%) 
2,659 (1.4%)    0 
7,264 (3.9%)    0 
4,237 (2.3%)    0 
344 (0.2%) 
0 
1,330 (0.7%)    0 
2,860 (1.6%)    0 
 Gender 
 
...Males; n (%) 
...Females; n (%) 
18,512 (54.3%) 
15,555 (45.7%) 
18,548 (54.4%) 
15,519 (45.6%) 
-0.002007613 
0.002007613 
18,799 (60.8%)    18,833 (60.9%) 
12,124 (39.2%)    12,090 (39.1%) 
-0.002048821 
0.002048821 
54,420 (45.7%)     54,409 (45.7%)    0 
64,697 (54.3%)     64,708 (54.3%)    0 
91,731 (49.8%) 
91,790 (49.9%)  -0.00200001 
92,376 (50.2%) 
92,317 (50.1%)  0.00200001 
 Region 
 
...Northeast; n (%) 
...South; n (%) 
...Midwest; n (%) 
...West; n (%) 
...Unknown+missing; n (%) 
4,345 (12.8%) 
13,622 (40.0%) 
7,027 (20.6%) 
9,032 (26.5%) 
41 (0.1%) 
4,345 (12.8%) 
13,709 (40.2%) 
7,052 (20.7%) 
8,917 (26.2%) 
44 (0.1%) 
0 
-0.0040808 
-0.002470397 
0.00681 
0 
6,750 (21.8%) 
6,748 (21.8%) 
11,708 (37.9%)    11,808 (38.2%) 
8,193 (26.5%) 
8,151 (26.4%) 
4,114 (13.3%) 
4,065 (13.1%) 
158 (0.5%) 
151 (0.5%) 
0 
-0.006179102 
0.002267233 
0.005908606 
0 
23,184 (19.5%)     23,389 (19.6%)    -0.002521529 
47,598 (40.0%)     47,456 (39.8%)    0.004084202 
26,441 (22.2%)     26,377 (22.1%)    0.002408153 
21,776 (18.3%)     21,778 (18.3%)    0 
118 (0.1%) 
117 (0.1%) 
0 
34,279 (18.6%) 
34,482 (18.7%)  -0.002567333 
72,928 (39.6%) 
72,973 (39.6%)  0 
41,661 (22.6%) 
41,580 (22.6%)  0 
34,922 (19.0%) 
34,760 (18.9%)  0.002551639 
317 (0.2%) 
312 (0.2%) 
0 
 Combined comorbidity score, 180 days 
 
...mean (sd) 
...median [IQR] 
2.27 (2.15) 
2.25 (2.14) 
0.009323984 
2.00 [1.00, 3.00] 
2.00 [1.00, 3.00] 
0 
1.60 (1.63) 
1.60 (1.63) 
0 
1.00 [0.00, 2.00]   1.00 [0.00, 2.00] 
0 
1.88 (1.84) 
1.88 (1.85) 
0 
1.00 [0.00, 3.00]   1.00 [0.00, 3.00]  0 
1.91 (1.87) 
1.19 (1.87) 
1.90 (1.87) 
0.005347594 
1.19 (1.87) 
0 
 Lifestyle Factors 
 
Lifestyle - Smoking ; n (%) 
Lifestyle - Drug abuse or dependence; n (%) 
Lifestyle - Alcohol abuse or dependence ; n (%) 
6,621 (19.4%) 
588 (1.7%) 
820 (2.4%) 
6,611 (19.4%) 
606 (1.8%) 
837 (2.5%) 
0 
-0.00762637 
-0.00646853 
3,005 (9.7%) 
248 (0.8%) 
580 (1.9%) 
3,021 (9.8%) 
252 (0.8%) 
588 (1.9%) 
-0.003371124 
0 
0 
26,041 (21.9%)     26,032 (21.9%)    0 
815 (0.7%) 
825 (0.7%) 
0 
1,297 (1.1%) 
1,301 (1.1%) 
0 
35,667 (19.4%) 
35,664 (19.4%)  0 
1,651 (0.9%) 
1,683 (0.9%)    0 
2,697 (1.5%) 
2,726 (1.5%)    0 
 Comorbidities 
 
DM - Diabetic Retinopathy; n (%) 
DM - Diabetic Neuropathy; n (%) 
DM - Diabetic Nephropathy; n (%) 
DM - Diabetes with peripheral circulatory disorders; n (%) 
DM - Diabetes with peripheral circulatory disorders and lower extremity amputation; n (%) 
DM - Diabetes with unspecified complications; n (%) 
DM - Diabetes mellitus without mention of complications; n (%) 
CV - Hypertension; n (%) 
CV - Hyperlipidemia; n (%) 
CV -Acute MI; n (%) 
CV - ACS/unstable angina; n (%) 
CV - Old MI; n (%) 
CV - Stable angina; n (%) 
CV - Coronary atherosclerosis and other forms of chronic ischemic heart disease; n (%) 
CV - Other atherosclerosis; n (%) 
CV - Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA; n (%) 
CV - Ischemic stroke; n (%) 
CV - Hemorrhagic stroke; n (%) 
CV - TIA; n (%) 
CV - Other cerebrovascular disease; n (%) 
CV - Late effects of cerebrovascular disease; n (%) 
CV - Heart failure (CHF); n (%) 
CV - Peripheral Vascular Disease (PVD) or PVD Surgery; n (%) 
CV - Other cardiac dysrhythmia; n (%) 
CV - Cardiac conduction disorders; n (%) 
CV - Other CVD; n (%) 
CV Medications - ACE inhibitors; n (%) 
CV Medications - ARBs; n (%) 
CV Medications - Alpha blockers; n (%) 
CV Medications - Beta blockers; n (%) 
CV Medications - Loop Diuretics; n (%) 
CV Medications - Other diuretics; n (%) 
CV Medications - Use of nitrates; n (%) 
CV Medications - Use of statins; n (%) 
CV Medications - Use of other lipid-lowering drugs; n (%) 
CV Medications - calcium channel blockers; n (%) 
Other Comorbidity - Osteoporosis; n (%) 
Other Comorbidity - Dementia; n (%) 
Other Comorbidity - Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland ; n (%) 
Other Comorbidity - Edema; n (%) 
Other Comorbidity - Depression; n (%) 
Other Comorbidity - Anxiety; n (%) 
Other Comorbidity - Pneumonia; n (%) 
Other Comorbidity - COPD; n (%) 
Other Comorbidity - Asthma; n (%) 
Other Comorbidity - Acute renal disease; n (%) 
Other Comorbidity CKD Stage 1; n (%) 
Other Comorbidity - CKD Stage 2; n (%) 
Other Comorbidity - CKD Stage 3; n (%) 
Other Comorbidity - Occurrence of chronic renal insufficiency w/o CKD ; n (%) 
Other Comorbidity - Occurrence of miscellaneous renal insufficiency; n (%) 
Other Comorbidity - Hypertensive nephropathy; n (%) 
Other Comorbidity - Obstructive sleep apnea; n (%) 
Other Comorbidity - Osteoarthritis; n (%) 
Other Comorbidity - Other arthritis, arthropathies and musculoskeletal pain; n (%) 
Other Comorbidity - Dorsopathies; n (%) 
Other Comorbidity - Fractures; n (%) 
Other Comorbidity - Falls; n (%) 
Other Comorbidity - Sleep Disorder; n (%) 
Other Comorbidity - Delirium; n (%) 
Other Comorbidity - Psychosis; n (%) 
530 (1.6%) 
1,924 (5.6%) 
1,713 (5.0%) 
168 (0.5%) 
320 (0.9%) 
581 (1.7%) 
7,987 (23.4%) 
26,217 (77.0%) 
19,147 (56.2%) 
766 (2.2%) 
771 (2.3%) 
1,430 (4.2%) 
1,478 (4.3%) 
8,484 (24.9%) 
323 (0.9%) 
2,189 (6.4%) 
3,524 (10.3%) 
78 (0.2%) 
1,291 (3.8%) 
1,205 (3.5%) 
989 (2.9%) 
7,175 (21.1%) 
2,650 (7.8%) 
29,592 (86.9%) 
3,110 (9.1%) 
11,779 (34.6%) 
10,342 (30.4%) 
7,534 (22.1%) 
3,937 (11.6%) 
22,348 (65.6%) 
6,871 (20.2%) 
1,520 (4.5%) 
1,576 (4.6%) 
17,122 (50.3%) 
1,232 (3.6%) 
12,788 (37.5%) 
2,752 (8.1%) 
2,507 (7.4%) 
7,094 (20.8%) 
3,550 (10.4%) 
2,913 (8.6%) 
3,874 (11.4%) 
2,186 (6.4%) 
4,968 (14.6%) 
2,169 (6.4%) 
1,700 (5.0%) 
120 (0.4%) 
781 (2.3%) 
3,259 (9.6%) 
1,622 (4.8%) 
1,895 (5.6%) 
2,673 (7.8%) 
3,823 (11.2%) 
7,142 (21.0%) 
13,179 (38.7%) 
7,796 (22.9%) 
1,609 (4.7%) 
2,104 (6.2%) 
1,567 (4.6%) 
901 (2.6%) 
402 (1.2%) 
543 (1.6%) 
1,921 (5.6%) 
1,643 (4.8%) 
149 (0.4%) 
299 (0.9%) 
565 (1.7%) 
7,960 (23.4%) 
26,232 (77.0%) 
19,028 (55.9%) 
779 (2.3%) 
751 (2.2%) 
1,379 (4.0%) 
1,501 (4.4%) 
8,497 (24.9%) 
319 (0.9%) 
2,169 (6.4%) 
3,518 (10.3%) 
73 (0.2%) 
1,264 (3.7%) 
1,187 (3.5%) 
974 (2.9%) 
7,124 (20.9%) 
2,666 (7.8%) 
29,680 (87.1%) 
3,141 (9.2%) 
11,695 (34.3%) 
10,318 (30.3%) 
7,581 (22.3%) 
3,937 (11.6%) 
22,416 (65.8%) 
6,783 (19.9%) 
1,532 (4.5%) 
1,606 (4.7%) 
17,176 (50.4%) 
1,231 (3.6%) 
12,824 (37.6%) 
2,723 (8.0%) 
2,505 (7.4%) 
7,038 (20.7%) 
3,521 (10.3%) 
2,935 (8.6%) 
3,869 (11.4%) 
2,163 (6.3%) 
5,013 (14.7%) 
2,178 (6.4%) 
1,706 (5.0%) 
112 (0.3%) 
781 (2.3%) 
3,190 (9.4%) 
1,627 (4.8%) 
1,886 (5.5%) 
2,586 (7.6%) 
3,809 (11.2%) 
7,114 (20.9%) 
13,129 (38.5%) 
7,732 (22.7%) 
1,603 (4.7%) 
2,019 (5.9%) 
1,567 (4.6%) 
884 (2.6%) 
392 (1.2%) 
0 
0 
0.00926502 
0.014941191 
0 
0 
0 
0 
0.006044439 
-0.006742995 
0.006742995 
0.010086356 
-0.004902461 
0 
0 
0 
0 
0 
0.005263632 
0 
0 
0.004910301 
0 
-0.005947037 
-0.003468388 
0.006313097 
0.002175005 
-0.004812436 
0 
-0.004213095 
0.007493037 
0 
-0.004749134 
-0.00200005 
0 
-0.002065043 
0.003675589 
0 
0.002465992 
0.003282882 
0 
0 
0.00410072 
-0.002828003 
0 
0 
0.01693335 
0 
0.006820975 
0 
0.004367708 
0.007502169 
0 
0.002457295 
0.004108214 
0.00476711 
0 
0.012583567 
0 
0 
0 
253 (0.8%) 
1,054 (3.4%) 
574 (1.9%) 
159 (0.5%) 
213 (0.7%) 
431 (1.4%) 
6,409 (20.7%) 
21,209 (68.6%) 
15,159 (49.0%) 
647 (2.1%) 
621 (2.0%) 
606 (2.0%) 
935 (3.0%) 
6,205 (20.1%) 
253 (0.8%) 
776 (2.5%) 
2,627 (8.5%) 
31 (0.1%) 
1,087 (3.5%) 
766 (2.5%) 
504 (1.6%) 
4,778 (15.5%) 
1,330 (4.3%) 
22,573 (73.0%) 
2,216 (7.2%) 
9,666 (31.3%) 
9,033 (29.2%) 
6,867 (22.2%) 
2,825 (9.1%) 
20,697 (66.9%) 
4,918 (15.9%) 
1,206 (3.9%) 
1,188 (3.8%) 
14,087 (45.6%) 
1,353 (4.4%) 
11,453 (37.0%) 
1,291 (4.2%) 
1,220 (3.9%) 
4,914 (15.9%) 
2,259 (7.3%) 
1,926 (6.2%) 
2,613 (8.5%) 
1,557 (5.0%) 
2,812 (9.1%) 
1,771 (5.7%) 
1,002 (3.2%) 
47 (0.2%) 
237 (0.8%) 
1,063 (3.4%) 
691 (2.2%) 
1,098 (3.6%) 
978 (3.2%) 
4,198 (13.6%) 
4,883 (15.8%) 
10,699 (34.6%) 
6,222 (20.1%) 
1,056 (3.4%) 
720 (2.3%) 
2,121 (6.9%) 
494 (1.6%) 
246 (0.8%) 
261 (0.8%) 
1,085 (3.5%) 
549 (1.8%) 
157 (0.5%) 
213 (0.7%) 
442 (1.4%) 
6,433 (20.8%) 
21,234 (68.7%) 
15,017 (48.6%) 
639 (2.1%) 
595 (1.9%) 
633 (2.0%) 
935 (3.0%) 
6,178 (20.0%) 
234 (0.8%) 
779 (2.5%) 
2,602 (8.4%) 
26 (0.1%) 
1,085 (3.5%) 
771 (2.5%) 
496 (1.6%) 
4,738 (15.3%) 
1,323 (4.3%) 
22,627 (73.2%) 
2,206 (7.1%) 
9,600 (31.0%) 
9,039 (29.2%) 
6,809 (22.0%) 
2,855 (9.2%) 
20,720 (67.0%) 
4,920 (15.9%) 
1,219 (3.9%) 
1,207 (3.9%) 
14,047 (45.4%) 
1,326 (4.3%) 
11,469 (37.1%) 
1,266 (4.1%) 
1,211 (3.9%) 
4,969 (16.1%) 
2,290 (7.4%) 
1,938 (6.3%) 
2,665 (8.6%) 
1,506 (4.9%) 
2,783 (9.0%) 
1,816 (5.9%) 
993 (3.2%) 
46 (0.1%) 
250 (0.8%) 
1,066 (3.4%) 
691 (2.2%) 
1,131 (3.7%) 
940 (3.0%) 
4,221 (13.7%) 
4,861 (15.7%) 
10,712 (34.6%) 
6,260 (20.2%) 
1,090 (3.5%) 
724 (2.3%) 
2,093 (6.8%) 
479 (1.5%) 
247 (0.8%) 
0 
-0.005479185 
0.007421163 
0 
0 
0 
-0.002465992 
-0.002155565 
0.008002369 
0 
0.007232055 
0 
0 
0.002497663 
0 
0 
0.003595367 
0 
0 
0 
0 
0.005540974 
0 
-0.004510205 
0.003881118 
0.006478024 
0 
0.004820215 
-0.003468388 
-0.002125882 
0 
0 
-0.005197523 
0.004016307 
0.004902461 
-0.002070657 
0.005013965 
0 
-0.005455468 
-0.003832079 
-0.004131191 
-0.003576233 
0.004610229 
0.00348558 
-0.008556468 
0 
0.025841432 
0 
0 
0 
-0.00533248 
0.011539699 
-0.002912748 
0.002745207 
0 
-0.002493018 
-0.005479185 
0 
0.003958805 
0.008095242 
0 
1,208 (1.0%) 
4,403 (3.7%) 
2,524 (2.1%) 
753 (0.6%) 
1,121 (0.9%) 
1,218 (1.0%) 
28,342 (23.8%) 
100,576 (84.4%) 
61,613 (51.7%) 
2,681 (2.3%) 
2,555 (2.1%) 
4,808 (4.0%) 
3,675 (3.1%) 
29,809 (25.0%) 
1,179 (1.0%) 
8,544 (7.2%) 
13,171 (11.1%) 
196 (0.2%) 
4,630 (3.9%) 
3,895 (3.3%) 
3,164 (2.7%) 
22,497 (18.9%) 
7,895 (6.6%) 
83,159 (69.8%) 
9,015 (7.6%) 
35,021 (29.4%) 
37,734 (31.7%) 
28,936 (24.3%) 
14,595 (12.3%) 
81,685 (68.6%) 
27,836 (23.4%) 
5,513 (4.6%) 
7,347 (6.2%) 
63,600 (53.4%) 
5,124 (4.3%) 
46,948 (39.4%) 
11,020 (9.3%) 
8,916 (7.5%) 
14,854 (12.5%) 
9,467 (7.9%) 
9,465 (7.9%) 
10,377 (8.7%) 
7,900 (6.6%) 
16,610 (13.9%) 
7,281 (6.1%) 
5,417 (4.5%) 
215 (0.2%) 
1,262 (1.1%) 
6,931 (5.8%) 
4,903 (4.1%) 
5,248 (4.4%) 
7,114 (6.0%) 
7,739 (6.5%) 
25,295 (21.2%) 
43,434 (36.5%) 
24,994 (21.0%) 
5,648 (4.7%) 
2,511 (2.1%) 
5,615 (4.7%) 
2,966 (2.5%) 
1,949 (1.6%) 
1,193 (1.0%) 
4,477 (3.8%) 
2,577 (2.2%) 
767 (0.6%) 
1,129 (0.9%) 
1,240 (1.0%) 
28,423 (23.9%) 
100,572 (84.4%) 
61,604 (51.7%) 
2,693 (2.3%) 
2,574 (2.2%) 
4,745 (4.0%) 
3,654 (3.1%) 
29,653 (24.9%) 
1,172 (1.0%) 
8,511 (7.1%) 
13,113 (11.0%) 
205 (0.2%) 
4,670 (3.9%) 
3,849 (3.2%) 
3,157 (2.7%) 
22,414 (18.8%) 
7,884 (6.6%) 
83,157 (69.8%) 
8,944 (7.5%) 
34,673 (29.1%) 
37,793 (31.7%) 
28,724 (24.1%) 
14,663 (12.3%) 
81,727 (68.6%) 
27,874 (23.4%) 
5,482 (4.6%) 
7,306 (6.1%) 
63,607 (53.4%) 
5,109 (4.3%) 
46,720 (39.2%) 
10,950 (9.2%) 
8,905 (7.5%) 
14,982 (12.6%) 
9,467 (7.9%) 
9,554 (8.0%) 
10,419 (8.7%) 
7,890 (6.6%) 
16,533 (13.9%) 
7,253 (6.1%) 
5,506 (4.6%) 
216 (0.2%) 
1,268 (1.1%) 
7,025 (5.9%) 
4,977 (4.2%) 
5,332 (4.5%) 
7,243 (6.1%) 
7,701 (6.5%) 
25,311 (21.2%) 
43,465 (36.5%) 
24,900 (20.9%) 
5,751 (4.8%) 
2,515 (2.1%) 
5,611 (4.7%) 
2,937 (2.5%) 
1,973 (1.7%) 
0 
-0.005263632 
-0.006894503 
0 
0 
0 
-0.002346503 
0 
0 
0 
-0.006894503 
0 
0 
0.002310945 
0 
0.003881118 
0.003189675 
0 
0 
0.005639422 
0 
0.002556822 
0 
0 
0.003785069 
0.006594737 
0 
0.004669699 
0 
0 
0 
0 
0.004162423 
0 
0 
0.004094872 
0.003451489 
0 
-0.003018552 
0 
-0.003696624 
0 
0 
0 
0 
-0.004798523 
0 
0 
-0.004261013 
-0.005013965 
-0.0048496 
-0.004194449 
0 
0 
0 
0.002457295 
-0.004701343 
0 
0 
0 
-0.007850082 
1,991 (1.1%) 
7,381 (4.0%) 
4,811 (2.6%) 
1,080 (0.6%) 
1,654 (0.9%) 
2,230 (1.2%) 
42,738 (23.2%) 
148,002 (80.4%) 
95,919 (52.1%) 
4,094 (2.2%) 
3,947 (2.1%) 
6,844 (3.7%) 
6,088 (3.3%) 
44,498 (24.2%) 
1,755 (1.0%) 
11,509 (6.3%) 
19,322 (10.5%) 
305 (0.2%) 
7,008 (3.8%) 
5,866 (3.2%) 
4,657 (2.5%) 
34,450 (18.7%) 
11,875 (6.5%) 
135,324 (73.5%) 
14,341 (7.8%) 
56,466 (30.7%) 
57,109 (31.0%) 
43,337 (23.5%) 
21,357 (11.6%) 
124,730 (67.7%) 
39,625 (21.5%) 
8,239 (4.5%) 
10,111 (5.5%) 
94,809 (51.5%) 
7,709 (4.2%) 
71,189 (38.7%) 
15,063 (8.2%) 
12,643 (6.9%) 
26,862 (14.6%) 
15,276 (8.3%) 
14,304 (7.8%) 
16,864 (9.2%) 
11,643 (6.3%) 
24,390 (13.2%) 
11,221 (6.1%) 
8,119 (4.4%) 
382 (0.2%) 
2,280 (1.2%) 
11,253 (6.1%) 
7,216 (3.9%) 
8,241 (4.5%) 
10,765 (5.8%) 
15,760 (8.6%) 
37,320 (20.3%) 
67,312 (36.6%) 
39,012 (21.2%) 
8,313 (4.5%) 
5,335 (2.9%) 
9,303 (5.1%) 
4,361 (2.4%) 
2,597 (1.4%) 
1,997 (1.1%)    0 
7,483 (4.1%)    -0.005072843 
4,769 (2.6%)    0 
1,073 (0.6%)    0 
1,641 (0.9%)    0 
2,247 (1.2%)    0 
42,816 (23.3%)  -0.00236728 
148,038 (80.4%) 0 
95,649 (52.0%) 
4,111 (2.2%) 
3,920 (2.1%) 
6,757 (3.7%) 
6,090 (3.3%) 
44,328 (24.1%) 
1,725 (0.9%) 
11,459 (6.2%) 
19,233 (10.4%) 
304 (0.2%) 
7,019 (3.8%) 
5,807 (3.2%) 
4,627 (2.5%) 
34,276 (18.6%) 
11,873 (6.4%) 
0.002001684 
0 
0 
0 
0 
0.00233649 
0.010309004 
0.004131191 
0.00326896 
0 
0 
0 
0 
0.002567333 
0.004070982 
135,464 (73.6%) -0.002267233 
14,291 (7.8%)   0 
55,968 (30.4%)  0.006513011 
57,150 (31.0%) 0 
43,114 (23.4%)  0.002360241 
21,455 (11.7%)  -0.003116982 
124,863 (67.8%) -0.002139345 
39,577 (21.5%) 
8,233 (4.5%) 
10,119 (5.5%) 
94,830 (51.5%) 
7,666 (4.2%) 
71,013 (38.6%) 
14,939 (8.1%) 
12,621 (6.9%) 
26,989 (14.7%) 
15,278 (8.3%) 
14,427 (7.8%) 
16,953 (9.2%) 
11,559 (6.3%) 
24,329 (13.2%) 
11,247 (6.1%) 
8,205 (4.5%) 
374 (0.2%) 
2,299 (1.2%) 
11,281 (6.1%) 
7,295 (4.0%) 
8,349 (4.5%) 
10,769 (5.8%) 
15,731 (8.5%) 
37,286 (20.3%) 
67,306 (36.6%) 
38,892 (21.1%) 
8,444 (4.6%) 
5,258 (2.9%) 
9,271 (5.0%) 
4,300 (2.3%) 
2,612 (1.4%) 
0 
0 
0 
0 
0 
0.002053611 
0.003654958 
0 
-0.002828003 
0 
0 
0 
0 
0 
0 
-0.0048496 
0 
0 
0 
-0.00513398 
0 
0 
0.003576233 
0 
0 
0.002448749 
-0.004798523 
0 
0.004566758 
0.006601343 
0 
Matched 

 Procedures 
 
Procedure - Hip Surgery; n (%) 
198 (0.6%) 
209 (0.6%) 
0 
92 (0.3%) 
116 (0.4%) 
-0.01693335 
607 (0.5%) 
640 (0.5%) 
0 
897 (0.5%) 
965 (0.5%) 
0 
 Medications 
 
DM Medications - Meglitinides; n (%) 
DM Medications - AGIs; n (%) 
DM Medications - Insulin; n (%) 
DM Medications - Glitazones; n (%) 
DM Medications - 1st and 2nd Generation SUs ; n (%) 
DM Medications - DPP-4 Inhibitors; n (%) 
DM Medications - GLP-1 RA; n (%) 
DM Medications - SGLT-2 Inhibitors ; n (%) 
DM Medications - Metformin; n (%) 
Other Medications - Use of NSAIDs; n (%) 
Other Medications - Use of other hypertension drugs; n (%) 
Other Medications - Digoxin; n (%) 
Other Medications - Use of Anti-arrhythmics; n (%) 
Other Medications - Use of antipsychotics; n (%) 
Other Medications - Use of dementia meds; n (%) 
Other Medications - Use of antiparkinsonian meds; n (%) 
Other Medications - Use of anxiolytics/hypnotics; n (%) 
Other Medications - Use of anticonvulsants; n (%) 
Other Medications - Use of antidepressants; n (%) 
Other Medications - Use of lithium; n (%) 
Other Medications - Use of Benzos; n (%) 
Other Medication - Use of CNS stimulants; n (%) 
Other Medications - Use of opioids; n (%) 
Other Medications - Use of COPD/asthma meds; n (%) 
Other Medications - Use of oral corticosteroids; n (%) 
Other Medications - Use of Sympatomimetic agents; n (%) 
Other Medications - Use of bisphosphonates; n (%) 
Other Medications - Use of thiazide; n (%) 
Other Medications - Use of estrogens, progestins, androgens; n (%) 
72 (0.2%) 
20 (0.1%) 
1,478 (4.3%) 
357 (1.0%) 
2,118 (6.2%) 
860 (2.5%) 
345 (1.0%) 
317 (0.9%) 
4,637 (13.6%) 
4,170 (12.2%) 
2,254 (6.6%) 
2,219 (6.5%) 
5,454 (16.0%) 
632 (1.9%) 
1,093 (3.2%) 
857 (2.5%) 
1,623 (4.8%) 
3,791 (11.1%) 
6,889 (20.2%) 
35 (0.1%) 
3,954 (11.6%) 
103 (0.3%) 
6,999 (20.5%) 
5,766 (16.9%) 
6,493 (19.1%) 
167 (0.5%) 
1,107 (3.2%) 
3,766 (11.1%) 
1,067 (3.1%) 
77 (0.2%) 
24 (0.1%) 
1,479 (4.3%) 
374 (1.1%) 
2,081 (6.1%) 
888 (2.6%) 
349 (1.0%) 
317 (0.9%) 
4,625 (13.6%) 
4,141 (12.2%) 
2,221 (6.5%) 
2,219 (6.5%) 
5,437 (16.0%) 
603 (1.8%) 
1,091 (3.2%) 
861 (2.5%) 
1,628 (4.8%) 
3,820 (11.2%) 
6,906 (20.3%) 
41 (0.1%) 
4,018 (11.8%) 
106 (0.3%) 
6,990 (20.5%) 
5,805 (17.0%) 
6,450 (18.9%) 
179 (0.5%) 
1,123 (3.3%) 
3,761 (11.0%) 
1,092 (3.2%) 
0 
0 
0 
-0.009810761 
0.004162423 
-0.006343679 
0 
0 
0 
0 
0.004041947 
0 
0 
0.007421163 
0 
0 
0 
-0.003177126 
-0.002488413 
0 
-0.006222413 
0 
0 
-0.002665298 
0.005098144 
0 
-0.005639422 
0.003189675 
-0.005725279 
74 (0.2%) 
14 (0.0%) 
1,294 (4.2%) 
353 (1.1%) 
1,622 (5.2%) 
978 (3.2%) 
452 (1.5%) 
387 (1.3%) 
3,972 (12.8%) 
4,177 (13.5%) 
1,668 (5.4%) 
2,082 (6.7%) 
6,102 (19.7%) 
409 (1.3%) 
625 (2.0%) 
625 (2.0%) 
1,745 (5.6%) 
2,559 (8.3%) 
5,413 (17.5%) 
29 (0.1%) 
3,432 (11.1%) 
160 (0.5%) 
6,296 (20.4%) 
5,002 (16.2%) 
5,641 (18.2%) 
281 (0.9%) 
583 (1.9%) 
3,186 (10.3%) 
1,536 (5.0%) 
75 (0.2%) 
17 (0.1%) 
1,306 (4.2%) 
354 (1.1%) 
1,634 (5.3%) 
979 (3.2%) 
454 (1.5%) 
384 (1.2%) 
3,996 (12.9%) 
4,205 (13.6%) 
1,691 (5.5%) 
2,078 (6.7%) 
6,071 (19.6%) 
407 (1.3%) 
634 (2.1%) 
631 (2.0%) 
1,763 (5.7%) 
2,524 (8.2%) 
5,378 (17.4%) 
26 (0.1%) 
3,418 (11.1%) 
172 (0.6%) 
6,393 (20.7%) 
5,008 (16.2%) 
5,733 (18.5%) 
296 (1.0%) 
568 (1.8%) 
3,151 (10.2%) 
1,560 (5.0%) 
0 
-0.044743737 
0 
0 
-0.004483651 
0 
0 
0.009000794 
-0.002988238 
-0.002921785 
-0.004405265 
0 
0.002516669 
0 
-0.007057056 
0 
-0.004331176 
0.003634718 
0.002634779 
0 
0 
-0.013521541 
-0.007424571 
0 
-0.007750476 
-0.010309004 
0.007421163 
0.003297019 
0 
345 (0.3%) 
94 (0.1%) 
4,175 (3.5%) 
1,266 (1.1%) 
7,542 (6.3%) 
3,422 (2.9%) 
793 (0.7%) 
524 (0.4%) 
15,017 (12.6%) 
15,933 (13.4%) 
8,885 (7.5%) 
10,307 (8.7%) 
21,156 (17.8%) 
3,028 (2.5%) 
5,249 (4.4%) 
3,737 (3.1%) 
7,389 (6.2%) 
13,875 (11.6%) 
26,364 (22.1%) 
124 (0.1%) 
16,809 (14.1%) 
357 (0.3%) 
28,924 (24.3%) 
22,985 (19.3%) 
25,623 (21.5%) 
374 (0.3%) 
4,155 (3.5%) 
14,993 (12.6%) 
4,507 (3.8%) 
347 (0.3%) 
95 (0.1%) 
4,109 (3.4%) 
1,269 (1.1%) 
7,589 (6.4%) 
3,455 (2.9%) 
774 (0.6%) 
519 (0.4%) 
15,014 (12.6%) 
15,888 (13.3%) 
8,941 (7.5%) 
10,355 (8.7%) 
21,105 (17.7%) 
3,074 (2.6%) 
5,267 (4.4%) 
3,654 (3.1%) 
7,356 (6.2%) 
13,931 (11.7%) 
26,349 (22.1%) 
119 (0.1%) 
16,796 (14.1%) 
360 (0.3%) 
28,893 (24.3%) 
22,848 (19.2%) 
25,580 (21.5%) 
375 (0.3%) 
4,096 (3.4%) 
14,980 (12.6%) 
4,549 (3.8%) 
0 
0 
0.005479185 
0 
-0.00410072 
0 
0.012444223 
0 
0 
0.002940191 
0 
0 
0.002617178 
-0.006343679 
0 
0 
0 
-0.003116982 
0 
0 
0 
0 
0 
0.002536376 
0 
0 
0.005479185 
0 
0 
491 (0.3%) 
128 (0.1%) 
6,947 (3.8%) 
1,976 (1.1%) 
11,282 (6.1%) 
5,260 (2.9%) 
1,590 (0.9%) 
1,228 (0.7%) 
23,626 (12.8%) 
24,280 (13.2%) 
12,807 (7.0%) 
14,608 (7.9%) 
32,712 (17.8%) 
4,069 (2.2%) 
6,967 (3.8%) 
5,219 (2.8%) 
10,757 (5.8%) 
20,225 (11.0%) 
38,666 (21.0%) 
188 (0.1%) 
24,195 (13.1%) 
620 (0.3%) 
42,219 (22.9%) 
33,753 (18.3%) 
37,757 (20.5%) 
822 (0.4%) 
5,845 (3.2%) 
21,945 (11.9%) 
7,110 (3.9%) 
499 (0.3%) 
136 (0.1%) 
6,894 (3.7%) 
1,997 (1.1%) 
11,304 (6.1%) 
5,322 (2.9%) 
1,577 (0.9%) 
1,220 (0.7%) 
23,635 (12.8%) 
24,234 (13.2%) 
12,853 (7.0%) 
14,652 (8.0%) 
32,613 (17.7%) 
4,084 (2.2%) 
6,992 (3.8%) 
5,146 (2.8%) 
10,747 (5.8%) 
20,275 (11.0%) 
38,633 (21.0%) 
186 (0.1%) 
24,232 (13.2%) 
638 (0.3%) 
42,276 (23.0%) 
33,661 (18.3%) 
37,763 (20.5%) 
850 (0.5%) 
5,787 (3.1%) 
21,892 (11.9%) 
7,201 (3.9%) 
0 
0 
0.005263632 
0 
0 
0 
0 
0 
0 
0 
0 
-0.003696624 
0.002617178 
0 
0 
0 
0 
0 
0 
0 
-0.002959053 
0 
-0.002378059 
0 
0 
-0.014941191 
0.005725279 
0 
0 
 Healthcare Utilization 
 
HU - Bone mineral density; n (%) 
HU - Occurrence of creatinine tests ordered ; n (%) 
HU - Number of D-dimer tests 
...mean (sd) 
...median [IQR] 
HU - Number of CRP, high-sensitivity CRP tests 
...mean (sd) 
...median [IQR] 
HU - Colonoscopy; n (%) 
HU - Flu vaccine; n (%) 
HU - Mammogram; n (%) 
HU - PSA test or Prostate exam for DRE; n (%) 
HU - Pap smear; n (%) 
HU - Pneumonia vaccine; n (%) 
Frailty Score: Empirical Version 365 days 
...mean (sd) 
...median [IQR] 
CHADS2 score, 180 days 
...mean (sd) 
...median [IQR] 
HU - Number of Hospitalizations 
...mean (sd) 
...median [IQR] 
HU - Number of hospital days 
...mean (sd) 
...median [IQR] 
HU - Number of Emergency Department (ED) visits 
...mean (sd) 
...median [IQR] 
HU - Number of internal medicine/family medicine visits 
...mean (sd) 
...median [IQR] 
HU - Number of different/distinct medication prescriptions 
...mean (sd) 
...median [IQR] 
HU - Number of Office visits 
...mean (sd) 
...median [IQR] 
HU - Number of Cardiologist visits 
...mean (sd) 
...median [IQR] 
HU - Number electrocardiograms 
...mean (sd) 
...median [IQR] 
HU - Number of echocardiograms 
...mean (sd) 
...median [IQR] 
HU - Number of neurologist visits 
...mean (sd) 
...median [IQR] 
HU - Fecal occult blood (FOB) test; n (%) 
HU - Number of PT or aPTTt tests 
...mean (sd) 
...median [IQR] 
1,247 (3.7%) 
1,673 (4.9%) 
1,253 (3.7%) 
1,669 (4.9%) 
0 
0 
481 (1.6%) 
1,312 (4.2%) 
487 (1.6%) 
1,307 (4.2%) 
0 
0 
4,954 (4.2%) 
8,163 (6.9%) 
4,933 (4.1%) 
8,199 (6.9%) 
0.005013965 
0 
6,682 (3.6%) 
11,148 (6.1%) 
6,673 (3.6%) 
7,909 (4.3%) 
0 
0.081137899 
0.04 (0.22) 
0.00 [0.00, 0.00] 
0.04 (0.20) 
0.00 [0.00, 0.00] 
0 
0 
0.04 (0.24) 
0.00 [0.00, 0.00] 
0.04 (0.23) 
0.00 [0.00, 0.00] 
0 
0 
0.04 (0.21) 
0.00 [0.00, 0.00] 
0.04 (0.21) 
0.00 [0.00, 0.00] 
0 
0 
0.04 (0.22) 
0.00 (0.22) 
0.04 (0.21) 
0.00 (0.21) 
0 
0 
0.07 (0.39) 
0.00 [0.00, 0.00] 
1,320 (3.9%) 
6,264 (18.4%) 
3,020 (8.9%) 
4,669 (13.7%) 
549 (1.6%) 
7,071 (20.8%) 
0.07 (0.40) 
0.00 [0.00, 0.00] 
1,259 (3.7%) 
6,278 (18.4%) 
3,010 (8.8%) 
4,706 (13.8%) 
509 (1.5%) 
7,077 (20.8%) 
0 
0 
0.0104606 
0 
0.003520876 
-0.002903819 
0.008095242 
0 
0.05 (0.28) 
0.00 [0.00, 0.00] 
1,336 (4.3%) 
3,830 (12.4%) 
1,914 (6.2%) 
3,774 (12.2%) 
744 (2.4%) 
3,494 (11.3%) 
0.05 (0.29) 
0.00 [0.00, 0.00] 
1,346 (4.4%) 
3,779 (12.2%) 
1,943 (6.3%) 
3,742 (12.1%) 
757 (2.4%) 
3,528 (11.4%) 
0 
0 
-0.004902461 
0.006089472 
-0.004131191 
0.003060846 
0 
-0.003152559 
0.09 (0.43) 
0.00 [0.00, 0.00] 
4,808 (4.0%) 
38,751 (32.5%) 
12,335 (10.4%) 
14,754 (12.4%) 
2,839 (2.4%) 
30,996 (26.0%) 
0.09 (0.42) 
0.00 [0.00, 0.00] 
4,900 (4.1%) 
38,699 (32.5%) 
12,404 (10.4%) 
14,815 (12.4%) 
2,838 (2.4%) 
30,949 (26.0%) 
0 
0 
-0.005072843 
0 
0 
0 
0 
0 
0.08 (0.68) 
0.00 (0.68) 
7,464 (4.1%) 
48,845 (26.5%) 
17,269 (9.4%) 
23,197 (12.6%) 
4,132 (2.2%) 
41,561 (22.6%) 
0.08 (0.40) 
0.00 (0.40) 
7,505 (4.1%) 
48,756 (26.5%) 
17,357 (9.4%) 
23,263 (12.6%) 
4,104 (2.2%) 
41,554 (22.6%) 
0 
0 
0 
0 
0 
0 
0 
0 
0.18 (0.06) 
0.17 [0.14, 0.20] 
0.18 (0.06) 
0.17 [0.14, 0.21] 
0 
0 
0.17 (0.05) 
0.16 [0.14, 0.19] 
0.17 (0.05) 
0.16 [0.14, 0.19] 
0 
0 
0.19 (0.06) 
0.17 [0.14, 0.21] 
0.19 (0.06) 
0.17 [0.14, 0.21] 
0 
0 
0.18 (0.06) 
0.17 (0.06) 
0.18 (0.06) 
0.17 (0.06) 
0 
0 
1.38 (1.24) 
1.00 [0.00, 2.00] 
1.37 (1.24) 
1.00 [0.00, 2.00] 
0.008064516 
0 
1.19 (1.21) 
1.00 [0.00, 2.00] 
1.19 (1.20) 
1.00 [0.00, 2.00] 
0 
0 
1.24 (1.18) 
1.00 [0.00, 2.00] 
1.25 (1.18) 
1.00 [0.00, 2.00] 
-0.008474576 
0 
1.26 (1.20) 
1.00 (1.20) 
1.26 (1.19) 
1.00 (1.19) 
0 
0 
0.27 (0.55) 
0.00 [0.00, 0.00] 
0.26 (0.52) 
0.00 [0.00, 0.00] 
0.018684246 
0 
0.28 (0.50) 
0.00 [0.00, 1.00] 
0.28 (0.49) 
0.00 [0.00, 1.00] 
0 
0 
0.37 (0.63) 
0.00 [0.00, 1.00] 
0.37 (0.62) 
0.00 [0.00, 1.00] 
0 
0 
0.34 (0.60) 
0.00 (0.60) 
0.33 (0.58) 
0.00 (0.58) 
0.016946719 
0 
1.44 (4.38) 
0.00 [0.00, 0.00] 
1.41 (4.34) 
0.00 [0.00, 0.00] 
0.006880662 
0 
1.26 (3.31) 
0.00 [0.00, 1.00] 
1.26 (3.39) 
0.00 [0.00, 1.00] 
0 
0 
1.98 (5.21) 
0.00 [0.00, 3.00] 
1.98 (5.14) 
0.00 [0.00, 3.00] 
0 
0 
1.76 (4.79) 
0.00 (4.79) 
1.75 (4.74) 
0.00 (4.74) 
0.002098607 
0 
0.79 (1.49) 
0.00 [0.00, 1.00] 
0.79 (1.42) 
0.00 [0.00, 1.00] 
0 
0 
0.60 (2.29) 
0.00 [0.00, 0.00] 
0.60 (2.09) 
0.00 [0.00, 0.00] 
0 
0 
0.98 (1.66) 
0.00 [0.00, 2.00] 
0.98 (1.65) 
0.00 [0.00, 2.00] 
0 
0 
0.88 (2.95) 
0.00 (2.95) 
0.88 (1.69) 
0.00 (1.69) 
0 
0 
9.03 (12.31) 
5.00 [2.00, 12.00] 
8.97 (12.19) 
5.00 [2.00, 11.00] 
0.0048979 
0 
6.28 (9.23) 
4.00 [1.00, 8.00] 
6.34 (9.57) 
4.00 [1.00, 8.00] 
-0.006381935 
0 
7.88 (9.58) 
5.00 [2.00, 11.00] 
7.86 (9.63) 
0.002082242 
7.82 (16.98) 
4.83 (16.98) 
7.81 (10.14) 
4.83 (10.14) 
0.000715071 
0 
5.00 [2.00, 11.00] 0 
8.36 (4.50) 
8.00 [5.00, 11.00] 
8.36 (4.48) 
8.00 [5.00, 11.00] 
0 
0 
8.01 (4.42) 
7.00 [5.00, 10.00] 
8.03 (4.39) 
7.00 [5.00, 10.00] 
-0.004540269 
0 
8.93 (4.38) 
8.00 [6.00, 11.00] 
8.92 (4.37) 
0.002285713 
8.67 (7.42) 
7.83 (7.42) 
8.67 (4.39) 
7.83 (4.39) 
0 
0 
8.00 [6.00, 11.00] 0 
5.06 (3.74) 
4.00 [2.00, 7.00] 
5.08 (3.67) 
4.00 [2.00, 7.00] 
-0.00539787 
0 
4.95 (3.80) 
4.00 [2.00, 7.00] 
4.95 (3.73) 
4.00 [2.00, 7.00] 
0 
0 
12.49 (11.61) 
9.00 [5.00, 16.00] 
12.47 (11.44) 
0.001735311 
10.00 [5.00, 16.00] -0.120883684 
 
9.85 (16.16) 
7.23 (16.16) 
9.84 (9.46) 
7.88 (9.46) 
0.000755242 
-0.049090715 
4.28 (5.12) 
3.00 [1.00, 6.00] 
4.34 (4.74) 
3.00 [1.00, 6.00] 
-0.012161357 
0 
3.24 (4.47) 
2.00 [0.00, 5.00] 
3.25 (4.26) 
2.00 [0.00, 5.00] 
-0.002290288 
0 
5.00 (6.19) 
3.00 [1.00, 7.00] 
5.02 (5.68) 
3.00 [1.00, 7.00] 
-0.003366734 
0 
4.57 (9.67) 
2.83 (9.67) 
4.60 (5.30) 
2.83 (5.30) 
-0.003847436 
0 
2.15 (2.34) 
2.00 [1.00, 3.00] 
2.14 (2.14) 
2.00 [1.00, 3.00] 
0.004459844 
0 
1.97 (2.07) 
1.00 [1.00, 3.00] 
1.98 (1.94) 
1.00 [1.00, 3.00] 
-0.004984912 
0 
2.29 (2.09) 
2.00 [1.00, 3.00] 
2.29 (2.02) 
2.00 [1.00, 3.00] 
0 
0 
2.21 (3.59) 
1.83 (3.59) 
2.21 (2.03) 
1.83 (2.03) 
0 
0 
1.10 (3.08) 
0.00 [0.00, 1.00] 
1.09 (2.86) 
0.00 [0.00, 1.00] 
0.003364696 
0 
0.89 (1.40) 
1.00 [0.00, 1.00] 
0.90 (1.34) 
1.00 [0.00, 1.00] 
-0.007297521 
0 
0.92 (1.26) 
1.00 [0.00, 1.00] 
0.92 (1.20) 
1.00 [0.00, 1.00] 
0 
0 
0.95 (2.97) 
0.81 (2.97) 
0.95 (1.66) 
0.81 (1.66) 
0 
0 
0.33 (1.74) 
0.00 [0.00, 0.00] 
1,205 (3.5%) 
0.33 (1.52) 
0.00 [0.00, 0.00] 
1,192 (3.5%) 
0 
0 
 -0.26526667 
 
0.19 (1.06) 
0.00 [0.00, 0.00] 
891 (2.9%) 
0.19 (1.15) 
0.00 [0.00, 0.00] 
873 (2.8%) 
0 
0 
0.006009774 
0.37 (1.90) 
0.00 [0.00, 0.00] 
3,603 (3.0%) 
0.37 (1.60) 
0.00 [0.00, 0.00] 
3,648 (3.1%) 
0 
0 
-0.005815379 
0.33 (2.96) 
0.00 (2.96) 
5,699 (3.1%) 
0.33 (1.52) 
0.00 (1.52) 
5,713 (3.1%) 
0 
0 
0.030052126 
0.39 (1.11) 
0.00 [0.00, 0.00] 
0.40 (1.18) 
0.00 [0.00, 0.00] 
-0.008729547 
0 
0.38 (1.09) 
0.00 [0.00, 0.00] 
0.39 (1.18) 
0.00 [0.00, 0.00] 
-0.008803656 
0 
0.33 (1.01) 
0.00 [0.00, 0.00] 
0.33 (1.06) 
0.00 [0.00, 0.00] 
0 
0 
0.35 (1.76) 
0.00 (1.76) 
0.35 (1.10) 
0.00 (1.10) 
0 
0 
 Socioeconomic Status Proxy Variables 
 
SES - Mean Copay for per prescription cost (charges in U.S. $) 
...mean (sd) 
...median [IQR] 
...Missing; n (%) 
SES - Copay: pharmacy cost 
...mean (sd) 
...median [IQR] 
SES - Business type: Commercial vs Medicare 
...Commerical; n (%) 
...Medicare; n (%) 
SES - Low income indicator; n (%) 
SES - Urban vs Rural (MSA variable) 
...Urban; n (%) 
...Rural; n (%) 
...Unknown/Missing; n (%) 
SES - Dual Status; n (%) 
SES - Generic name prescription - unique value 
...mean (sd) 
...median [IQR] 
SES - Brand name prescription - unique value 
...mean (sd) 
21.17 (29.07) 
21.30 (29.55) 
-0.004435198 
13.65 [5.74, 26.67]   13.44 [5.62, 26.67]    0.00716455 
14.41 (21.23) 
14.37 (20.17) 
9.79 [3.69, 18.75]  9.86 [3.86, 18.80] 
3,256 (10.5%) 
3,225 (10.4%) 
0.001931734 
-0.003380535 
0.00326896 
115.29 (139.28)    115.21 (121.85)   0.000611361 
90.50 [63.50, 132.09 91.00 [64.22, 132.2 -0.003821008 
2,615 (2.2%) 
2,654 (2.2%) 
0 
80.93 (190.30) 
62.72 (190.30) 
7,311 (4.0%) 
80.90 (99.18)   0.000197705 
63.02 (99.18)   -0.001977051 
7,294 (4.0%) 
1,440 (4.2%) 
1,415 (4.2%) 
0 
200.41 (308.17) 
202.34 (320.10) 
-0.006142748 
123.97 (196.24)   123.68 (197.22) 
60.00 [1.55, 162.30] 60.00 [2.43, 165.00] 
0.001474097 
0 
186.85 (323.76)    187.35 (341.03)   -0.001503727 
78.74 [9.00, 234.36] 75.00 [5.00, 231.62 0.011247879 
178.80 (510.13) 
79.89 (510.13) 
179.43 (317.40) 
-0.001482917 
101.98 [29.10, 261.82] 101.76 [29.70, 260.02] 0.00070021 
77.43 (317.40) 
0.005790437 
8,158 (23.9%) 
25,909 (76.1%) 
4,230 (12.4%) 
8,126 (23.9%) 
25,941 (76.1%) 
4,250 (12.5%) 
0 
0 
-0.00302892 
15,370 (49.7%) 
15,553 (50.3%) 
0 (0.0%) 
15,482 (50.1%) 
15,441 (49.9%) 
0 (0.0%) 
-0.00800008 
0.00800008 
0 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 
0 
0 
23,528 (12.8%) 
41,462 (22.5%) 
4,230 (2.3%) 
23,608 (12.8%) 
41,382 (22.5%) 
4,250 (2.3%) 
0 
0 
0 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 
0 
0 
0 
20,469 (66.2%) 
2,559 (8.3%) 
7,895 (25.5%) 
0 (0.0%) 
20,580 (66.6%) 
2,532 (8.2%) 
7,811 (25.3%) 
0 (0.0%) 
-0.008468572 
0.003634718 
0.00459457 
0 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
18,556 (15.6%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
18,490 (15.5%) 
0 
0 
0 
20,469 (11.1%) 
2,559 (1.4%) 
7,895 (4.3%) 
18,556 (10.1%) 
20,580 (11.2%) 
2,532 (1.4%) 
7,811 (4.2%) 
18,490 (10.0%) 
-0.003177126 
0 
0.004957212 
0.00332596 
8.36 (4.50) 
8.00 [5.00, 11.00] 
8.36 (4.48) 
8.00 [5.00, 11.00] 
0 
0 
8.01 (4.42) 
7.00 [5.00, 10.00] 
8.03 (4.39) 
7.00 [5.00, 10.00] 
-0.004540269 
0 
8.93 (4.38) 
8.00 [6.00, 11.00] 
8.92 (4.37) 
0.002285713 
8.67 (7.42) 
7.83 (7.42) 
8.67 (4.39) 
7.83 (4.39) 
0 
0 
8.00 [6.00, 11.00] 0 
8.45 (4.59) 
8.45 (4.56) 
0 
8.12 (4.52) 
8.14 (4.49) 
-0.004439487 
9.03 (4.47) 
9.03 (4.46) 
0 
8.77 (7.58) 
8.77 (4.48) 
0 

...median [IQR] 
8.00 [5.00, 11.00]    8.00 [5.00, 11.00]     0 
7.00 [5.00, 11.00]  7.00 [5.00, 11.00]    0 
8.00 [6.00, 11.00]  8.00 [6.00, 11.00] 0 
7.83 (7.58) 
7.83 (4.48) 
0 

  
Optum 
 
  
MarketScan 
 
  
Medicare 
 
The c-statistics for the propensity score model, pre-matching was 0.687. The post-matching c-statistic was 0.514 
The c-statistics for the propensity score model, pre-matching was 0.707. The post-matching c-statistic was 0.513 
The c-statistics for the propensity score model, pre-matching was 0.668. The post-matching c-statistic was 0.506